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Summary of Thesis 
This thesis investigates the effects of intravesical agents, doxorubicin, mitomycin C 
(MMC), and epirubicin on release of mediators and inflammatory cytokines from the 
urothelium, and tissue responses and morphological integrity of the bladder. 
Intravesical therapy which administers cytotoxic agents into the bladder lumen is an 
important approach for treatment of superficial bladder cancer. Despite evidence of 
significant local adverse effects such as chemical cystitis (dysuria, increased urinary 
frequency and urgency) following this treatment, few studies have assessed their 
effects on non-malignant tissues of the bladder and the changes in urinary function 
resulting from this therapy. A better understanding of the mechanisms of bladder 
toxicity by these agents may lead to the identification of novel approaches for 
reducing the severity of reported adverse effects. Moreover, the effects of ageing on 
bladder function were also investigated in this thesis. 
Two in vitro bladder models, human urothelial cell lines (RT4 & UROtsa) and 
porcine bladder tissues (young & aged) were used to evaluate the effects of the three 
cytotoxic drugs on bladder function at clinically relevant concentrations and 
durations of treatment. Tissue responses to carbachol, isoprenaline and electrical 
field stimulation (EFS) were assessed in isolated bladder tissues, and integrity of 
bladder structure was also evaluated in terms of changes in urothelial thickness. 
Urothelial mediators (ATP, ACh and PGE2) were measured in both cells and tissues 
under basal and stretch-induced conditions (mechanically or hypo-osmotically). 
Release of inflammatory cytokines (IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70) 
and nitric oxide (NO) were also measured, and recovery studies (24 hour- and 1 
week-post treatment, and 1 week-post repeat treatment) were also conducted using 
urothelial cultures.  
The first study comparing function of the bladder between young (4 to 6 months old) 
and aged (2 to 3 years old) pigs revealed age-associated decreases in contractile 
responses to muscarinic stimulation and also reduced urothelial thickness, while 
increases in urothelial mediator release, efferent neurogenic responses and relaxation 
responses of the urothelium/LP were observed with increasing age. In bladders from 
both young and aged pigs, pretreatment with doxorubicin enhanced ATP release 
from the urothelium/LP and also increased contractile responses of the 
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urothelium/LP to muscarinic stimulation. In bladders from young pigs, doxorubicin 
pretreatment enhanced efferent neurogenic responses of the detrusor muscle without 
affecting the muscle response itself, but in bladders from aged pigs, doxorubicin 
enhanced contractile response (muscarinic) of the detrusor muscle and also depressed 
neurogenic detrusor contractility.  
The second study using bladders from aged pigs alone demonstrated that in tissues 
pretreated with MMC, efferent neurotransmission in detrusor muscle was depressed, 
relaxation of the detrusor muscle to adrenergic stimulation was reduced, and 
urothelial contractility to muscarinic stimulation was decreased, compared to control 
tissues. Pretreatment with both MMC and epirubicin caused urothelial thinning, 
abolished the ability of the urothelium to inhibit detrusor contractility, and depressed 
detrusor contractility to muscarinic stimulation. Also, stretch-induced release of ATP 
from the urothelium/LP was decreased after MMC and epirubicin pretreatment, 
while basal release of PGE2 and ACh was increased by MMC and epirubicin, 
respectively.  
Experiments using urothelial cells demonstrated a decrease in stretch-induced ATP 
release immediately and 1 week following MMC pretreatment, but recovery was 
observed 1 week after repeat MMC pretreatment. Basal release of ACh was 
enhanced immediately and 24 hours following pretreatment, but 1 week following 
pretreatment, basal ACh release was decreased while stretch-induced release of ACh 
was increased. Immediately following pretreatment, a decrease in basal PGE2 release 
was observed. However, 24 hours and 1 week following pretreatment, an increase in 
basal PGE2 release was demonstrated. One week after repeat pretreatment, stretch-
induced release of PGE2 was enhanced. In addition, enhancement in NO release 24 
hours and 1 week following MMC pretreatment was shown, with recovery observed 
1 week following repeat pretreatment.  
Further experiments revealed that immediately and 24 hour following epirubicin 
pretreatment, both basal and stretch-induced ATP release were enhanced while 
stretch-induced ATP release was depressed 1 week following pretreatment. An 
increase in basal ACh release and a decrease in stretch-induced ACh release were 
observed immediately and 24 hour after pretreatment. One week following 
pretreatment, an increase in stretch-induced ACh release was observed. The release 
of PGE2 was only affected immediately after pretreatment, in which basal release 
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was increased while stretch-induced release was depressed. NO release was 
enhanced 24 hour following pretreatment, but a recovery was observed 1 week after 
pretreatment.  
One of the most important findings in this study was the persistent induction of 
inflammatory cytokines in urothelial cell culture models following pretreatment with 
the each of the chemotherapeutic drugs tested. All three agents enhanced IL-8 release, 
while IL-6 and IL-1β were enhanced by epirubicin and doxorubicin, respectively. 
This suggests that changes in inflammatory response may be the key to pathogenesis 
of the urological adverse effects reported in bladder cancer patients treated with these 
intravesical agents.  
Thus, these studies have identified a number of changes in bladder function that may 
contribute to the adverse effects observed following intravesical chemotherapy. A 
number of pathological changes were observed in muscle, nerve and urothelium/LP 
that may influence sensory and motor functions of the bladder, but the changes 
following treatment appear to differ for each drug and even the age of the bladder, 
the only consistent change being an inflammatory state that was observed with all the 
drugs tested. 
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Chapter 1 - Introduction 
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Bladder cancer 
Epidemiology 
Bladder cancer is the 9th most common type of cancer (429,800 new cases, 330,400 
male and 99,400 females) and the 13th most common cause of cancer death (165,100 
deaths, 123,100 male and 42,000 females) worldwide in 2012 (Ferlay et al., 2013). 
The incidence varies significantly between geographical regions and countries, being 
particularly high in many developed countries including southern and eastern 
European countries, parts of Africa and the Middle East, and North America (Parkin, 
2008; Ploeg et al., 2009). The highest estimated mortality is in Egypt, where the rate 
was three times and eight times greater in comparison to Europe and the USA, 
respectively (Parkin, 2008). While, incidence rates of bladder cancer were declining 
or were stable in most Western countries in recent decades following a prior period 
of increase (American Cancer Society, 2015), relative survival for bladder cancer has 
decreased over time. Between the periods 1982-1987 and 2006-2010, five-year 
relative survival decreased from 67.9 per cent to 57.5 per cent in Australia while 
relative survival rate for most other cancers increased over the same time period 
(AIHW, 2012). Similar declining trends were also observed in England and Wales 
(Cancer Research UK, 2014). According to the Australian Institute of Health and 
Welfare, bladder cancer is the tenth most common cancer in Australia (AIHW, 2012).  
There were 2,459 new cases of bladder cancer diagnosed in Australia in 2010 and 
1031 deaths occurred in 2011. Both incidence and mortality of bladder cancer is 
expected to grow higher (AIHW and AACR, 2012). 
Age is a major risk factor for bladder cancer. It is rare under the age of 50 years but 
thereafter the risk increases with age. The overall median age at diagnosis is 70 years 
in men and women combined (Sexton et al., 2010). Gender is another important risk 
factor, with males having approximately three to four times higher risk of developing 
bladder cancer compared to women and the worldwide age standardised incidence 
rate is 10.1 per 100,000 for men and 2.5 per 100,000 for women (Ploeg et al., 2009). 
Its incidence is particularly high in industrialised countries mainly because of its 
association with tobacco use and exposure to industrial carcinogens. Evidence 
suggests that there are particular occupations that are at higher risk of developing 
bladder cancer than others. For example, people working in rubber, metal and mining 
industries as well as painters, leather workers and truck drivers have been identified 
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as having higher risks. Tobacco use is one of the most prominent risk factor for 
bladder cancer. Smokers have up to a 4-fold increased risk of developing bladder 
cancer compared with patients who have never smoked (Sexton et al., 2010). 
 
Types and Histology of bladder cancer 
The majority of bladder cancer patients (approximately 75-85%) initially present 
with a disease that is non-muscle invasive bladder cancer (NMIBC) of which 15% to 
25% progress to muscle invasive bladder cancer or metastatic disease (Babjuk et al., 
2011; Botteman et al., 2003). The most common type of bladder cancer is 
transitional cell carcinomas (TCC), accounting for approximately 90% of patients 
with bladder cancer (Avritscher et al., 2006; Sexton et al., 2010). Whereas 5% have 
squamous cell carcinomas and 1% to 2% have adenocarcinomas (Table 1.1) (Sexton 
et al., 2010).  
Table 1.1: Bladder tumour histologies (Sexton et al., 2010). 
Malignant  
 
Transitional cell carcinoma (TCC) 
Pure TCC 
TCC with mixed features (squamous or glandular differentiation) 
Micropapillary 
Nested 
Lymphoepithelioma-like 
Squamous cell carcinoma 
Adenocarcinoma (primary bladder) 
Small cell carcinoma 
Carcinosarcoma (mixed epithelial and mesenchymal elements) 
Sarcomatoid (epithelial elements only) 
 
Classification of bladder cancer 
Classification of bladder cancer plays an important role in determining the 
appropriate treatment strategy and also predicting outcomes for patients. Tumour, 
Node, Metastasis classification (TNM) approved by the Union International Contre 
Le Cancer (UICC) has been widely accepted for classifying stagging of bladder 
cancer. In general, the extent of tumour tissue invasion is defined from stage TX to 
stage T4 (Table 1.2). Non-muscle invasive bladder cancers which are confined to the 
first two layers of the bladder: epithelium and suburothelium (lamina propria) 
includes stage Ta, T1 and Tis. Muscle invasive bladder cancer is defined as tumours 
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that invade the detrusor smooth muscle or beyond (stage T2 to T4) (Botteman et al., 
2003). There has been a change in the WHO grading of bladder cancer with the 2004 
grading system incorporating a range of histologic descriptions such as Urothelial 
Carcinoma in situ (CIS), urothelial papilloma (completely benign lesion), and 
papillary urothelial neoplasm of low malignant potential (PUNLMP), rather than the 
previous three grades of well (Grade 1), moderately (Grade 2) or poorly 
differentiated (Grade 3) papillary urothelial carcinoma (Table 1.3). 
 
Table 1.2: 2009 TNM classification of urinary bladder cancer (Babjuk et al., 2011) 
T – Primary tumour 
 
Tx Primary tumour cannot be assessed  
T0 No evidence of primary tumour 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: ‘flat tumour’ 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invade muscle 
 T2a Tumour invades superficial muscle (inner half) 
 T2b Tumour invades deep muscle (outer half) 
T3 Tumour invades perivesical tissue 
 T3a Microscopically 
 T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall,     
             abdominal wall 
 T4a Tumour invades prostate, uterus or vagina 
 T4b Tumour invades pelvic wall or abdominal wall 
 
Table 1.3: WHO grading in 1973 and in 2004 (Babjuk et al., 2011) 
1973 WHO grading 
 
Urothelial papilloma 
Grade 1:     well differentiated 
Grade 2:     moderately differentiated 
Grade 3:     poorly differentiated  
2004 WHO grading 
 
Flat lesions 
Hyperplasia (flat lesion without atypia or papillary aspects) 
Reactive atypia (flat lesion with atypia) 
Atypia of unknown significance  
Urothelial dysplasia  
Urothelial Carcinoma in situ (CIS) 
Papillary lesions 
Urothelial papilloma (completely benign lesion) 
Papillary urothelial neoplasm of low malignant potential (PUNLMP) 
Low-grade papillary urothelial carcinoma  
High-grade papillary urothelial carcinoma 
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Symptoms and Diagnosis of bladder cancer 
Painless haematuria is the single most common symptom presenting in patients with 
bladder cancer that alerts patients to seek medical advice. Additionally, irritative 
lower urinary tract symptoms such as urgency, increased urinary frequency and 
dysuria are also common but are more predominant in patients with CIS or invasive 
disease (Sexton et al., 2010). 
For several decades, standard white light cystoscopy (WLC) has been used to detect 
and resect bladder tumours (Figure 1.1); however advances in technologies have 
improved the quality of cystoscopy and transurethral resection of bladder tumour 
(TURBT) (Cheung et al., 2013). Photodynamic diagnosis/blue-light cystoscopy 
(PDD/BLC) improves the detection rates for inconspicuous bladder cancer by 
instilling 5-aminolevulinic acid (5-ALA) dye or its hexyl ester hexaminolevulinate 
(HAL) into the bladder. The dye is absorbed by dysplastic tissue, enabling 
photosensitisation in which the abnormal tissue emits a red colour under blue 
reference light and normal tissue appears blue. PDD/BLC is recommended during 
initial TUBRT to aid diagnosis, and in patients with positive urine cytology but 
negative WLC results (Mowatt et al., 2011; Witjes et al., 2010). Narrow-band 
imaging (NBI) cystoscopy without the use of dyes, improves the fine structure of 
bladder mucosal surface via deeper penetration enabled by the longer wavelength of 
light (Herr and Donat, 2008). The most widely used non-invasive test is urine 
cytology. While urine cytology has good specificity and sensitivity for the detection 
of high-grade tumours, it has not been adopted into routine standard of care, owing to 
poor sensitivity for low-grade tumours and expense (Cheung et al., 2013). Also, 
many urine biomarker tests for detecting bladder cancer have been developed, 
including Fluorescence in situ hybridisation (FISH) that detects urinary cells that 
have chromosomal abnormalities consistent with a diagnosis of bladder cancer 
(Junker et al., 2003), and nuclear mitotic apparatus protein (NMP) 22 which is a 
marker that can be detected in voided urine (Shariat et al., 2011).  
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Figure 1.1: Illustration of how cystoscope is inserted through the urethra into the bladder to 
view the inner wall of the bladder on a computer monitor (Terese Winslow, 2010). 
 
Treatment of bladder cancer 
Transurethral resection of bladder tumour (TURBT) 
For the initial management of non-muscle invasive bladder cancer, transurethral 
resection of bladder tumour (TURBT) is performed. Any visible tumours are 
resected using electrodes or laser during TURBT (Sexton et al., 2010). The 
information on the number of tumours, tumour size, tumour grade, the depth of 
invasion and prior recurrences collected during this procedure provide important data 
for risk stratification (Logan et al., 2012). Muscle-invasive bladder cancer requires 
more intensive therapy than non-muscle invasive bladder cancer. Generally, patients 
with muscle-invasive bladder cancer undergo a ‘radical cystectomy’, removal of the 
bladder and some surrounding organs such as uterus or prostate (Fry et al., 2010). 
Systemic chemotherapy where drugs are administered intravenously may be 
recommended as a treatment following a radical cystectomy (Hazard et al., 1952).  
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Intravesical treatment 
Although TURBT can effectively remove a tumour completely, the high rate of 
recurrence and progression after TURBT necessitates the consideration of adjuvant 
treatments in all patients. The recurrence rates range from 48% to 70% and 
progression occurs between 7% and 40% of the time depending on tumour 
characteristics (Logan et al., 2012). Hence, after TURBT, patients receive treatment 
called an ‘intravesical treatment’ to reduce the re-implantation of tumour cells after 
TURBT, eradicate any residual disease, prevent tumour recurrence and reduce 
tumour progression.  Intravesical treatment involves instillation of a therapeutic 
agent directly into the bladder via a catheter (Duque and Loughlin, 2000; Herr et al., 
1995) (Figure 1.2). 
 
Figure 1.2: Diagram showing how intravesical agent is administered into the bladder 
(Cancer Research UK, 2013).  
 
A study by Sylvester et al. (2004) found that one immediate postoperative instillation 
of chemotherapy after TURBT significantly reduced recurrence rate compared to 
TURBT alone from 48.4% to 36.7% (the reduction was 11.7%). Hence, guidelines 
published by the European Association of Urology (EAU) recommend one 
immediate postoperative dose of intravesical chemotherapy at the time or soon 
Copyright © Cancer Research UK  
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(within 6 hours) after resection of suspected non-muscle invasive bladder cancer 
(Babjuk et al., 2011). However, an immediate postoperative instillation has to be 
avoided when there is overt or even suspicion of bladder wall perforation, since 
severe morbidity may occur if leakage outside the bladder into retroperitoneal or 
intraperitoneal space happens.  
An additional adjuvant intravesical therapy is performed after TURBT. For at least 
six consecutive weeks, bladder cancer patients receive a weekly instillation of 
immunomodulatory or chemotherapeutic agents. Therapy is initiated approximately 2 
to 4 weeks following the patient’s TURBT and each instillation is performed for 
approximately 1 to 2 hours (Sexton et al., 2010). The most commonly used agents for 
intravesical chemotherapy and immunotherapy includes doxorubicin, epirubicin, 
mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG). 
Intravesical chemotherapy is an excellent targeted approach delivering effective 
concentrations of cytotoxic agents directly to the affected bladder lining. 
Administration of the drug through the urethra directly to the lumen of the bladder 
effectively minimizes systemic exposure to these toxic agents however there is 
evidence of local side effects (Dalton et al., 1991).  
There is an extensive research effort focused on the enhancement of the toxicity of 
intravesical agents. Some examples include combination of intravesical 
chemotherapy with local hyperthermia or the use of nanocarriers (i.e. liposomes and 
solid lipid nanoparticles) for drug delivery (GuhaSarkar and Banerjee, 2010). 
However, there have been few studies that have assessed the effects of intravesical 
chemotherapeutic agents on normal bladder function. This is the focus of this thesis. 
 
Intravesical immunotherapy 
Intravesical use of the immunotherapeutic agent, Bacillus Calmette-Guerin (BCG) 
was first reported to be successful in treating superficial bladder cancer in 1976 by 
Morales et al. (1976). Intravesical BCG treatment is considered as the most 
successful immunotherapy to date (Chapman and Houghton, 1993; Ratliff et al., 
1991) and is proven to be highly effective treatment for patients with intermediate- 
and high-risk non-muscle invasive bladder cancer (Babjuk et al., 2011; Brausi et al., 
2011).  An initial intravesical treatment with BCG for bladder cancer is 
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recommended by both the American Urological Association and European 
Association of Urology (Lightfoot et al., 2011).   
The incidence of side effects is one of the main reasons why clinicians try to avoid 
the use of BCG. Intravesically administered BCG are generally well tolerated, 
however local and systemic adverse effects are reported to be more severe and more 
frequent compared with intravesical chemotherapy. During induction therapy, 5% of 
patients had to stop and 20% of patients stopped during maintenance therapy (van 
der Meijden et al., 2003). A study by Lamm et al. (1991) has reported that in patients 
with Ta and T1 tumours without carcinoma in situ, the probability of being disease 
free at 5 years was 17% after intravesical doxorubicin, as compared with 37 percent 
after intravesical BCG (P<0.05). The median times to treatment termination due to 
persistence (treatment failure), recurrence or progression of disease were 10.4 and 
22.5 months, respectively. For patients with carcinoma in situ the estimated 
probability of documented disappearance of disease were 34% for doxorubicin (23 of 
67 patients) and 70% for BCG (45 of 64 patients) (P<0.001). The median times to 
treatment failure were 5.1 and 39 months, respectively. The probability of being 
disease free at 5 years’ survival was 18% and 45% respectively. Patients treated with 
BCG observed a higher incidence of toxic systemic effects and local irritative 
bladder symptoms than patients treated with doxorubicin.   
The therapeutic mechanisms of BCG is under investigation; however available 
evidence suggests that an intact immune system, particularly the cellular system, is 
required for its antitumour activity (Prescott et al., 2000). Therefore, for elderly 
patients and in individuals who have impaired immune function, this agent is not an 
option (Heiner and Terris, 2008). Hence, chemotherapeutic agents such as 
doxorubicin, MMC and epirubicin are also commonly used for the treatment of 
bladder cancer as an alternative treatment option if immunotherapy fails or is 
ineffective (Lightfoot et al., 2011; Matsui et al., 2010).  
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Intravesical chemotherapy  
Doxorubicin, mitomycin C (MMC) and epirubicin are the most widely used 
intravesical chemotherapeutic agents for the treatment of bladder cancer. Hence, they 
were used as representative chemotherapeutic agents for this research study where 
their effects on normal bladder function were assessed.  
 
Doxorubicin 
Doxorubicin (commercial name, Adriamycin) is a common chemotherapeutic drug 
for the treatment of bladder cancer and is classified as an anthracycline antibiotic 
(isolated from cultures of Streptomyces peucetius var. caesius) (Burden, 1998; 
Burden et al., 1998) which is composed of an aglycone and a sugar. The aglycone 
(doxorubicinone) consists of a tetracyclic ring with adjacent quinone-hydroquinone 
moieties and a short side chain with a carbonyl group (Salvatorelli et al., 2006). The 
sugar (daunosamine) is an amino-substituted trideoxy fucosyl moiety (Figure 1.3). 
Doxorubicin is also used systemically in the treatment of other types of cancer 
including acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, 
neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, 
transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's 
disease, malignant lymphoma, and bronchogenic carcinoma (Fornari et al., 1994).  
 
 
Figure 1.3: Structures of anthracyclines in current clinical use: (1) doxorubicin, (2) 
idarubicin, (3) daunorubicin, and (4) epirubicin (Cutts et al., 2005). 
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The most commonly used clinical dose of intravesical doxorubicin is 50mg in 50mL 
of saline retained in the bladder for 1 hour (Cheng et al., 2005; Cheng et al., 2004; 
Ilett et al., 1990). 
Due to the high molecular weight of doxorubicin (580kd), systemic side effects are 
rare but the major systemic adverse effects which may limit its use is cardiotoxicity. 
The incidence of acute cardiotoxicity is approximately 11%, usually observed as 
chest pain due to myopericarditis and/or palpitations (Swain et al., 2003; Takemura 
and Fujiwara, 2007). The incidence of chronic doxorubicin cardiotoxicity 
(cardiomyopathy and arrhythmias) is much lower with estimated incidence of about 
1.7% (Von Hoff et al., 1979). Systemic use of doxorubicin is also reported to be 
causing myelosuppression in some patients (Bally et al., 1990). Local side effects are 
relatively common in patients following intravesical treatment. Chemical cystitis 
presenting with symptoms such as dysuria (painful urination), increased urinary 
frequency and also hematuria (blood in the urine) are the most common side effects 
of doxorubicin (Badalament and Farah, 1997; Duque and Loughlin, 2000). An in 
vivo study using mice by Post et al. (1995) has shown a transient 3-fold increase in 
the urinary frequency induced by doxorubicin. Furthermore, intravesically 
administered doxorubicin has been reported to cause bladder toxicity in 13 to 56% of 
patients (Thrasher and Crawford, 1992). In a report by Ausfeld et al. (1987), 6.6% of 
patients treated with doxorubicin stopped the treatment due to toxicity.  
The mechanism of action for doxorubicin and other anthracyclines have been 
extensively studied during the last several decades, but the mechanism still remains 
unclear and controversial (Yang et al., 2014). One of the potential mechanisms by 
which doxorubicin exert its cytotoxic effects on cancer cells is its action as 
topoisomerase II poison which targets topoisomerase II enzyme to induce apoptosis 
of cells. In addition, intercalation of doxorubicin and the formation of DNA adducts 
at active promoters, which increase stress and enhance nucleosome turnover, is 
another potential mechanism of doxorubicin-mediated cell death. Furthermore, 
doxorubicin also results in the generation of reactive oxygen species (ROS) which 
can damage DNA and cause cell death (Figure 1.4) (Yang et al., 2014).  
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Figure 1.4: Graphical illustration of the potential mechanisms of doxorubicin-mediated cell 
death which includes poisoning of topoisomerase II enzyme, generation of reactive oxygen 
species, intercalation of doxorubicin and the formation of DNA adducts (Yang et al., 2014). 
 
Doxorubicin along with other anthracyclines is one of the topoisomerase II poisoning 
agents (Nitiss, 2009). Topoisomerases are found in virtually all life forms, from 
bacteria to humans, and they are highly conserved enzymes that regulate DNA 
topology to facilitate DNA replication, transcription, and other nuclear process. 
Topoisomerase II is an ATP-dependent enzyme and there are two isoforms found in 
humans, topoisomerase IIα and topoisomerase IIβ (Pommier et al., 2010). The 
enzyme binds DNA supercoils and entangled DNA, breaks both strands of one DNA 
duplex (called the ‘gate’ or G segment), passes the other DNA duplex (called the T 
segment) through this transient cleavage and reseals the break. This process results in 
the release of torsional stress formed during biological processes such as DNA 
replication and transcription (Liu et al., 1983; Pommier et al., 2010; Tewey et al., 
1984; Wang, 1996). Doxorubicin interferes with enzymatic DNA breakage-reunion 
by trapping topoisomerase II on DNA in a covalently bound state (Capranico and 
Zunino, 1992; Liu, 1989; Tewey et al., 1984). The complex composed of enzyme, 
drug, and DNA has been termed the ‘cleavable complex’ because its disruption with 
detergent results in DNA double strand-break and covalent attachment of each 
subunit in the topoisomerase II homodimer, one to each 5’ phosphate end via a 
phosphotyrosyl linkage (Capranico and Zunino, 1992; Deffie et al., 1989; Liu, 1989). 
This stabilizes the cleavage complex and impedes religation of cleaved duplex, a 
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lesion that results in a DNA double-strand break. An apoptotic response occurs when 
these DNA double-strand break are not repaired (Liu et al., 1983; Tewey et al., 1984; 
Wu et al., 2011). Thus, the interaction of doxorubicin with topoisomerase II to form 
DNA-cleavable complexes appears to be an important mechanism of doxorubicin 
cytocidal activity (Fornari et al., 1994; Momparler et al., 1976). In addition, 
decatenation of DNA during mitosis is topoisomerase II specific reaction, therefore 
doxorubicin which poisons topoisomerase II prevents cytokinesis resulting in cell 
death (Carpenter and Porter, 2004). The cytocidal activity of doxorubicin on cancer 
cells is most likely to be due to its effects on dividing cells by topoisomerase IIα 
whereas, cytotoxic effect of doxorubicin on normal cells which causes heart muscle 
failure is a side effect resulting from damage to non-dividing cells by topoisomerase 
IIβ. It has been shown that cardiomyocyte-specific deletion of topoisomerase IIβ 
protected mice from developing heart failure induced by doxorubicin (Zhang et al., 
2012a). Also, topoisomerase II inhibitors have been shown to protect cardiomyocytes 
from doxorubicin-induced toxicity (Vavrova et al., 2013). These findings suggest 
that trapping topoisomerase II by doxorubicin especially topoisomerase IIβ in non-
dividing heart cells may be responsible for doxorubicin-induced cardiotoxicity (Yang 
et al., 2014).  
Doxorubicin-DNA adducts were originally characterised in a cell-free activation 
system, where transcriptional blockages induced by doxorubicin were observed at 5′ 
GpC sequences (Cullinane and Phillips, 1990), demonstrating that doxorubicin 
formed covalent adducts with DNA at these sites (Swift et al., 2006). Doxorubicin 
which is a DNA intercalator prefers the intercalation site containing adjacent GC 
base pairs. This may be due to formation of specific hydrogen bond between 
doxorubicin and guanine (Chaires et al., 1987; Chaires et al., 1990; Chen et al., 1986). 
Doxorubicin-DNA adducts have been shown to activate DNA damage responses and 
induce cell death that are independent of topoisomerase II (Forrest et al., 2012; Swift 
et al., 2006). Further analysis of the cell-free activation system used to form adducts 
has shown that formaldehyde was a byproduct of the reaction conditions (Taatjes et 
al., 1997). Doxorubicin-DNA adducts can be stabilised by a covalent bond mediated 
by cellular formaldehyde that is generated by free radical reactions from carbon 
sources such as lipids and spermine (Taatjes et al., 1996, 1997). This interaction 
involves formation of a covalent bond between 3′ amino group of doxorubicin and 
the N2 of guanine on one strand of DNA mediated by formaldehyde and of a 
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hydrogen bond between doxorubicin and guanine on the opposing strand of DNA 
(Figure 1.5) (Kato et al., 2000; Kato et al., 2001; Taatjes et al., 1997). A study by 
Coldwell and his colleagues (2008) has demonstrated that doxorubicin-DNA adducts 
are detectable at clinically relevant drug concentrations. Despite the evidence of 
DNA adducts formation during doxorubicin treatment, the major mechanism of 
cytocidal action of doxorubicin is unlikely to be due to formation of DNA adducts 
since clinical doses result in only 4.4±1.0 adducts/107 base pair DNA, which 
accounts for just a small fraction of total doxorubicin (Coldwell et al., 2008). 
Furthermore, it has been shown that preactivated form of doxorubicin, doxoform can 
be produced by formaldehyde which consists of two doxorubicin molecules bound 
together with three methylene groups (Fenick et al., 1997). Doxoform is 
approximately 200-fold more cytotoxic than doxorubicin alone, displays an 
accelerated uptake by cells, is retained longer in nucleus, and is particularly cytotoxic 
to doxorubicin-resistant cell line (Fenick et al., 1997; Taatjes et al., 1999). 
  
 
Figure 1.5: Structure of the doxorubicin-DNA complex. (a) Doxorubicin forms a covalent 
bond (shown in red) with guanine on one strand of DNA mediated by formaldehyde and 
hydrogen bonds with guanine on the opposing strand. (b) A structure of intercalation of 
doxorubicin into DNA. Doxorubicin intercalates into DNA and pushes apart the flanking 
base pairs with the sugar moiety sitting in the minor groove (Yang et al., 2014). 
 
Doxorubicin-mediated generation of reactive oxygen species (ROS) has been 
discussed as one of the possible mechanisms of cytocidal effects of doxorubicin on 
both cancer cells and normal cells (for example doxorubicin causes cardiotoxicity) 
(Figure 1.4). Several mechanisms by which doxorubicin induce generation of ROS 
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have been proposed. The quinone structure of doxorubicin is prone to the generation 
of ROS through enzymatic mechanism utilizing mitochondrial respiratory chain and 
non-enzymatic pathway, which incorporates iron (Gutierrez, 2000; Shadle et al., 
2000). The quinone moiety of doxorubicin can be oxidised to a semiquinone radical 
through one-electron reduction mediated by several enzymes including cytochrome 
P450 reductase, NADPH dehydrogenase, endothelial nitric oxide (NO) synthase and 
xanthine oxidase (Berlin and Haseltine, 1981; Childs et al., 2002; Davies and 
Doroshow, 1986; Fogli et al., 2004; Kostrzewa-Nowak et al., 2005; Menna et al., 
2007; Minotti et al., 2004; Pawlowska et al., 2003; Ravi and Das, 2004). Once 
semiquinone radical has been generated, it can quickly react with oxygen to generate 
reactive oxygen species including superoxide and hydrogen perioxide to causing 
DNA damage (Berlin and Haseltine, 1981; Minotti et al., 2004) or be oxidised back 
to the quinone form (Ramji et al., 2003). Hence, release of free radicals induced by 
doxorubicin may cause oxidative stress, resulting in DNA damage and cell death 
(Thorn et al., 2011).  
It has been postulated that doxorubicin may cause cardiotoxicity via both depression 
of cardiac antioxidant levels, particularly glutathione peroxidase, and increased 
generation of oxygen free radical, thereby overwhelming the limited cardiac defence 
system (Doroshow and Davies, 1983). However, a study by Alderton et al. (1992) 
has demonstrated that neither doxorubicin nor doxorubicin in conjunction with 
cardioprotective agent (ICRF-187) caused any significant effect on the cardiac 
antioxidant capacity of mice. Thus, it appears that doxorubicin cause cardiac damage 
via the generation of oxygen free radicals rather than depression of antioxidant 
defences. In addition, doxorubicin which is an iron chelator can strongly bind iron 
through its quinone-hydroquinone functional groups and this complex catalyses the 
conversion of hydrogen peroxide to highly reactive hydroxyl radicals (Myers, 1998; 
Swain et al., 1997). Furthermore, doxorubicin has been reported to be inducing 
generation of ROS via alteration of Ca2+ homeostasis (Kim et al., 2006c). It has been 
demonstrated that doxorubicin-mediated ROS generation and apoptosis are inhibited 
by reducing intracellular Ca2+ levels using Ca2+ chelator (Kalivendi et al., 2005; 
Kalivendi et al., 2001). Also, doxorubicin has been reported to increase the open 
probability of sarcoplasmic reticulum (SR) calcium release channels (Kim et al., 
1989; Zorzato et al., 1985), inhibits Na+-Ca2+ exchanger (Caroni et al., 1981), or 
activates L-type cardiac calcium channel (Keung et al., 1991). These effects of 
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doxorubicin on Ca2+ channels can result in Ca2+ overload of cardiac cells that may 
lead to mitochondrial calcium overloading, causing alteration of energy metabolism 
and generation of ROS (Kim et al., 2006c).  To protect patients treated with 
doxorubicin from cardiotoxicity, free radical scavengers have been used but many of 
them failed. This suggest that free radical formation is not the only mechanism of 
cardiotoxicity (De Beer et al., 2001). 
 
Epirubicin  
Epirubicin (commercial name, Ellence) is another anthracycline drug which is a 
modern derivative (epimer) of doxorubicin. Epirubicin differs from doxorubicin in an 
axial-to-equatorial epimerisation of the hydroxyl group at C-4′ in daunosamine (the 
sugar) (Figure 1.6) (Salvatorelli et al., 2006). This drug is favoured over doxorubicin, 
the most popular anthracyclines, in some chemotherapy regimens because it has an 
equivalent spectrum of antitumor action to that of doxorubicin but exhibits less 
systemic and cardiac toxicity (El-Mahdy Sayed Othman, 2000; Perreault et al., 2013; 
Smith et al., 2010).  
 
Figure 1.6: The chemical structure of epirubicin (Cutts et al., 2005). 
 
It is commonly used as an intravesical chemotherapeutic agent for the treatment of 
bladder cancer (Onrust et al., 1999) and is also used to treat various types of cancer, 
including breast cancer, ovarian cancer, stomach cancer, lung cancer, bowel cancer, 
myeloma and some types of lymphoma and leukaemia (Cersosimo and Hong, 1986; 
Coukell and Faulds, 1997; Muggia and Green, 1991; Vermorken et al., 1999). After 
intravenous administration to patients, depending on dose, epirubicin causes bone 
marrow depression (decrease in erythrocyte, leukocyte and thrombocyte in blood) as 
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well as nausea, vomiting, diarrhea, lack of appetite and cardiac toxicity (Ulakoglu 
and Altun, 2004).   
The common dosage of intravesical epirubicin is 50mg in 50mL of saline retained in 
the bladder for 1 hour. The dose can be increased to 80mg in patients with carcinoma 
in situ (Onrust et al., 1999). The concentrations of epirubicin and durations of 
treatment tested in the studies described in this thesis are based on these clinical 
values. 
Major adverse effects associated with intravesical epirubicin were localised to the 
bladder which included chemical cystitis, urinary tract infection and haematuria. In 
addition, contracted bladder and haemorrhagic cystitis occurred in a few trials. 
Systemic adverse events after intravesical epirubicin were not reported in many trials 
(cardiac, haematological or related to hypersensitivity) (Hendricksen et al., 2008; 
Onrust et al., 1999).  
The exact mechanisms of antitumor action of epirubicin have not been completely 
elucidated. Cytotoxic activity of epirubicin is active in all phases of the cell cycle and 
it is most active in the S and G2 phases (Coukell and Faulds, 1997; Ozcan et al., 
1997). It was demonstrated that epirubicin extended the duration of meiotic divisions 
in mouse spermatocytes for 48 hour (Attia et al., 2014). Therefore, this observation 
supports previous findings that inhibition of topoisomerase II function induced by 
epirubicin during different phases of the cell cycle slows down cell cycle progression 
and causes cells to arrest at the G2/M phase (Coukell and Faulds, 1997). Epirubicin 
like its parent drug, doxorubicin is also a topoisomerase II poison. Topoisomerase II 
normally functions during the process of DNA replication to produce transient 
double strand breaks in the replicating DNA to relieve torsional stress, and reseals 
the break (Liu et al., 1983; Pommier et al., 2010; Tewey et al., 1984; Wang, 1996). 
Epirubicin interferes with this enzymatic DNA breakage-reunion by trapping 
topoisomerase II on DNA in a covalently bound state to form the drug-DNA-
topoisomerase II ternary complex, which is called the cleavable complex. Thus, 
epirubicin inhibits the resealing of DNA breaks creased by topoisomerase II, 
resulting in cytocidal activity (Cantoni et al., 1989; Niitsu et al., 2000; Plosker and 
Faulds, 1993; Spadari et al., 1986).  
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The other mechanism of epirubicin’s cytotoxicity is intercalation of epirubicin 
between DNA base pairs which leads to the inhibition of DNA replication and 
transcription (Lollini et al., 1989; Piestrzeniewicz et al., 2004; Skladanowski and 
Konopa, 1994; Wilmanska et al., 2001). Epirubicin also interferes with DNA 
unwinding or DNA strand separation and helicase activity. In addition, epirubicin 
induces generation of free radicals leading to DNA damage or lipid peroxidation 
(which results in cell damage) (Cantoni et al., 1989; Minotti et al., 2004). Also, a 
study by Malisza and Hasinoff (1995) demonstrated that epirubicin, bound to Fe (III), 
can produce highly reactive hydroxyl radical by enzymatic and non-enzymatic 
mechanism.  
Epirubicin was found to be less toxic than doxorubicin in animal models (Alderton et 
al., 1992; Llesuy et al., 1990; Robert, 2007) and also less cardiotoxicity for 
epirubicin was demonstrated in some in vivo studies (Dardir et al., 1989; Weiss, 
1992). The dose of epirubicin equicardiotoxic to 1mg of doxorubicin has been 
reported to be 1.8mg for cardiac symptoms and 2.2mg for injury on endomyocardial 
biopsies (Henderson et al., 1982). However, meta-analysis of randomised clinical 
trial data conducted by van Dalen and his colleagues (2010) concluded that there was 
no significant difference between occurrence of clinical heart failure between 
doxorubicin and epirubicin. The exact reason why epirubicin is less cardiotoxic than 
doxorubicin is unknown but it may be associated with its ability to yield oxygen free 
radicals and/or its stimulation of lipid peroxidation. Studies using acute and chronic 
models which measured endogenous lipid peroxidation and hydroperoxide-intiated 
chemiluminescence demonstrated that the hearts exhibited less oxidative stress for 
epirubicin compared with doxorubicin (Llesuy et al., 1990; Llesuy et al., 1985). 
However, other investigations have been unable to find any difference in the ability 
to generate superoxide anions (Grankvist and Henriksson, 1987) or promote lipid 
peroxidation (Vile and Winterbourn, 1989) between the two anthracyclines. A study 
by Alderton et al. (1992) has demonstrated that neither epirubicin nor epirubicin in 
conjunction with cardioprotective agent (ICRF-187) caused any significant effect on 
the cardiac antioxidant capacity of mice. Therefore, it is likely that epirubicin causes 
cardiac damage by the generation of oxygen free radical rather than compromised 
antioxidant defences.  
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Alternatively, it has been discussed in the previous section that doxorubicin may be 
cardiotoxic by altering cardiac calcium concentrations (Kim et al., 2006c). Epirubicin 
causes less inhibition of calcium turnover in cultured heart cells (Villani et al., 1980) 
and less inhibition of Na+-Ca2+ pump (Caroni et al., 1981) compared to doxorubicin, 
which may explain its lower cardiotoxicity. Another contributing factor for lower 
cardiotoxicity of epirubicin may be the fact that it has different pharmacokinetic 
properties compared to doxorubicin. The minor structural difference compared to 
doxorubicin makes epirubicin a much better substrate than doxorubicin for human 
liver UDP-glucuronosyltransferase-2B7 (UGT2B7) (Dardir et al., 1989). Unlike 
doxorubicin, epirubicin undergoes glucuronidation (Torti et al., 1986). 
Glucuronidation, which transfers a highly hydrophilic glucuronide group to 
hydrophobic substrates, is a major detoxification pathway for numerous endo- and 
xenobiotics. The resulting glucuronide products are generally more easily excreted in 
bile and urine and less toxic than the initial molecules (Dardir et al., 1989).  
 
Mitomycin C 
The mitomycins are a group of highly potent antibiotics first isolated in 1950’s in 
Japan from Streptomyces caespitosus (Hata et al., 1956). Currently 17 mitomycins 
are known and sixteen of the known mitomycins have shown broad spectrum 
antibiotic and potent antitumor activity. One particular member of the family, 
mitomycin C (MMC) (commercial name, Mutamycin/Ametycine), has been used 
clinically for cancer chemotherapy since the 1960’s. It is currently one of the most 
important cytotoxic drugs in the treatment of cancer due to having a wide clinical 
antitumour spectrum with efficacy in various tumour types including gastric cancer, 
pancreatic cancer, breast cancer, non-small cell lung cancer, cervical cancer, prostate 
cancer and bladder cancer (Rjiba-Touati et al., 2014; Verweij and Pinedo, 1990).  
The most commonly used clinical dose of intravesical MMC is 40mg in 40mL of 
sterile water administered for 1 to 2 hours. Higher concentrations may show 
additional benefit (Logan et al., 2012). A study by Au et al. (2001) showed that 
higher concentration of MMC (40mg in 20mL) improved its efficacy with only 
dyuria occurring more frequently compared to the patients treated with normal dose 
of MMC (20mg/20mL), but did not lead to more frequent treatment termination.   
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Owing to the high molecular weight (334 kDa) of MMC, systemic absorption is low 
and hence, systemic reactions are uncommon (Pashos et al., 2002). It has been 
reported that only 3% of intravesically administered MMC reaches the urothelium 
(Wientjes et al., 1993). However, common adverse side effects associated with the 
systemic use of MMC include bone marrow toxicity (thrombocytopenia and 
leukocytopenia), with cardiotoxicity (congestive heart failure), nephrotoxicity 
(haemolytic uremic syndrome), pulmonary toxicity (pneumonitis) and hepatotoxicity 
occurring less frequently (Rjiba-Touati et al., 2014; Verweij and Pinedo, 1990). The 
adverse effects associated with intravesical MMC are confined to local site.  
Chemical cystitis has been reported in 41% of patients which includes dysuria, 
increased urinary urgency and frequency, suprapubic pain and discomfort (Kamat 
and Lamm, 2000). In addition, decreased bladder volume and a contracted bladder 
have been reported in patients (Duque and Loughlin, 2000; Kim and Lee, 1989). 
These cases are consistent with the finding by Michielsen et al. (2005) which 
observed decreased volume and compliance of the bladder in mice treated with 
MMC. Three weeks after the cessation of therapy recovery of bladder function was 
not observed in MMC treated mice (Michielsen et al., 2005). There have also been 
reports of allergic skin reactions and myelosuppression, which is rare (Koya et al., 
2006; Sylvester et al., 2002).  
MMC itself as a prodrug does not have significant cytotoxicity. However, upon 
enzymatic or chemical reductive activation, highly reactive monofunctional and 
bifunctional DNA-alkylating agents (six covalent DNA adducts) are formed which 
can cause lethal intrastrand and interstrand DNA cross-links (Bargonetti et al., 2010; 
Tomasz and Palom, 1997). The intracellular activation of MMC is catalysed by 
endogenous flavoreductases and proceeds by either anaerobic one electron reduction 
or oxygen-independent two-electron reduction. Various enzymes that are capable of 
activating MMC have been characterised within the cells. These includes NADPH 
dehydrogenase, quinone 1(NQO1; DT-diaphorase) (Siegel et al., 1992; Siegel et al., 
1990) and xanthine dehydrogenase (Gustafson and Pritsos, 1992) which are able to 
activate MMC by a two-electron reduction. Also, NADPH-cytochrome P450 
reductase, xanthine oxidase (Pan et al., 1984) and cytochrome b5 reductase (Hodnick 
and Sartorelli, 1993) are responsible for one-electron reduction. Degree of toxicity 
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can vary depending on whether MMC undergoes one- or two-electron reduction 
(Snodgrass et al., 2010). 
 
Figure 1.7: The reductive activation of mitomycin C (MMC). Reduction of the quinone of 
MMC initiates a cascade of spontaneous transformations that results in the production of 
quinone methide (2). When compound 2 reacts with a DNA nucleophile at C1 (to from 
adduct 3), a second alkylating center develops at C10 by reverse Michael elimination of the 
carbamate (adduct 4). Adduct 4 is attacked by another DNA nucleophile to give the 
reoxidised DNA crosslink (adduct 5) (Tomasz, 1995). 
 
A key step in both routes is the enzymatic reduction of the quinone moiety of MMC, 
which initiates a cascade of spontaneous transformations that result in the production 
of quinone methide (2) which has high alkylating reactivity at the C1 position 
(Cummings et al., 1998; Spanswick et al., 1998). Adduct 3 is formed when 
compound 2 reacts with a DNA nucleophile at C1. During this process, second 
alkylating center develops at C10 by reverse Michael elimination of the carbamate 
and forms adduct 4. Adduct 4 is attacked by another DNA nucleophile to give the 
reoxidised DNA crosslink (adduct 5) (Figure 1.7) (Moore, 1977; Szybalski and Iyer, 
1964; Tomasz, 1995; Tomasz and Lipman, 1981; Tomasz et al., 1987). The fact that 
MMC is activated by reduction plays significant role in the selectivity of its 
antitumour activity. Many solid tumours compared to normal tissues are in shortage 
of oxygen. As activation of MMC is inhibited by an oxidizing environment, toxicity 
of MMC is selective for these hypoxic solid tumours, and potently inhibits their 
growth (Sartorelli et al., 1994). 
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Figure 1.8: Chemical structure of six major adducts of reductively activated MMC 
(Bargonetti et al., 2010). 
 
The structures of six major adducts of reductively activated MMC are shown in 
Figure 1.8. The first alkylation step by the quinone methide leads to MMC 
monoadducts (1″-α isomer) (1a).  In some conditions, this is the only alkylation that 
occurs (Tomasz et al., 1986). Under conditions in which the second alkylating center 
develops, MMC biadducts (1″-α isomer) (3a) is a major product which forms a 
crosslink between the DNA strands (Tomasz et al., 1987). At much lower frequency, 
the second alkylation step also produces another MMC biadduct (4) which forms a 
crosslink with one strand (Bizanek et al., 1992). Decarbamoyl mitomycin C (DMC) 
monoadduct (1″-α isomer) (2a) is also a major product of monofunctional activation, 
and results from nucleophilic attack by water at C10″ position (Tomasz et al., 1988). 
The same adducts have been detected and identified in vivo (Bizanek et al., 1993; 
Tomasz et al., 1987). In addition, monofunctional activation of DNA by the 
metabolite of MMC, 2,7-diaminomitosene (2,7-DAM) forms two adducts, 2,7-
DAM/Gua-N7 (5) and 2,7-DAM/dG-N2 (6) (Palom et al., 1998; Palom et al., 2000).  
 23 
It has been reported that 2,7-DAM is not cytotoxic and does not activate the p53 
pathway (Abbas et al., 2002). Conversely, MMC and DMC are cytotoxic and able to 
activate the p53 pathway (Abbas et al., 2002; Boamah et al., 2007). DMC appears to 
be more cytotoxic than MC and can also kill p53-deficient cells (Abbas et al., 2002; 
Boamah et al., 2007) by inducing degradation of Checkpoint 1 protein, which is not 
seen with MMC treatment of the p53-deficient cells (Boamah et al., 2007).  
The first, monoalkylation step which forms crosslinked adduct is selective for 
guanine nucleosides in the sequence 5′-CpG-3′ (Kumar et al., 1992; Li and Kohn, 
1991) but not dramatically. Alkylation at CpG is on average 5-fold (Kohn et al., 1992) 
or 10-fold (Kumar et al., 1992) enhanced over that at other NpG sequences. In 
contrast, the second step is absolutely selective for a G opposite the C. G residues 
flanking the NpG sequence on the opposite strand are never crosslinked, though 
intrastrand crosslinks can form on NpGpG sequence (Borowy-Borowski et al., 1990; 
Millard et al., 1990; Teng et al., 1989).  
Despite of this direct evidence for MMC-DNA adduct from cell-free or in vitro 
studies, there is evidence suggesting that DNA may not be the primary target of the 
mitomycin C in vivo. Snodgrass and his colleagues (2010) proposed that MMC-
rRNA interactions are more functionally plausible with respect to drug distribution 
and metabolism than the current hypothesis focusing on MMC-DNA interactions.  
Since most enzymes that reduce MMC are located in the cytosol, it suggests that the 
drug activation in vivo is also cytosolic (Snodgrass et al., 2010). Due to the chemical 
similarities to DNA and the relative abundance of RNA in the cytosol, RNA appears 
to be a potential primary cellular site for MMC activation. Also, the fact that rRNA 
constitutes approximately 71% of total cellular RNA in eukaryotes and as well as the 
fact that it contains G/C rich regions for preferred MMC binding (Schmid et al., 1994) 
suggest that rRNA is likely the primary cellular RNA target. It has been speculated 
that MMC rapidly binds 18S rRNA in the cytosol causing degradation and decreases 
levels in the cytosol. Decreases of this magnitude can potentially prevent the 
formation and/or function of ribosomal complexes inducing cell death through 
genome-wide translational silencing (Snodgrass et al., 2010).  
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Economic burden 
Overall, bladder cancer has the highest lifetime treatment costs per patient of all 
cancer (Sievert et al., 2009) and is the 5th most expensive cancer in terms of total 
medical care expenditures, accounting for almost $US3.7 billion (2001 values) in 
direct treatment-related costs in the US (Botteman et al., 2003). The estimated mean 
lifetime cost for treating bladder cancer was determined to be $65,158 in the US and 
the economic burden of bladder cancer is likely to increase as survival rates increase. 
In addition, almost one third of the total mean costs of bladder cancer were attributed 
to the treatment of complications (indirect-treatment related costs) (Avritscher et al., 
2006). Hence, it is important to precisely evaluate the toxic effects of treatments used 
for bladder cancer. The magnitude of the burdens of bladder cancer appears to be 
comparable in other developed countries such as Australia (Botteman et al., 2003). 
Some studies have investigated the systemic and local side effects of 
chemotherapeutic agents on the bladder, but there is still a gap in this field which 
demands that more comprehensive studies be undertaken to determine the effects of 
these drugs on the bladder at a cellular and functional level.  Hence, this study, which 
measured changes in urothelial and detrusor function following drug treatment, was 
the first to our knowledge that assessed the functional effects of the 
chemotherapeutic agents, doxorubicin, MMC and epirubicin on the bladder. 
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The Bladder 
Bladder structure 
The bladder is a hollow, muscular and elastic organ situated below the peritoneum. 
The bladder wall is composed of three distinct layers. An epithelial layer lines the 
internal surface of the bladder and is known as the urothelium. The next layer is 
known as the suburothelium and is composed of the submucosa and lamina propria 
which is richly supplied by blood vessels and nerves and also contains 
myofibroblasts. Immediately underneath this is the detrusor smooth muscle, divided 
into an inner (circular) and outer (longitudinal) tunica muscularis, and the outer 
surface is covered with adventitia.  The control of normal bladder function is 
dependent on the functions of these layers (Figure 1.9) (Birder et al., 2010b).  
The bladder serves its primary role as a short-term storage organ for urine which 
contains waste substances filtered from the kidneys. It is roughly spherical in shape 
and varies in size as it is filled with urine. Normal bladder capacity ranges between 
400 and 600ml, and filling with 150-300ml triggers the first urge to urinate 
(GuhaSarkar and Banerjee, 2010). Maximum urine concentration in human is 1160 
mOsm/kg (Verma et al., 2011). 
 
 
Figure 1.9: (A) Anterior cross section of the bladder. (B) The detrusor muscle of the bladder 
(OpenStax College, 2014). 
Download for free at http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@6.27. 
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Lower urinary system 
The lower urinary system, composed of the bladder and urethra, is distinctive from 
other organ systems. For example, the bladder has only two modes of operation, 
storage and elimination of urine. Thus, many of the neural circuits that are involved 
in bladder control have switch-like or phasic patterns of activity, unlike tonic patterns 
that are characteristics of the autonomic pathways that regulate cardiovascular organs. 
Also, micturition (or urination) occurs voluntarily and depends on learned behaviour 
that develops during maturation of the nervous system, whereas many other visceral 
functions are regulated involuntarily. This process is controlled by the neural 
circulatory which is complex and highly distributed. It involves pathways at many 
levels of the brain, the spinal cord and the peripheral nervous system and is regulated 
by various neurotransmitters (Figure 1.10) (Fowler et al., 2008). 
The regulation of the bladder functions such as filling, voiding and sensation of 
bladder fullness depends on a complex interplay between autonomic (sympathetic 
and parasympathetic nerves) and somatic (pudendal nerves) efferent pathways. The 
sympathetic innervation originates in the thoracolumbar outflow of the spinal cord, 
whereas the parasympathetic and somatic innervation arises in the sacral segments of 
the spinal cord (Figure 1.10A). In addition, afferent axons of the lower urinary tract 
also travel in these nerves (Fowler et al., 2008). The detrusor smooth muscles are 
innervated mainly by parasympathetic nerves, smooth muscles of bladder neck and 
urethra (internal sphincter) are innervated by sympathetic nerves and the striated 
skeletal muscle of external internal sphincter is innervated by somatic nerves 
(Chancellor and Yoshimura, 2004). 
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Figure 1.10: Efferent pathways of the lower urinary tract. (A) Sympathetic fibres (shown in 
blue) originate in the T11–L2 segments in the spinal cord and run through the inferior 
mesenteric ganglia (inferior mesenteric plexus, IMP) and the hypogastric nerve (HGN) or 
through the paravertebral chain to enter the pelvic nerves at the base of the bladder and the 
urethra. Parasympathetic preganglionic fibres (shown in green) arise from the S2–S4 spinal 
segments and travel in sacral roots and pelvic nerves (PEL) to ganglia in the pelvic plexus 
(PP) and in the bladder wall. This is where the postganglionic nerves that supply 
parasympathetic innervation to the bladder arise. Somatic motor nerves (shown in yellow) 
that supply the striated muscles of the external urethral sphincter arise from S2–S4 motor 
neurons and pass through the pudendal nerves. (B) Efferent pathways and neurotransmitter 
mechanisms that regulate the lower urinary tract. Parasympathetic postganglionic axons in 
the pelvic nerve release acetylcholine (ACh), which produces a bladder contraction by 
stimulating M3 muscarinic receptors in the bladder smooth muscle. Sympathetic 
postganglionic neurons release noradrenaline (NA), which activates β3 adrenergic receptors 
to relax bladder smooth muscle and activates α1 adrenergic receptors to contract urethral 
smooth muscle. Somatic axons in the pudendal nerve also release ACh, which produces a 
contraction of the external sphincter striated muscle by activating nicotinic cholinergic 
receptors. Parasympathetic postganglionic nerves also release ATP, which excites bladder 
smooth muscle, and NO, which relaxes urethral smooth muscle (not shown). L1, first lumbar 
root; S1, first sacral root; SHP, superior hypogastric plexus; SN, sciatic nerve; T9, ninth 
thoracic root (Fowler et al., 2008). 
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Autonomic and Somatic efferent pathways 
Sympathetic innervations (bladder filling) 
During the filling stage, noradrenaline (NA) released from sympathetic 
postganglionic nerves (e.g., the hypogastric nerve) acts on α1-adrenoceptors 
(excitatory receptor) in the urethra and the bladder neck region causing contraction, 
which maintains closure of the bladder outlet. NA also acts on β-adrenoceptors 
(inhibitory receptor) on the bladder dome to cause relaxation of the detrusor muscle 
to prevent any increase in intravesical pressure during filling (Chess-Williams, 2002; 
Fowler et al., 2008). NO is co-released with NA which further enhances relaxation 
(Apodaca et al., 2007). During the stage of bladder filling, the parasympathetic 
innervation of the detrusor muscle is inhibited and the smooth and striated parts of 
the urethral sphincter are contracted, preventing involuntary voiding of the urine. 
This process is known as the ‘guarding reflex’ (Fowler et al., 2008) and they are 
triggered by afferent activity of the bladder that is conveyed through the pelvic 
nerves, and are organised by interneuronal circuitry in the spinal cord (de Groat, 
1995; deGroat et al., 1996). Some inputs from the lateral pons, which is also known 
as ‘pontine storage centre’, appear to facilitate sphincter reflexes or play a role 
involuntary sphincter control (Holstege et al., 1986). The processing of bladder 
sensations in human such as desire to void is thought to be mapped in insula (Craig, 
2002), since brain imaging studies have shown activation of the periaquenductal gray 
(PAG) during bladder filling which is postulated to play a role in receiving bladder 
afferents and relaying them (perhaps through the thalamus) to the insula (DasGupta 
et al., 2007; Kavia et al., 2005). Consistent with this postulate, it was found that the 
insula was active in most imaging studies of urine storage (Griffiths and Tadic, 2008) 
and its activation was noticeably enhanced during bladder filling (Griffiths et al., 
2005). The anterior cingulated cortex which also has connection with the PAG 
appears to determine how much attention one pays to signals coming from bladder 
afferents and how one reacts to them, whether by deciding to void or by recruiting 
mechanisms (for example, urethral sphincter contraction) that allow voiding to be 
postponed (Griffiths and Tadic, 2008). In addition, the frontal lobes especially the 
prefrontal cortex have been suggested by both clinical studies and studies from 
functional imaging that it might be responsible for tonic suppression of voiding that 
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is relaxed only when voiding is both desired and socially appropriate (Holstege, 2005; 
Pardo et al., 1991).  
 
Parasympathetic innervations (bladder voiding)  
It has been indicated that the circuitry, that conveys afferent nerve activity of the 
bladder to midbrain and pontine centres and transmits efferent signals from the pons 
to the sacral cord, is responsible for a switch-like function of the spinobulbospinal 
micturition reflex pathway that is either in complete ‘off’ mode during storage phase 
or a maximally ‘on’ mode during voiding phase (de Groat, 1995). During bladder 
filling the parasympathetic efferent pathway to the bladder, including a population of 
pontine micturition centre (PMC) neurons in which a spinobulbospinal pathway 
passes through, is turned off but at a critical level of bladder distension the afferent 
activity arising from tension receptors in the bladder switches the pathway to 
maximal activity (de Groat et al., 1998; De Groat et al., 1982; Sugaya et al., 2005).  
During emptying, a reduction in sympathetic and an increase in parasympathetic 
activity occurs to reverse the functions of the bladder dome and neck. 
Parasympathetic postganglionic nerves release the cholinergic transmitter, 
acetylcholine (ACh) which is the major excitatory mechanism in the human bladder 
(Figure 1.10B) act on muscarinic receptors (G-protein coupled), causing detrusor 
contraction and consequent urinary flow (Andersson and Arner, 2004). It is mediated 
principally by the M3 muscarinic receptor, although bladder smooth muscle also 
expresses M2 muscarinic receptors (Matsui et al., 2002). Activation of muscarinic 
receptors on parasympathetic nerve terminals at the neuromuscular junction and in 
the parasympathetic ganglia can enhance transmitter release through muscarinic M1 
receptors or suppress transmitter release through muscarinic M4 receptors, depending 
on the intensity of the neural firing (Somogyi et al., 1998). ACh also acts on nicotinic 
receptors (ionotropic) which mediate fast synaptic transmission in autonomic ganglia, 
and activation of nicotinic receptors in parasympathetic bladder neurons causes 
detrusor muscle contraction. Autonomic ganglia contain transcripts for α3, α4, α5, α7, 
β2, and β 4 nicotinic subunits, which can assemble to form multiple receptor subtypes. 
It was reported that α3 and β4 subunits have the higher expression levels. However, 
the exact nicotinic receptor subunit composition in bladder ganglia is unknown (De 
Biasi et al., 2000). Adenosine triphosphate (ATP) which is a non-cholinergic 
excitatory transmitter is co-released with ACh following muscarinic nerve 
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stimulation. ATP acts on P2X purinergic receptors in the detrusor muscle, initiating 
micturition while ACh maintains bladder voiding (Burnstock, 2014). Muscarinic 
receptor stimulation induces NO release from the parasympathetic nerves to cause 
relaxation of the urethral smooth muscle, allowing bladder voiding to occur with 
little increase in intravesical pressure (Andersson and Arner, 2004; Chess-Williams, 
2002). Prostanoids such as PGE2 are also released from the urothelium and are 
thought to play a role in stimulating the micturition reflex (Aoki et al., 2009). 
 
Somatic innervations 
The striated skeletal muscles of the external urinary sphincter and pelvic floor are 
innervated by somatic nerves. The efferent motor nerves arise in the lateral border of 
the ventral horn in sacral cord segments S2 to S4, located in Onuf’s nucleus (Fowler 
et al., 2008; Thor et al., 1989; Yoshimura and de Groat, 1997), and reach the 
periphery through the pudendal nerve to release ACh. The ACh acts on nicotinic 
receptors (the exact subunit composition unknown) in the striated muscle to cause 
muscle contraction, maintaining closure of the external urinary sphincter (Blaivas, 
1982; Thor et al., 1989; Yoshimura and de Groat, 1997).  
 
Neurotransmitters 
It can be seen from the above that neurotransmitters play an active role in regulating 
functions of the lower urinary tract. Other neurotransmitters including glutamic acid, 
tachykinis and pituitary-adenylate-cyclase-activating polypeptide appears to have an 
excitatory effect on contraction (Matsuura et al., 2002; Sugaya et al., 2005), and 
GABA (γ-aminobutyric acid), glycine and opioid peptides (enkephalins) which are 
inhibitory amino acids exert a tonic inhibitory control in the PMC and regulate 
bladder capacity (Mallory et al., 1991). Some transmitters have either inhibitory or 
excitatory effects depending on the type of receptor that is activated and these 
include dopamine, serotonin (5-HT) and non-opioid peptides (Andersson and 
Pehrson, 2003).  
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Bladder sensations (afferent pathway) 
Information about the degree of bladder distension is carried to the spinal cord by the 
pelvic and hypogastric nerves, whereas sensory input from the bladder neck and 
urethra is conveyed in the pudendal and hypogastric nerves. Myelinated (Aδ) and 
unmyelinated (C) axons form the afferent components of these nerves and the cell 
bodies of these fibres are located in the dorsal root ganglia (DRG) at the level of S2-
S4 and T11-L2 spinal segments (Fowler et al., 2008). Information about bladder 
filling is conveyed by the Aδ-fibres which respond to passive distension and active 
contraction (Janig and Morrison, 1986). The C-fibres which is also known as ‘silent’ 
C-fibres are insensitive to bladder filling under physiological conditions and respond 
predominantly to noxious stimuli such as chemical irritation or cooling (Fall et al., 
1990; Habler et al., 1990).  
Furthermore, studies have shown that non-neuronal cells such as urothelial cells and 
suburothelial myofibroblasts also play a part in regulating bladder functions and 
these will be discussed further in following sections.  
 
Detrusor muscle 
The detrusor muscle, which is also known as muscularis propria, is a layer which 
consists of smooth muscle fibres arranged in spiral, longitudinal and circular bundles 
that form the wall of the bladder (Marieb and Hoehn, 2010). 
Human detrusor muscle is enriched with muscarinic receptors; the majority of which 
are the M2 subtype whereas the remaining minority are the M3 subtype (Hegde et al., 
1997). The ratio of M2 to M3 muscarinic receptors varies among the species but 
human is known to have a ratio of 3:1 (Wang et al., 1995). In vitro functional 
responses to muscarinic receptor stimulation which leads to bladder contraction is 
mediated via the minor population of M3 muscarinic receptor in pig (Sellers et al., 
2000) and human bladder (Chess-Williams et al., 2001). The role of the larger 
population of M2 muscarinic receptors is not fully understood, however they are 
assumed to be responsible for inhibiting the cAMP-induced relaxations of the 
detrusor muscle to allow the contraction to occur (Yamanishi et al., 2002a; 
Yamanishi et al., 2002b). The roles of other muscarinic receptors M1, M4 and M5 in 
bladder function are as yet not well understood.  
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There is increasing evidence suggesting that β-adrenoceptors (β-ARs) are abundant 
in the detrusor muscle of the bladder of various species (Limberg et al., 2010). The 
β-ARs can be subclassified into β1-, β2-, and β3 and the β-AR subtype mediating 
relaxation of detrusor muscle appears to be species dependent (Limberg et al., 2010; 
Masunaga et al., 2010). In most species, including rabbit and rat, detrusor relaxation 
is mediated predominantly through the action of the β2-ARs. However, in humans, 
the β3-AR subtype predominates and mediates detrusor relaxation (Limberg et al., 
2010; Masunaga et al., 2010; Tyagi et al., 2009). 
Previously, bladder function was believed to be largely dependent on the 
innervations of the autonomic system through muscarinic and adrenergic receptors 
on detrusor muscle. However, there is increasing evidence suggesting that the 
urothelium and suburothelium also play an important role in modulating normal 
function of the bladder. 
 
Lamina propria (suburothelium) 
Immediately beneath the urothelium is a layer known as the lamina propria which 
contains a number of cell types including afferent and efferent nerve terminals (Fry 
et al. 2007). The different types of afferent fibres have been shown to be present in 
the bladder including unmyelinated C fibres and myelinated Aδ fibres (Birder et al., 
2010a; Gillespie et al., 2006). Conceptually, Aδ fibres are known to carry 
information regarding physiological stretch or contraction of the bladder wall, 
whereas C fibres are associated with volume or higher threshold sensations (pain) 
(Morrison, 1999). 
In both humans and animals, the cells with similar morphological characteristics to 
those of myofibroblasts or interstitial cells (ICs) have been recently reported within 
the lamina propria layer (Brading and McCloskey, 2005; Fry et al., 2007; Ost et al., 
2002; Sui et al., 2004). Myofibroblasts in lamina propria consist of long spindle-
shaped cells and are connected to each other through gap junctions (Fry et al., 2007). 
These cells also have close contacts with nerves, display numerous receptors and ion 
channels (i.e. epithelium sodium channel (ENaC), purinergic, cholinergic and 
adrenergic) and can respond to neurotransmitters such as ATP released from nerves 
or the urothelium (Birder et al., 2010b; Fry et al., 2007). These suggest that the 
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function of myofibroblasts in lamina propria is to act as intermediaries in urothelial-
nerve interactions potentially via their ability to propagate signals over many cell 
lengths (Fry et al., 2007). However, their role within the bladder has yet to be 
elucidated. 
 
Urothelium 
The urothelium is composed of basal cells connected to the basement membrane, 
intermediate cells and the most superficial layer, ‘umbrella cells’ (Figure 1.11B) 
(Khandelwal et al., 2009).  
 
 
Figure 1.11: Structure of the urinary bladder wall and urothelium. (A) Detailed view of the 
layers of the bladder wall showing the epithelial, mucosal and muscle layers. (B) Layers of 
cells in the transitional epithelium, or urothelium, of the bladder wall, showing the 
characteristic umbrella cells joined by tight junctions and covered by plaques and a mucin 
layer. Each plaque has 1000 subunits. (C) Uroplakins (UPIa, UPIb, UPII and UPIII) arranged 
to form a single plaque subunit (GuhaSarkar and Banerjee, 2010). 
 
Since, the urine contains waste substances; the urothelium forms a functional 
distensible barrier that prevents unregulated exchange of substances between the 
urine and the systemic circulation (GuhaSarkar and Banerjee, 2010). This task is 
achieved by the umbrella cells joined by high-resistance tight junction and with an 
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apical surface covered by densely packed plaques (Figure 1.11B). During bladder 
filling, the umbrella cells become flat and squamous by vesicular traffic (i.e. 
exocytosis/endocytosis) and this shape change allows the bladder to fill with urine 
without compromising barrier function (Birder et al., 2010b). The barrier property of 
urothelium is further enhanced by the presence of sulphated polysaccharide 
glycosaminoglycans (GAGs) adherent to the luminal side. GAGs effectively block 
solutions and solutes from penetrating and reaching underlying layers by preventing 
adhesion of foreign particles (act as a defensive mechanism against infection) (Birder 
et al., 2010b; Birder et al., 2010g; GuhaSarkar and Banerjee, 2010; Khandelwal et al., 
2009).  
This barrier of umbrella cells with their tight junctions, densely packed plaques and 
GAGs also prevent effective diffusion of drugs used for intravesical therapy to treat 
bladder cancer. Hence, the permeability of drug solutions into the urothelium 
depends on the degree of structural or chemical disruption occurring on GAGs and 
umbrella cells (GuhaSarkar and Banerjee, 2010).  
Increased permeability to intravesical drugs may occur in neoplastic urothelial cells 
due to dedifferentiation and impaired production of membrane plaques, GAGs and 
tight junctions. Drug permeability may also be facilitated by cystitis and transurethral 
resection (Badalament and Farah, 1997). Since the urothelium serves as an effective 
barrier only a small percentage of drug is absorbed into the systemic circulation. This 
is evident in an in vitro study conducted by Wientjes, Badalament, Wang, Hassan 
and Au (1993) which used human bladders from bladder cancer patients who 
received instillation of mitomycin C (20mg/40mL) at the time of radical cystectomy. 
This study has shown that mitomycin C concentration dropped by 35-fold across the 
urothelium. The mean plasma concentrations were 0.003, 0.1, and 0.4% of the mean 
concentration in urine, urothelium and the averaged bladder tissue concentrations, 
respectively. Further an in vitro study (using human bladder from bladder cancer 
patients who received instillation of 40mg/20mL of doxorubicin prior to radical 
cystectomy) conducted by Wientjes et al. (1996) has shown that the doxorubicin 
concentration dropped by 32-fold across the urothelium, and declined semi-
logarithmically with respect to depth in the capillary-perfused tissues beneath the 
urothelium with a 50% decrease over about 500µm. The plasma concentrations were 
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0.02, 0.03, 0.05, 0.27 and 0.67% of concentrations in the tumours, urothelium, 
lamina propria, superficial and deep muscle layers, respectively.  
  
 
Figure 1.12: Illustration of the possible interactions between the urothelium, bladder afferent 
and efferent nerves, myofibroblasts and detrusor muscle (Birder, 2010). 
 
While it was originally believed that the urothelium served solely as an effective 
barrier to limit the absorption of molecules and ions into the systemic circulation, it 
is now recognised as a more active tissue with specialised sensory properties that 
enable the urothelium to act as a primary transducer of some physical and chemical 
stimuli, and able to communicate with underlying cells including nerves, connective 
and muscular tissues, and inflammatory cells (Birder, 2013; Fowler et al., 2008). The 
urothelium is able to respond to a wide range of physical stimuli including changes 
in bladder pressure, tension in the urothelium or bladder wall, torsion, geometrical 
tension and ranges of urine composition as well as tonicity during bladder filling and 
voiding. Additional lines of studies in human and animals suggest that urothelial 
cells are able to respond to not only physical but also to chemical stimuli (Birder, 
2013; Birder and Wyndaele, 2013). There is evidence that both afferent and 
autonomic afferent nerves are located in close proximity, with some penetrating the 
urothelium. These nerves can be activated by a range of transmitters and mediators 
released in part by the urothelium (Birder and Wyndaele, 2013). Various stimuli can 
lead to a number of outputs from the urothelium including the secretion of numerous 
transmitters and mediators, such as neurotrophins, peptides, ATP, acetylcholine, 
noradrenaline, prostaglandins, prostacyclin, NO, cytokines and an unidentified factor 
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that inhibit detrusor contraction (Figure 1.12) (Apodaca et al., 2007; Birder, 2013; 
Fowler et al., 2008; Hawthorn et al., 2000). The urothelium also expresses various 
receptors and ion channels including nicotinic, muscarinic, tachykinin, adrenergic, 
cholinergic, bradykinin, epithelium sodium channel (ENaC) and transient-receptor-
potential vanilloid receptors (such as TRPV1) (Birder, 2013; Fowler et al., 2008). 
More detailed information on release of urothelial factors will be discussed in the 
following sections. 
 
Urothelial receptors and mediators 
Acetylcholine (ACh) 
The discovery of muscarinic and nicotinic receptors on the urothelium has attracted 
further interest in the role of ACh in bladder function as a chemical mediator of 
neural-urothelial interactions (Birder, 2010). Muscarinic receptors are primarily 
known for their role in voiding but there is evidence showing that the urothelium 
expresses the full complement of muscarinic receptors (M1-M5) as well as the 
enzymes and transporters necessary for the synthesis, release and metabolism of ACh.  
A study by Lips et al. (2007) reported that the enzyme involved in urothelial ACh 
synthesis was not choline acetyltransferase (ChAT) but carnitine acetyltransferase 
(CarAT). The exact mechanism of urothelial-derived ACh release is as yet unknown 
but it appears not to be vesicular acetylcholine transporter (VAChT) which is 
responsible for transporting neuronal ACh, since it was absent from the urothelium. 
Also, the organic cation transporters (OCTs) 1 and 3, which can transport ACh in 
either direction across cell membranes, even though they are present in mouse and 
human urothelium, were demonstrated to be not involved in ACh release (Lips et al., 
2007). A recent study by McLatchie et al. (2014) has suggested potential 
involvement of cystic fibrosis transmembrane conductance regulator (CFTR) in ACh 
release. Studies have shown that ACh is released from the urothelium in response to 
stretch (mechanical stimulation) as well as chemical stimulation (Birder, 2010). Once 
released, urothelial-derived ACh is likely to exert effects on a number of sites. ACh 
may act in a paracrine manner to stimulate nicotinic and/or muscarinic receptors on 
detrusor muscle, myofibroblasts and afferent nerves, or in an autocrine manner to 
stimulate urothelium associated muscarinic receptors (Birder, 2010; Hanna-Mitchell 
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et al., 2007). The role of cholinergic signalling in the urothelium is still being 
identified. However, a study by Kanai et al. (2007) which applied muscarinic 
receptor agonist to strips of rat bladder tissue induced membrane-potential transients 
and Ca2+ transients that begin near the urothelial-suburothelial interface and then 
spread to the detrusor smooth muscle, raising the possibility that the urothelium 
could regulate the generation of spontaneous, non-voiding contraction in the bladder.  
Various cell studies have suggested that both M1-like (M1, M3 and M5) and M2-like 
muscarinic receptors (M2 and M4) can be involved in tissue remodelling and promote 
cell growth and proliferation (Belo et al., 2011; Gosens et al., 2004; Gosens et al., 
2006; Matthiesen et al., 2007; Tong et al., 2009) and those of the M1-family can even 
act as conditional oncogenes (Gutkind et al., 1991). Such growth-promoting and pro-
survival effects of muscarinic receptors may involve the extracellular signal-
regulated kinases (ERK) and phosphoinositide (PI)-3 kinase/Akt pathway (Wu and 
Wong, 2006). Also, a study conducted by Arrighi et al. (2011) demonstrated that cell 
proliferation of human urothelium (UROtsa cell line) was stimulated by the 
cholinergic receptor agonist, carbachol via pathway involving muscarinic M3 
receptors, ERK and PI-3 kinase supporting the cell growth and proliferation 
promoting effects of muscarinic receptors in the urothelium. Hence, bladder 
remodelling via cholinergic system might be responsible for urothelial hypertrophy 
which can develop in pathological settings such as bladder outlet obstruction.  
It is well established that patients with overactive bladder (OAB) can be effectively 
treated with muscarinic receptor antagonists. This agent enhances the storage phase 
of micturition by targeting post-junctional excitatory muscarinic receptors (M2 and 
M3) in the detrusor smooth muscle to silence parasympathetic innervations (Hegde, 
2006; Pathak and Aboseif, 2005; Staskin and MacDiarmid, 2006). Since, the 
urothelium also expresses the full complement of muscarinic receptors, it has 
attracted interest in the role of urothelial derived ACh in the OAB (Yoshida et al., 
2006). Increased cholinergic afferent effects, specifically sensitisation of 
acetylcholine-evoked signalling in the urothelium have been reported in patients with 
OAB (Yoshida et al., 2010). It is postulated that upregulation of the cholinergic 
targets (possibly muscarinic M2 receptors on afferent nerve terminals) is responsible 
for this rather than just increased acetylcholine production itself (Matsumoto et al., 
2010). In contrast, decreased expression of muscarinic receptors in urothelial and 
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suburothelial cells in OAB patients has been reported (Mansfield et al., 2007; 
Mukerji et al., 2006). In addition, upregulation of the urothelial muscarinic M1 and 
M5 receptors in cystitis has been shown, suggesting that alterations in the urothelial 
expression of muscarinic receptors may take part in pathophysiology of cystitis 
(Giglio et al., 2008; Giglio et al., 2005). Furthermore, activation of the mucosal 
muscarinic receptors has been reported to be coupled with NO release, and this 
pathway seems to be altered in the inflamed urinary bladder (Andersson et al., 2012; 
Andersson et al., 2008).  
In addition, there is growing evidence showing that the urothelium expresses 
multiple nicotinic receptors (Beckel and Birder, 2012; Beckel et al., 2006; 
Bschleipfer et al., 2007; Zarghooni et al., 2007). A study using human bladder 
mucosal biopsies has demonstrated the expression of nicotinic α-subunits 7, 9 and 10 
(rank order of α7>α10>α9) in the human urothelium (Bschleipfer et al., 2007). 
Furthermore, study by Beckel & Birder (2012) which used rat urothelial cells, when 
stimulated with α7 nicotinic receptor agonist, increased intracellular Ca2+ through 
internal stores and decreased basal ATP release suggesting inhibitory effect of an α7 
receptor activation on bladder reflexes. Stimulation with an α3 nicotinic receptor 
agonist also increased intracellular calcium through extracellular influx as well as 
basal ATP release, indicating possible excitatory effect. When the cells were 
pretreated with an α7 agonist, the cellular effects of α3 stimulation previously 
observed was blocked, suggesting interactions between nicotinic subtypes whereby 
activation of α7 receptors inhibits the response to subsequent activation of α3 
receptors, preventing the increase in calcium concentration. These observations 
suggest that urothelial nicotinic acetylcholine receptors may modulate ATP release, 
indicating a role in nociceptive signalling in the lower urinary tract. 
 
Adenosine Triphosphate (ATP) 
ATP was the first neurotransmitter shown to be released directly from the urothelium. 
Since the first discovery of ATP release from non-neuronal sources in the rat bladder 
by Ferguson et al. (1997), there is now abundant evidence supporting an important 
role of ATP release from the urothelium in sensory and motor functions of the 
bladder.  
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ATP is released from both the apical and basolateral epithelial surfaces in response to 
bladder stretch during filling (Wang et al., 2005). Various studies have shown 
stretch-induced ATP release from the urothelium in both tissues (Kumar et al., 2004; 
Kumar et al., 2007; Munoz et al., 2011; Sadananda et al., 2009) and cells (Kang et al., 
2013; Mansfield and Hughes, 2014a, e). The ATP released from the urothelium can 
act in both an autocrine and a paracrine manner. The main source of ATP release in 
the bladder is the urothelium and not the detrusor muscle (Kumar et al., 2004; 
Sadananda et al., 2009). The mechanism of urothelial-derived ATP release is not 
fully understood yet. Studies have shown that involvement of extracellular calcium is 
contradictory, since removing extracellular calcium had no effect in one study (Sui et 
al., 2014) but increased (Ferguson et al., 1997; Young et al., 2012) or decreased 
(Birder et al., 2003; Cheng et al., 2011; Olsen et al., 2011) ATP release in other 
studies. One of the potential mechanisms appears to be vesicular release (Birder et al., 
2003; McLatchie and Fry, 2014; Sui et al., 2014; Wang et al., 2005) and another 
likely route includes connexin or pannexin hemichannels (McLatchie and Fry, 2014; 
Timoteo et al., 2014; Wang et al., 2005), transient receptor potential channels (TRPV) 
1 or 4 (Mochizuki et al., 2009; Wang et al., 2005), ATP-binding cassette (ABC) 
transporters (Wang et al., 2005) or mechanosensitive channels (Birder et al., 2003; 
Dunning-Davies et al., 2013). The urothelial-derived ATP can enhance its own 
release from urothelial cells by binding to urothelium-associated purinoceptors, P2X2 
and P2X3. The binding of ATP to purinergic receptors can also alter epithelial 
functions via exocytosis which can adjust the apical surface area during bladder 
filling (Birder, 2010; Khandelwal et al., 2009; Wang et al., 2005).  
The ATP released from the urothelium can directly depolarize and initiate firing in 
sensory nerves by activating ionotropic P2X channels or metabotropic P2Y receptors 
on afferent nerves as well as the urothelium to stimulate intracellular second 
messenger pathways that in turn modulate other ion channels (Khandelwal et al., 
2009; Tominaga et al., 2001).  
As the epithelium stretches during bladder filling, ATP is released and may stimulate 
the P2X receptors present on urothelial and suburothelial sensory Aδ and small 
diameter C fibres, stimulating the afferent arm of the micturition reflex and giving 
rise to the perception of pain respectively; therefore serving as a mediator for the 
degree of distension of bladder (Cockayne et al., 2000; Kumar et al., 2010; Kumar et 
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al., 2007; Souslova et al., 2000). The role of ATP release from the urothelium has 
attracted attention because intravesical administration of ATP induced detrusor 
overactivity by stimulating the purinergic receptor P2X3 or P2X2/3 on afferent nerves 
(Rong et al., 2002). In addition, reduced bladder activity and inefficient voiding was 
observed in mice that lack P2X3 receptors suggesting that activation of P2X3 
receptors on bladder afferent nerves by ATP released from the urothelium is essential 
for normal bladder function (Cockayne et al., 2000). Hence, the purinergic P2X 
transmission has a role in the initiation of detrusor contraction, thereby initiating 
bladder voiding, whereas cholinergic transmission maintains bladder contraction and 
flow (Kumar et al., 2004; Stevens et al., 2007).  
To date, eight P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14) have been 
identified with P2Y1, P2Y2, P2Y4, and P2Y6 receptors detected in peripheral sensory 
neurons located in dorsal root and nodose ganglia (Gerevich and Illes, 2004; Ruan 
and Burnstock, 2003). It has been reported that P2Y1, P2Y2, P2Y4 and P2Y11 are also 
expressed on urothelial cells (Birder et al., 2004; Chopra et al., 2008; Shabir et al., 
2013). The P2Y receptors respond to endogenous purine and pyrimidine nucleotides 
(ATP, ADP, UTP, UDP) released into the extracellular environment from various 
tissues (Lazarowski and Boucher, 2001; Lazarowski and Harden, 1999; von 
Kugelgen, 2006). While function of these receptors in the bladder has not been 
elucidated yet, there is some evidence supporting involvement of P2Y receptors in 
mechanosensation and or/ nociception under normal and pathological conditions. A 
study by Fry et al. (2012) reported increased spontaneous activity in rat bladder 
sheets after exogenous application of P2Y receptor agonist (ADP and UTP). Another 
study on mouse bladder sensory neurons has demonstrated increased excitability of 
bladder neurons by UTP (a P2Y2 and P2Y4 agonist) via depolarizing resting 
membrane potential, increasing action potential firing, and facilitating purinergic 
(P2X) currents (Chen et al., 2010). In addition, intravesical instillation of a P2Y6 
selective agonist in a rat cystometry model induced bladder overactivity 
characterised by increased urinary frequency, and also increased ATP release in the 
voided fluid (Timoteo et al., 2014). Furthermore, decreased expression of P2Y2 
receptor was reported in a feline model of interstitial cystitis (IC) (Birder et al., 2004). 
Thus, P2Y receptors might be also contributing to hyperexcitability and increased 
firing of bladder afferents that are associated with urinary urgency, frequency, and 
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pain, all of which are features of OAB and IC (also known as painful bladder 
syndrome (PBS)) (Nazif et al., 2007). 
Although, purinergic control is less important than that of cholinergic in normal 
conditions, it has increasingly been accepted as having more significant role in 
sensory abnormalities observed in a number of bladder disorders such as IC and 
OAB. Various in vitro studies using animal models of OAB and IC have suggested 
that increased urothelial ATP release from damaged or sensitised cells in response to 
injury or inflammation might be the contributing factor for triggering increased 
bladder activity and painful sensations via excitation of purinergic (P2X) receptors 
on sensory fibers (Khera et al., 2004; Munoz et al., 2011; Smith et al., 2005; Sun et 
al., 2001). Not only the alterations in the urothelial ATP release but also changes 
such as inhibition of ecto-ATPase activity (Nishiguchi et al., 2005) as well as 
increased density of P2X receptors (Moore et al., 1992) were observed in OAB, 
which renders detrusor muscle to be more responsive to ATP (Santoso et al., 2010).  
 
Prostaglandin E2 
 
 
Figure 1.13: Synthesis of prostanoids from arachidonic acid (Sorokin, 2011). 
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Prostaglandins, along with thromboxanes and prostacyclins are the products of the 
cyclooxygenase (COX) pathway, collectively known as the prostanoids. There are 
two isoforms of cyclooxygenase enzymes, COX-1 and COX-2. Both cyclooxygenase 
isoforms metabolize the fatty acid arachidonic acid into first PGG2 by 
cyclooxygenase activity of COX and PGG2 is further metabolised into PGH2 by 
peroxidise activity of COX. Then, PGH2 is converted into various prostanoids by 
respective synthases (Figure 1.13) (Rahnama'i et al., 2012).  
There are four primary prostaglandins synthesised and released in the bladders of 
various species during detrusor contraction (Bultitude et al., 1976; Khalaf et al., 1980; 
Klarskov, 1987) and under basal physiological conditions (Brown et al., 1980; 
Poggesi et al., 1980). These includes prostaglandin E2 (PGE2), prostacyclin I2 (also 
known as prostaglandin I2; PGI2), prostaglandin D2 (PGD2) and prostaglandin F2α 
(PGF2α). They are ubiquitously produced and act as an autocrine and paracrine lipid 
mediators to maintain local homeostasis in the body. However, prostaglandin 
production increases dramatically during an inflammatory response (Ricciotti and 
FitzGerald, 2011). In the human bladder, the major prostaglandin is PGI2, followed 
by PGE2 and PGF2α (Jeremy et al., 1984). Both COX-1 and COX-2 are expressed in 
the bladder. The expression of COX-1 by the basal layer of the urothelium (and, to a 
lesser extent, the cells of the intermediate urothelial layer) indicates that 
prostaglandins are synthesised and released from these sites (de Jongh et al., 2009; 
Rahnama'i et al., 2010). The detrusor smooth muscle might also synthesize 
prostaglandins as they also express both COX-1 and COX-2 (Klausner et al., 2011). 
PGE2 synthesis can be initiated by various factors such as stretch, nerve stimulation, 
injury, exposure to ATP and other inflammatory mediators (Dveksler et al., 1989; 
Khan et al., 1998).  
The exact role of urothelial-derived PGE2 is not elucidated yet but various studies 
have suggested excitatory effects on bladder contractility via modulation of nerve 
and detrusor functions (Apodaca et al., 2007; Birder, 2005). Also, PGE2 has been 
discussed extensively as one of the contributing factors that may cause urinary 
bladder overactivity. A study using mice has demonstrated that overexpression of 
PGE2 in the bladder stimulates the micturition reflex through activation of C-fibres 
(Aoki et al., 2009; Maggi et al., 1988a). Inhibition of COX-2 resulted in improved 
storage function in rats with detrusor overactivity, indicating potential stimulatory 
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effects of PGE2 on bladder micturition reflex (Yokoyama, 2010b). Also, 
administration of indomethacin (COX inhibitor) caused a reduction in tone and loss 
of spontaneous contractile activity of the isolated bladder (Bultitude et al., 1976). In 
addition, when PGE2 was instilled intravesically in the conscious, catheterised rats, 
micturition was facilitated and an increased basal intravesical pressure was generated 
(Ishizuka et al., 1995). On detrusor smooth muscle strips of mouse, PGE2 also 
increased the tone and caused phasic contractions of detrusor muscle (Kobayter et al., 
2012). In humans, intravesical administration of PGE2 caused detrusor overactivity, 
urgency and decreased bladder capacity (Schussler, 1990). Furthermore, local PGE2 
production was reported to be elevated in the bladders of animals with overactive 
detrusor muscles (Hu et al., 2003; Park et al., 1999) as well as patients with OAB 
(Kim et al., 2005; Kim et al., 2006a).  
There are four prostaglandin EP receptors (EP1-EP4) (Alexander et al., 2008) that 
PGE2 can act on and it mediates different effects depending on the receptors (Negishi 
et al., 1995). In general, stimulation of EP1 and EP3 appears to be responsible for 
causing contraction of the detrusor smooth muscle, whereas stimulation of EP2 and 
EP4 are thought to induce muscle relaxation (Coleman et al., 1994; Ikeda et al., 
2006). Increased bladder capacity and reduced voiding efficiency were observed in 
rats by EP1 receptor antagonist (Maggi et al., 1988f). Also, EP1 knockout (KO) mice 
have shown that PGE2 is not essential for normal micturition but does play a role for 
EP1 in detrusor overactivity (Schroder et al., 2004). The dual EP1 and EP2 receptor 
antagonist decreased the amplitude of detrusor contraction in isolated human bladder 
(Palea et al., 1998), indicating possible inhibitory role of EP2 receptor. In rats, 
reduced functional bladder capacity was observed with EP3 receptor agonist; 
whereas inhibition of this receptor resulted in opposite effect (Jugus et al., 2009). 
Also, diminished PGE2-mediated bladder hyperactivity was observed in EP3 receptor 
knockout mice and enhanced bladder capacity was also observed under basal 
conditions (McCafferty et al., 2008). Study of rats with bladder outlet obstruction by 
Beppu et al. (2011) has shown that activation of EP4 receptor using agonist 
suppressed detrusor contraction and afferent nerve activity, suggesting possible 
inhibitory role of EP4 receptor on bladder contractility. However, in contrast, 
upregulation via increased expression of EP4 receptors exacerbated 
cyclophosphamide-induced OAB in rats (Chuang et al., 2010).  
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Urothelial-derived inhibitory factor (UDIF) 
An unidentified substance is released from the healthy urothelium which diminishes 
contractility of detrusor smooth muscle. As a result of these unknown substances, 
bladder overactivity and consequent involuntary urine loss are prevented 
(Chaiyaprasithi et al., 2003; Hawthorn et al., 2000; Templeman et al., 2002). 
Research has shown that removal of the urothelium results in a significant increase in 
the detrusor muscle contractile response and further studies provided strong evidence 
of urothelium releasing a soluble factor that exerts an inhibitory effect on the 
contractility of the bladder detrusor muscle (Fovaeus et al., 1998, 1999; Hawthorn et 
al., 2000).  
The urothelial-derived inhibitory factor or UDIF has not been identified at the 
present time. NO, its metabolite nitrite or P1 purinoceptor agonist like adenosine are 
unlikely to be the unknown factor or involved in the release of the factor from the 
urothelium (Guan et al., 2014; Hawthorn et al., 2000). However, other purines such 
as ATP and related nucleotides, due to their significant release from the urothelium 
(Munoz et al., 2010; Sui et al., 2014), still remain as potential candidates for UDIF. 
A study by McMurray et al. (1998) first reported the possibility of relaxant effect of 
ATP in which both contractile and relaxant effects of ATP in urothelium denuded 
detrusor strips were observed. Expression of purinergic P2X and P2Y receptors on 
detrusor smooth muscle are suggested to participate in, respectively, contractions and 
relaxations (Chopra et al., 2008; Elneil et al., 2001; Fry et al., 2010). Also, a recent 
study by Santoso et al. (2010) supported the potential inhibitory role of urothelial 
ATP in mediating detrusor smooth muscle contractility, which may be impaired in 
diseased bladders such as OAB syndrome. In addition, cyclooxygenase (COX) 
products such as prostaglandins and prostacyclin, which are released from the 
urothelium, are not involved in the inhibition of detrusor muscle contraction (Guan et 
al., 2014; Hawthorn et al., 2000). Furthermore, UDIF is unlikely to be catecholamine, 
gamma aminobutyric acid (GABA), or an apamin-sensitive response to EDHF 
(Hawthorn et al., 2000).  
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Effect of chemotherapy on urothelial factors and detrusor 
function 
The effects of intravesical chemotherapeutic drugs on normal urothelial and detrusor 
function is not understood.  Given the immediate contact between high concentration 
of these agents and the urothelium it is likely that release of urothelial factors (Ach, 
ATP, NO, PGE2 and UDIF) is affected following treatment. This leads to one of the 
major aims of this study.   
The only study to date that has assessed how intravesical chemotherapeutic agents 
affect release of urothelial mediators was conducted for my honours degree (2012).  
My study demonstrated that a common intravesical chemotherapeutic agent, 
doxorubicin altered the release of urothelial mediators including Ach, ATP and PGE2 
from human urothelial cell line (RT4). Immediately following treatment, stimulated 
ATP release was inhibited at doxorubicin concentrations ≥1µg/ml and showed partial 
recovery at 24 hour. Immediately following doxorubicin treatment, basal Ach release 
was increased by doxorubicin at its clinical concentration (1mg/ml), while a 
concentration-dependent decrease in stimulated Ach release was observed. Twenty 
four hours after treatment, basal Ach release was increased in culture treated with 
0.01mg/ml doxorubicin while stimulated Ach release remained depressed. A 
significant increase in PGE2 release was observed in cells immediately and 24 hours 
after treatment with doxorubicin (Kang et al., 2013). In addition, the detrusor muscle 
was not directly affected by doxorubicin treatment (exposure to 1mg/ml for 1 hour), 
however the efferent nerves were sensitised or muscarinic M2 receptors were 
inhibited by doxorubicin, resulting in enhanced contractility of doxorubicin treated 
porcine detrusor muscle in response to electrical field stimulation (Kang et al., 2015).  
The findings of this study raised the possibility of other intravesical 
chemotherapeutic agents such as mitomycin C and epirubicin could also exert 
alterations in urothelial mediators and detrusor function. Differences in incidence of 
reported side effects between drugs may also be explained by extent of changes in 
urothelial function observed.  
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Aims and Hypothesis 
While there is an extensive research effort focused on enhancing the toxicity of 
intravesical cytotoxic agents, there have been few studies that have assessed their 
effects on normal bladder function. Some studies have investigated the systemic and 
local side effects of chemotherapeutic agents on the bladder, but there is still a gap in 
this field which demands that more comprehensive studies should be undertaken to 
determine the effects of these drugs on the bladder at a cellular and functional level.  
Hence, the overall aim of this study was to investigate changes in bladder function as 
a result of three chemotherapeutic drug treatments, doxorubicin, mitomycin C (MMC) 
and epirubicin. This will help to identify approaches to reduce the severity of side 
effects and ultimately improve life quality of the affected bladder cancer patients and 
also reduce economic burden. It is hypothesised that the three intravesical cytotoxic 
drugs have effects on bladder function, causing alterations in urothelial mediator 
release, inflammatory response, urothelial integrity, tissue responses and sensitivity 
and also efferent nerve responses.  
In addition, functions of bladder from young and aged pigs were compared to each 
other in an attempt to identify age-associated changes in the bladder function.  
Aims are addressed in more specific details in the respective experimental chapters.  
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Chapter 2 - Materials and Methods 
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Porcine tissue experiments  
Materials and equipment were obtained from the following sources. 
Chemicals & drugs Supplier 
 
α,β-methylene ATP 
Atropine 
Calcium chloride 
Carbachol 
Doxorubicin 
Glucose 
Isoprenaline 
Magnesium sulphate 
Potassium chloride 
Potassium dihydrogen phosphate 
Sodium bicarbonate 
Sodium chloride 
 
Sigma-Aldrich (St. Louis, USA) 
 
ARL 67156 trisodium salt 
Epirubicin 
Mitomycin C 
N(ω)-Nitro-L-Arginine 
Tocris Bioscience (Bristol, UK) 
 
 
 
 
Equipment & softwares Supplier 
Force Transducer 
LabChart 7 software 
Octal Bridge Amp 
PowerLab 8/35 
ADInstruments (NSW, Australia) 
8 channel tissue bath system 
Field stimulating electrodes Radnoti (Monrovia, USA) 
S48 Square pulse stimulator Grass Technologies (Warwick, USA) 
Stimulator splitter II Med-Lab Instruments (Loveland, USA) 
Accu-Cut SRM 200 Rotary microtome Sakura Finetek (Torrance, USA) 
Tissue-Tek Dispensing console 
Tissue-Tek Thermal console Sakura Finetek (Torrance, USA) 
BX41 microscope Olympus (Victoria, Australia) 
Infinity 2 miscroscopy camera 
Infinity capture software Lumenera (Ottawa, Canada) 
ImageJ software Open source 
InStat3 software GraphPad software (La Jolla, USA) 
Modulus Micoplate-reader Turner BioSystems (California, USA) 
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Fresh bladders from Large White-Landrace pigs were obtained from a local abattoir 
and immediately placed in cold Krebs-bicarbonate solution (composition, mM: NaCl 
118.4, NaHCO3 24.9, KCl 4.7, CaCl2 1.9, MgSO4 1.15, KH2PO4 1.15 and glucose 
11.7) at 4°C until use.   
 
Luminal treatment of porcine bladder tissue 
The bladders were opened longitudinally with a pair of surgical scissors and sheets of 
full thickness anterior wall from the dome of the porcine bladder were dissected. 
Isolated full thickness bladder sheets were set up in modified Ussing chambers 
(Figure 2.1), where the serosal side was superfused with Krebs-bicarbonate solution 
(37°C, 5% CO2 in O2), whilst doxorubicin, mitomycin C or epirubicin were applied 
to the urothelial surface at the concentration and duration used clinically. All three 
cytotoxic drugs were dissolved in Krebs-bicarbonate solution and were allowed to 
equilibrate for 30 minutes at 37°C immediately before use.  
 
Figure 2.1: Design of double-chamber treatment apparatus which was used to treat the 
luminal surface of full thickness bladder tissue with doxorubicin, mitomycin C or epirubicin 
at the clinical concentration and duration of treatment.  
 
Identical incubations with Krebs-bicarbonate solution in the absence of 
chemotherapeutic drugs were also conducted using matched control bladders 
(untreated). Following this pretreatment, bladder sheets were washed with Krebs-
Chemotherapeutic 
drug 
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bicarbonate solution gently for 3 times to ensure chemotherapeutic agents were 
removed from urothelial surface and three sets of tissue were isolated for further 
experiments: 
(i) Full thickness bladder wall with an intact urothelium and lamina propria 
(will be named “Intact bladder” throughout the thesis) 
(ii) Denuded detrusor muscle strips with the urothelium and lamina propria 
removed (will be named “Detrusor muscle” throughout the thesis) 
(iii) Strips of urothelium and lamina propria (will be named “Urothelium/LP” 
throughout the thesis)  
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Mediator release from pretreated porcine bladder tissue 
A common technique that is used to evaluate the involvement of urothelial-derived 
factors in bladder function is to study the surgically removed “urothelium”. However, 
since the urothelium is composed of only three to seven layers of cells (Khandelwal 
et al., 2009), it is difficult, if not impossible, to remove it surgically without 
including some parts of the underlying lamina propria (Birder, 2010). Hence, our aim 
was to remove the urothelium and lamina propria (“Urothelium/LP”) together and 
thereby examine its effects on the detrusor muscle.  
Four strips of urothelium/LP (tissues (iii) above) (each strip approx. 5 x 3 mm) were 
dissected from the pretreated and control bladders before mounting in tissue baths 
(Radnoti, USA) containing 3ml Krebs-bicarbonate solution warmed at 37°C to assess 
the effects of chemotherapeutic drugs on basal and stretch-induced mediators from 
the urothelium/LP. Treated and control urothelial/LP strips were allow to equilibrate 
for 1 hour under approximately 20mN tension and were washed with Krebs-
bicarbonate solution every 15 minutes. Isometric contractions of urothelial strips 
were monitored and recorded using a PowerLab data acquisition system 
(ADInstruments, Australia). 
After equilibrium was achieved, 3mL fresh Krebs-bicarbonate solution was added to 
the tissue baths and the bathing mediums were collected at four different time 
intervals (1, 2, 3 and 7 min later) for measuring basal ACh and PGE2 release from 
the urothelium/LP. The tissue baths were then drained and filled with 3mL fresh 
Krebs-bicarbonate solution. The bathing mediums were again collected at four 
different time intervals (1 min to stretch, 2 min to stretch, 1 min after stretch and 5 
min after stretch), this time while tissues were stretched over a period of 2 minutes 
(increasing strip length by 50% of the original length to mimic the physiological 
change that occurs during filling phase of the bladder) to measure the stretch-induced 
release of ACh and PGE2 from the urothelium/LP.  
Basal and stretch-induced ATP release from the urothelium/LP were collected by 
repeating the above steps in the presence of the ecto-ATP inhibitor ARL 67156 
trisodium salt (100µM). An ecto-ATP inhibitor was used to minimize the breakdown 
of ATP into ADP and allow quantification of ATP release from urothelial/LP strips. 
All the samples were collected on ice and were stored at -80°C for later assay of 
mediators.  
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Isolated tissue response from pretreated porcine bladder 
Strips of intact bladder (i), detrusor muscle (ii) and urothelium/LP (iii) were 
dissected from both control and pretreated bladders (each strip approx. 5 x 3 mm). 
Strips were suspended in tissue baths containing 6ml Krebs-bicarbonate solution 
under approximately 20mN tension and allowed to equilibrate using the same 
procedures used for the collection of samples for urothelial mediator release. 
Isometric contractions of isolated tissue strips were recorded using a PowerLab data 
acquisition system (ADInstruments, Australia) and saved for analysis.  
Contraction to Electrical Field Stimulation (EFS) 
Detrusor muscle strips (tissues (ii) above) were stimulated electrically (20V, 0.1ms 
pulse-width) for 5 seconds every 100 seconds at 1, 5, 10 and 20Hz via silver 
electrodes placed either side of the tissue.  At each stimulation frequency, tissues 
were allowed to equilibrate and when 3 consistent responses were observed, tissues 
were exposed to the next stimulation frequency (Figure 2.2). The above steps were 
repeated in the presence of N(ω)-Nitro-L-Arginine (100µM) first, then without 
washing off drug, contraction to EFS was repeated again in the presence of atropine 
(1µM) and lastly, again without washing off drugs, contraction to EFS was repeated 
in the presence of α,β-methylene ATP (10µM). 
 
Figure 2.2: Trace demonstrating the responses of detrusor muscle strip to electrical field 
stimulation (20V, 0.1ms pulse-width, at 1, 5, 10 and 20Hz) delivered as 5 second train every 
100 seconds.  
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Atropine is a non-selective, competitive antagonist of muscarinic acetylcholine 
receptors (M1-5) (Caulfield and Birdsall, 1998). Alpha, beta-methylene ATP is an 
agonist that stimulates and then desensitises P2X purinoceptors (Storr et al., 2000). 
N(ω)-Nitro-L-Arginine is a competitive inhibitor of nitric oxide synthase (NOS) with 
selectivity for the neuronal and endothelial isoforms of the enzyme (Griffith and 
Kilbourn, 1996). These were used to investigate if the chemotherapeutic drugs have 
any influence on the contribution of neurotransmitters NO, ACh and ATP to 
contractility of the detrusor muscle. 
Contraction to Carbachol  
To assess the effects of chemotherapeutic drugs on tissue responsiveness, cumulative 
concentration-response curve to carbachol (up to 273.9µM) were obtained on tissues 
(i), (ii) and (iii) described above (Figure 2.3). 
 
 
Figure 2.3: Trace demonstrating the cumulative concentration-response curve to carbachol. 
Strip of intact bladder [A], detrusor muscle [B], and urothelium/LP [C].  
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Relaxation to Isoprenaline  
After the carbachol contraction experiment, the tissues ((i), (ii) and (iii) above) in the 
organ baths were washed with fresh Krebs-bicarbonate solution every 15 minutes 
and will be allowed to re-equilibrate back to base tension (20mN) for approximately 
one and half hours.  Then, 27.39µM of carbachol was added into each bath to 
achieve approximately 50 to 80% of maximal response and waited until contractions 
to plateau. To investigate if chemotherapeutic drugs impact the ability of the tissue to 
relax, drug stimulated relaxation was observed to cumulative additions of 
isoprenaline up to 67.3µM (Figure 2.4).  
 
Figure 2.4: Trace demonstrating the cumulative concentration-response curve to 
isoprenaline. Strip of intact bladder [A], detrusor muscle [B], and urothelium/LP [C].  
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Microscopic examination of pretreated porcine bladder tissue 
Sections of control and pretreated intact bladder dome (tissue (i) above) (each section 
approx. 5 x 3 mm) were isolated immediately after treatment. These sections were 
fixed in 4% neutral buffered formalin and left for at least 24 hours at 4°C.  
The tissues were then mounted in paraffin wax by placing tissues in solutions as 
follows: 
(1) 75% ethanol for 1 hour at 4°C.  
(2) 90% ethanol for 1 hour at 4°C.  
(3) 100% ethanol for 1 hour at 4°C.  
(4) 1:1 xylene:ethanol for 30 minutes.  
(5) 100% xylene for 30 minutes.  
(6) Change with fresh 100% xylene for further 30 minutes.  
(7) 1:1 xylene:paraplast bath for 1 hour at 57°C.  
(8) Liquid paraplast for 1 hour at 57°C.  
(9) Change with fresh liquid paraplast for 1 hour at 57°C. 
 
Next, tissues were placed in aluminium rectangle moulds for cross sectioning (cut 
perpendicular to the surface of the tissue) and completely covered with liquid 
paraplast and left overnight to set.  
Sections were cut at approximately 5µm thickness and placed on uncharged slides 
and left overnight to dry. Prior to staining with Haematoxylin and Eosin, paraffin on 
the slides was removed as follows.  
(1) 100% xylene for 1 minute.  
(2) 1:1 ethanol:xylene for 3 minutes.  
(3) 100% ethanol for 3 minutes.  
(4) 90% ethanol for 3 minutes.  
(5) 70% ethanol for 3 minutes.  
(6) Distilled water for 3 minutes.  
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The sections on the slides were stained as follows. (1) Haematoxylin for 4 minutes. 
(2) Rinse excess stain with distilled water. (3) Acid alcohol (1ml HCl with 29ml 
distilled water) for 30 seconds. (4) Rinse with distilled water. (5) Scott’s Blue for 30 
seconds. (6) Rinse with distiller water. (7) Eosin for 2 minutes. (8) Rinse with 
distilled water.  
The sections were dried overnight and viewed under an Olympus BX41 microscope 
(Olympus, Australia). Images were taken at 4x, 10x and 40x magnifications using 
Infinity 2 microscope camera (Lumenera, Canada) attached to a computer using 
Infinity Capture software (Lumenera, Canada). The urothelial thickness was 
measured using ImageJ software (open source) and were compared between the 
treated and control to evaluate the effects of chemotherapeutic drugs on structure of 
the urothelium. At least 10 urothelial thickness measurements were obtained from 
each bladder section, with 4 bladders examined from each group. 
 
Data and statistical analysis 
At the end of each experiment, the weights of tissues were recorded for normalising 
data. Mean (± SEM) increases in tension induced by carbachol or electrical field 
stimulation were calculated. For response to carbachol, mean (± SEM) -logEC50 
(pEC50) values and maximum responses were calculated from the best-fit 
concentration-response curves by use of GraphPad PRISM software. Mean (± SEM) 
percentage decreases in pre-contraction to carbachol induced by isoprenaline were 
calculated. Mean (± SEM) -logIC50 (pIC50) values and minimum responses were 
calculated from the best-fit concentration-response curves. Similarly for the mediator 
release study, mean (± SEM) concentrations were determined before and after stretch 
and data for treated and control bladders were compared. Data were analysed using a 
paired Student t-test or one-way ANOVA with Dunnett multiple comparisons test, 
using GraphPad InStat3 software. Significance levels were defined as P<0.05 (*), 
P<0.01 (**) and P<0.001 (***).  
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 Cell culture experiments  
Materials and equipment were obtained from the following sources. 
 
Chemicals & drugs Supplier 
Foetal bovine serum 
D-Glucose 
L-Glutamine 
McCoy’s 5A culture medium  
Phosphate buffered saline 
Penicillin/Streptomycin 
Trypan Blue dye 
Trypsin-EDTA 
Invitrogen (Victoria, Australia) 
Calcium chloride 
DMSO 
Dulbecco’s modified eagle’s medium 
Glucose 
HEPES sodium salt 
Magnesium chloride 
Potassium chloride 
Sodium chloride 
Sigma-Aldrich (St. Louis, USA) 
Epirubicin 
Mitomycin C Tocris Bioscience (Bristol, UK) 
Bovine serum albumin  Santa Cruz Biotechnology (Dallas, USA) 
  
Equipment & consumables Supplier 
24 well plate 
25 cm2 tissue culture flask 
75cm2 tissue culture flask 
Sterile pipettes 
TPP (Trasadingen, Switzerland) 
Countess automated cell counter Invitrogen (Victoria, Australia) 
Modulus Micoplate-reader Turner BioSystems (California, USA) 
BD FACSVerse™ BD Biosciences (NSW, Australia) 
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Two human urothelial cell lines (RT4 and UROtsa) were used to assess the cell 
specific effects of MMC and epirubicin on urothelial function. Specific details 
relating to choice of cells, routine culture and treatment are provided in Chapter 5 
and 6. 
 
Resazurin reduction assay - cell viability 
Immediately, 24 hour and 1 week after drug treatment and also 1 week after second 
treatment, reduction of the redox dye resazurin to resorufin was used to measure the 
viability of cell cultures. Viable cells can be monitored by using resazurin which is a 
cell permeable redox indicator. Resazurin (blue and non-fluorescent) can be reduced 
by viable cells with active metabolism into resorufin which is pink and fluorescent. 
The amount of resorufin produced is directly proportional to the number of viable 
cells which can be quantified using a microplate fluorometer (Riss et al., 2004). Cell 
specific details provided in Chapter 5 and 6.  
 
Data and statistical analysis 
Data for ACh, ATP and PGE2 response to hypotonic stimulation were calculated by 
subtracting the concentration of basal release from the concentration of hypo-
osmotically stimulated release. Results are expressed as mean (± SEM). Data were 
analysed using a paired Student’s t-test or one-way ANOVA with Dunnett multiple 
comparisons test, using GraphPad InStat3 software. Significance levels were defined 
as P<0.05 (*), P<0.01 (**) and P<0.001 (***). 
 
 59 
Assays for urothelial mediators, NO and inflammatory 
cytokines  
The urothelial mediators (ACh, ATP, and PGE2), NO and inflammatory cytokines in 
samples collected from each experiment were measured using commercially 
available kits. Throughout the thesis, the measured concentration of these factors in 
samples, which is affected by breakdown and reuptake mechanisms, will be referred 
to as ‘release’ (e.g., decreased ACh release in control cells, and increased release of 
ATP in tissues pretreated with cytotoxic drugs). 
 
Acetylcholine  
ACh was measured using Amplex® Red ACh Assay kit purchased from Molecular 
Probes. This is a fluorescence based assay that relies on acetylcholinesterase (AChE) 
converting ACh (present in samples and standards) into choline. Choline is then 
oxidised by choline oxidase to betaine and H2O2. In the presence of horseradish 
peroxidase, H2O2 reacts with Amplex Red reagent to generate the highly fluorescent 
product resorufin. Thus, this assay measures both ACh and hydrolised products of 
ACh.  
 
Figure 2.5: Representative acetylcholine (ACh) standard curve. R2= 0.9997. 
 
First, vial of Amplex Red Reagent was dissolved into 200µl DMSO. A 1X working 
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solution to 20ml of distilled water (dH2O). A 100mM solution of ACh was prepared 
by dissolving 5mg of acetylcholine chloride in 275µl of dH2O. ACh standard curve 
was prepared by diluting 100mM acetylcholine stock solution into 1X Reaction 
Buffer to produce ACh concentrations of 0 to 5µM. 100µl of the sample or standard 
were added into each well. A working solution of 400µM Amplex Red reagent 
containing 2U/ml HRP, 0.2U/ml choline oxidase and 1U/ml AChE by adding 200µl 
of Amplex Red reagent stock solution and 100µl of the HRP stock solution, 100µl of 
choline oxidase stock solution and 100µl of the AChE stock solution to 9.4ml of 1X 
Reaction Buffer. This 10ml volume is sufficient for ~100 assays. 100µl of working 
solution was added into each well and incubated for 30 minutes at 25°C protected 
from light. Fluorescence was measured on a Modulus Microplate reader (Ex. 540 / 
Em. 590nm). The ACh concentration in samples was calculated using standard 
curves constructed from known ACh standards (Molecular Probes, 2004) (Figure 
2.5). ACh concentrations measured were normalised to weight of strips measured at 
the end of porcine tissue experiments, or normalised to controls using corresponding 
resazurin reduction data for cell culture experiments. 
 
Adenosine triphosphate  
ATP release was measured using ATP Determination kits from Molecular Probes. 
This is a bioluminescence assay for determination of ATP using luciferase and its 
substrate D-luciferin. The assay was performed according to manufacturer’s protocol. 
 
  
Figure 2.6: Representative ATP standard curve. R2= 0.9998. 
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First, 1.0ml of 1X Reaction Buffer was prepared by adding 50µl of 20X Reaction 
Buffer to 950µl of distilled water (dH2O). This 1.0ml of 1X Reaction Buffer was 
added to a vial of D-luciferin to make a 10mM D-luciferin stock solution and this 
solution was protected from light until use. ATP standard curve was prepared by 
diluting 5mM ATP stock solution into dH2O (or solution containing 100µM 
ARL67156 trisodium salt) to produce ATP concentrations of 0 to 500nM. 10µl of 
samples or standards were added into each well. A reaction solution was prepared by 
adding 0.5ml of 20X Reaction Buffer, 0.1ml of 0.1M DTT, 0.5ml of 10mM D-
luciferin and 2.5µl of firefly luciferase (5mg/ml stock solution) to 8.9ml of dH2O. 
This 10ml volume is sufficient for ~100 assays. 100µl of reaction solution was added 
into each well and incubated for 15 minutes protected from light. Luminescence was 
measured on a Modulus microplate reader. A standard curve using known 
concentrations of ATP was constructed and used to calculate ATP concentration in 
samples (Molecular Probes, 2006) (Figure 2.6). ATP concentrations measured were 
normalised to weight of strips measured at the end of porcine tissue experiments, or 
normalised to controls using corresponding resazurin reduction data for cell culture 
experiments. 
 
Nitric oxide  
NO was measured using Nitrate/Nitrite Fluorometric Assay kit provided by Cayman 
Chemical Company. This kit provides an accurate and convenient method for 
measurement of total nitrate/nitrite concentration. The assay works by adding nitrate 
reductase to samples/standards to convert nitrate to nitrite. The second step is the 
addition of DAN reagent which results in the production of a fluorescent product, 1 
(H)-naphthotriazole. The fluorescence measurement of this compound accurately 
determines nitrite concentration in the sample.  
The contents of the Assay Buffer vial were diluted to 100ml with distilled water 
(dH2O). The contents of the Nitrate Standard vial were reconstituted with 1.0ml of 
Assay Buffer. 0.1ml of reconstituted Nitrate Standard was added to 0.9ml of Assay 
Buffer to make stock standard. A nitrate standard curve was prepared by diluting 
200µM nitrate stock solution into Assay Buffer to produce nitrate concentrations of 0 
to 500pmoles. 80µl of Assay Buffer (or culture medium when applicable) was added 
to the blank wells and 30µl to standard wells. 50µl of each Nitrate standard tubes 
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were added to the dedicated wells. 10µl of samples were added to the sample wells 
and the volume was adjusted to 80µl with Assay Buffer. 10µl of the Enzyme 
Cofactor Mixture was added to each well. 10µl of the Nitrate Reductase Mixture was 
added to each well. The place was covered and incubated at room temperature for 30 
minutes (or 1 hour when assaying tissue culture medium). After the required 
incubation time, 10µl of DAN reagent was added to each well and incubated for 10 
minutes. 20µ of NaOH was added to each well. Fluorescence was measured using a 
Modulus microplate reader (Ex. 360nm / Em. 430nm). A standard curve using 
known concentrations of nitrate was constructed (fluorescence vs. picomoles) 
(Figure 2.7).  
 
 
Figure 2.7: Representative trace of nitrate and nitrite standard curve. R2= 0.996. 
 
Sample nitrate concentrations were determined by following equation.  
[Nitrate+Nitrite] (µM) = !"#$%&'(&)(&!!  !"#$%&$'#!"#$% !!"#$%&  !"  !"#$%&  !"#$  (!!)   ×dilution 
Where dilution is a sample dilution done prior to addition of the sample to the plate 
(Cayman Chemical Company, 2011). Metabolites of NO (nitrate and nitrite) 
concentrations measured were normalised to weight of strips measured at the end of 
porcine tissue experiments, or normalised to controls using corresponding resazurin 
reduction data for cell culture experiments. 
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Prostaglandin E2  
The level of PGE2 released was measured spectrophotometrically using the 
Prostaglandin E2 EIA Kit - Monoclonal provided by Cayman Chemical Company. 
This kit is a competitive assay that can be used for quantification of PGE2. The 
competition between PGE2 and a PGE2-AchE conjugate (PGE2 Tracer) for a limited 
amount of PGE2 monoclonal antibody is the basis of this assay.  
 
 
Figure 2.8: Representative prostaglandin E2 standard curve. %B/B0 is standard 
bound/Maximum bound. R2= 0.9945. 
 
The contents of one vial of EIA Buffer Concentrate (10ml of 10X) were diluted with 
90ml of dH2O. The contents of the PGE2 EIA Standard were reconstituted with 1.0ml 
of EIA Buffer to make stock standard solution. A PGE2 standard curve was prepared 
by diluting 10ng/ml of PGE2 stock solution into EIA Buffer to produce PGE2 
concentrations of 0 to 1000pg/ml. 100µl of EIA Buffer was added to non-specific 
binding (NSB) wells. 50µl of EIA Buffer was added to maximum binding (B0) wells. 
50µl of standards were added to each standard wells. 50µl of sample per well was 
added. 50µl of PGE2 AChE Tracer was added to each well except the total activity 
(TA) and the blank (Blk) wells. 50µl of PGE2 Monoclonal Antibody was added to 
each well except the TA, the NSB and the Blk wells. The plate was covered with 
plastic film and incubated for 18 hours at 4°C. After the required incubation time, the 
wells were emptied and rinsed five times with Wash Buffer. 200µl of Ellman’s 
Reagent was added to each well. 5µl of PGE2 AChE Tracer was added to the TA 
wells. The plate was covered with plastic film and the plate was developed by using 
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orbital shaker with a cover (protect from light) for 60 to 90 minutes.  Samples and 
standards were analysed and the absorbance measured on Modulus Microplate reader 
(420nm) was directly proportional to the [bound tracer] and inversely proportional to 
the [PGE2] (Cayman Chemical Company, 2010) (Figure 2.8). PGE2 concentrations 
measured were normalised to weight of strips measured at the end of porcine tissue 
experiments, or normalised to controls using corresponding resazurin reduction data 
for cell culture experiments. 
 
Inflammatory cytokine  
Cytokines (IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70) were measured using a 
BD™ Cytometric Bead Array Human Inflammatory Cytokine Kit according to the 
manufacturer’s instructions. In this kit, six bead populations with distinct 
fluorescence intensities are coated with capture antibodies specific for IL-8, IL-1β, 
IL-6, IL-10, TNF, and IL-12p70 proteins. During the assay procedure, the 
inflammatory cytokine capture beads are mixed with the recombinant standards or 
unknown samples and are incubated with the PE-conjugated detection antibodies to 
form sandwich complexes. The intensity of PE fluorescence of each sandwich 
complex reveals the concentration of that cytokine. 
First, the number of assay tubes which includes samples, standards and controls 
required for the experiment are determined. For each assay tube to be analysed, a 5µl 
aliquot of each capture bead suspension were added into a single tube labelled 
‘Mixed Capture Beads’. The contents of one vial of lyophylised Human 
Inflammatory Cytokine Standards were reconstituted with 2.0ml of assay diluent. 
This is the highest standard concentration. A standard curve was prepared by diluting 
this standard into assay diluent to produce Human Inflammatory Cytokine 
concentrations of 0 to 5,000pg/ml. The mixed capture beads that were prepared 
previously were vortexed and 25µl was added to all assay tubes. 25µl of the 
standards were added to the control assay tubes. 25µl of each unknown sample was 
added to the appropriately labelled sample assay tubes. 25µl of the Human 
Inflammatory Cytokine PE Detection Reagent was added to all assay tubes. The 
assay tubes were incubated for 3 hours at room temperature, protected from light. 
Following incubation, 500µl of wash buffer was added to each assay tubes and 
centrifuged at 200g for 5 minutes. The supernatant was carefully aspirated and 
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discarded from each assay tube. 300µl of wash buffer was added to each assay tube 
to resuspend the bead pellet. Standards and samples were acquired on a BD 
FACSVerse™ flow cytometer to measure fluorescence (BD Biosciences, 2010). 
Concentrations of inflammatory cytokines were normalised to controls using 
corresponding resazurin reduction data. 
 66 
 67 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - The effects of doxorubicin on young and 
aged porcine bladder tissue 
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Introduction 
Efficacy and adverse effects of intravesical doxorubicin 
A previous study by Garnick et al. (1984) has evaluated the effects of intravesical 
doxorubicin therapy on disease recurrence and bladder toxicity for patients with 
multiple recurrent superficial transitional cell carcinoma of the bladder. Doxorubicin 
was administered intravesically in 27 patients for 60 minutes, with the starting 
concentration of 60mg diluted in 40 to 50ml saline solution and concentrations were 
increased to 90mg. Treatments were performed every 3 weeks for a total of 8 doses, 
then every 6 weeks for 2 doses and then every 12 weeks for 2 doses. Therapy ended 
for patients once rendered free of disease. Cystoscopy and urinary cytology analysis 
revealed that of the patients 30% experienced intermittent episodes of dysuria, 26% 
reported urinary frequency, 41% had hematuria and 15% had bladder spasms. 
However, none of these toxicities led to discontinuation of the drug. The study also 
found that 56% of the patients maintained complete eradication of bladder cancer 
while 33% developed recurrent disease while on therapy. Cystoscopy has remained 
grossly negative in 3 (11%) patients who have had positive class 5 (conclusive for 
malignancy) cytological analysis. 
Lamm et al. (1991) also evaluated efficacy and side effects of intravesical 
doxorubicin chemotherapy. A total of 135 eligible patients with rapidly recurrent 
(stage Ta or T1) or in situ transitional cell carcinoma of the bladder were 
administered intravesically with 50mg of doxorubicin diluted in 50ml saline. The 
initial treatment was given within 3 days after transurethral resection of bladder 
tumour (TURBT) (the solution was retained for 30 minutes), followed by 4 weekly 
treatments and then by 11 monthly treatments. The solution was retained for 2 hours 
for subsequent treatments. In patients with carcinoma in situ, the probability of being 
disease free at 5 years was 17% after intravesical doxorubicin. The median times to 
treatment termination due to persistence (treatment failure), recurrence or 
progression of disease was 10.4 months. In patients with carcinoma in situ, the 
estimated probability of documented disappearance of disease was 34%, the median 
times to treatment failure was 5.1 months, and the probability of being disease free at 
5 years was 18%. The study also reported local adverse effects which included 26.7% 
and 48.9% of the patients experiencing haematuria and irritative bladder symptoms 
(dysuria, increased frequency, or urgency), respectively. Systemic toxicities such as 
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nausea, vomiting or anorexia in 8.9%, fever or chills in 8.1%, malaise in 12.6% and 
diarrhea in 1.5%, of the patients were observed.  
The efficacy and side effects of intravesical doxorubicin in superficial bladder cancer 
following TURBT was assessed by Huang et al. (2003). Thirty patients with 
transitional cell carcinoma received 30mg doxorubicin in 50ml saline for 2 hours. 
The instillation was performed every week during first month followed by monthly 
instillation for 11 times. The recurrence rate was 30% and the median recurrence-free 
survival was 20 months. The bladder toxicities dysuria, urinary frequency, 
haematuria, urinary infection and bladder spasm occurred in 13.3%, 16.7% 13.3%, 
10% and 6.7% of the patients. 
A more recent study by Al-Gallab et al. (2009) incorporated 85 patients with non-
muscle invasive bladder cancer Ta (27%) and T1 (73%) who were treated 
intravesically with 50mg doxorubicin in 50ml saline for 2 hours. First session started 
a week after TURBT and repeated weekly 4 times then monthly 11 times. The study 
found that the total tumour recurrence rate was 23.5%. Of these, tumour recurred in 
35% of patients with Ta and in 65% of patients with T1. Also, it was demonstrated 
that 16.5%, 14.1%, 14.1%, and 9.4% of the patients developed urinary frequency, 
dysuria, haematuria, and urinary tract infection, respectively.  
 
In vitro model, Porcine Bladder  
In this study, porcine bladder tissue was used as an in vitro model to investigate the 
effects of doxorubicin treatment on normal bladder function. In scientific research, 
pig was one of the earliest animals used and this was due to the remarkable 
similarities between pigs and humans. The anatomical, physiological, immunological, 
metabolic and nutritional similarities with human makes pig a unique and viable 
model for studying many human diseases (Verma et al., 2011).  In the field of 
bladder research, porcine bladder is also used widely both in vivo and in vitro as they 
are known to closely resemble the human bladder (Akino et al., 2008; Arentsen et al., 
2011; Bramich and Brading, 1996; Bridgewater et al., 1993; Mills et al., 2000; Moro 
et al., 2012; Murakami et al., 2007).  
It has been demonstrated in various studies that the composition of bladder wall is 
similar between human and pig in which both consist of urothelium (~0.1 mm), 
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lamina propria (~0.3 mm), and the detrusor smooth muscle divided into an inner and 
an outer tunica muscularis (~3 mm total thickness) (Dixon and Gosling, 1983; 
Narumi et al., 1993; Teufl et al., 1997). Thus, pig and human bladder are structurally 
simular but this also extends to bladder physiology and pharmacology. The subtype 
of β-adrenoceptor in the detrusor smooth muscle that mediates relaxation appears to 
be species-dependant, but it has been reported that pigs have a similar population of 
β-adrenoceptor subtypes to human with β3-adrenoceptor predominating and a minor 
population of β2-adrenoceptors (Yamanishi et al., 2002b). The muscarinic M2 to M3 
receptor ratio in porcine bladder is similar to that in human (both 3:1) (Wang et al., 
1995) and also the muscarinic subtype that leads to bladder contraction is mediated 
via the minor population of M3 muscarinic receptor in both pig (Sellers et al., 2000) 
and human bladder (Chess-Williams et al., 2001). In addition, a study by Kumar et al. 
(2004) has demonstrated that the quantity of ATP release, the proportion of ATP 
release from neuronal and non-neuronal sources, and the activity of ecto-ATPases 
affecting ATP levels in response to mechanical stretch and electrical field stimulation 
are similar in pig and human bladder.  
Despite many advantages of using porcine bladder in scientific research, there are 
also limitations of this model.  A large animal model like pig is more expensive and 
difficult to manage compared to rodents. However, in the long-term, they often prove 
to be cost-effective in providing more reliable and worth-while results because of 
their excellent physiological similarity to humans (Doyle et al., 1968; Verma et al., 
2011). Another disadvantage when using tissues isolated from animal models is that 
they can only be kept for a short period of time without deterioration of function. For 
example, the life span of the detrusor muscle and the urothelium are limited to 
approximately 2 days and 1 day, respectively. This makes long-term studies difficult 
and recovery studies impossible. Furthermore, it has been reported that the immune 
response differs slightly from one pig to another, and also sex and age have been 
reported to affect the protein profile (Rothkotter et al., 2002), although this may 
simply reflect what also occurs in humans. 
The porcine bladders obtained from the local abattoir have been previously used in 
my Honours study to assess the effect of doxorubicin treatment on normal bladder 
function. Despite the fact that bladder cancer is primarily a disease of the elderly, 
with incidence peaking at 85 years of age (Schultzel et al., 2008), the bladders from 
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young pigs (4 to 6 months) were used in these experiments because it was more 
frequently available compared to tissues from older pigs (1 to 2 years; these tissues 
will be called “aged” throughout the thesis) in addition to the constrained timeframe 
for the Honours research.  
 
Effects of Ageing on bladder function 
In almost every physiological system, ageing is associated with declining function. 
The function of the gastrointestinal tract is altered as you age and some changes 
include impaired acid secretion and, decreased absorptive surface, splanchnic blood 
flow and gastrointestinal motility (Geokas and Haverback, 1969; Greenblatt et al., 
1982). A study by Wynne et al. (1989) has reported that between the ages of 20 and 
80 years, liver size decreases by 18 to 44% and hepatic blood flow declines at a rate 
of 0.3 to 1.5% per year after the age of 25. Also, decline in renal weight, renal blood 
flow, the number of glomeruli and the glomerular filtration rate occurs in a linear 
fashion after the age of 30 years (Anderson and Brenner, 1986; Brown et al., 1986). 
In addition, it is well established that lung function declines with age such as 
decrease in the vital capacity and forced expiratory volume, and reduced elastic force 
of the lung (Knudson, 1991). Ageing is also associated with deteriorated function of 
the bladder.  
Changes in the morphology of the bladder in response to ageing has been reported by 
Gosling (1997). The aged bladders demonstrated a normal morphology of smooth 
muscles cells packed closely together with relatively little intervening connective 
tissue, but a reduction in the innervation of the smooth muscle cells (autonomic 
presumptive cholinergic nerve) was observed compared to normal bladders.  
In a report by Chun et al. (1988), a 52% and 100% increase in frequency of 
micturition and voiding pressure, respectively, were demonstrated in aged male rats 
(22 to 24 months old) compared to young male rats (5 to 7 months old).  
A previous study by Saito et al. (1999) compared blood flow to the bladder and 
detrusor function in young (6 months old) and aged (24 months old) male rats and 
reported various age-related changes. The study found that in both young and aged 
rats, blood flow to the bladder decreased as intravesical volume increased and was 
smaller in aged rats compared to young rats. Also, voiding pressure was smaller and 
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bladder capacity was larger in aged rats. Impairment in the pressure increase, in 
response to bethanechol and to low frequency field stimulation was observed in aged 
rats. In addition, compliance of isolated bladders of aged rats was greater and peak 
response to field stimulation was observed at a larger capacity. These findings 
suggest that the changes in bladder function with ageing may correlate with a 
decrease in blood flow to the bladder. 
Lluel et al. (2000) also reported changes in the bladder function of female rats with 
ageing. While 60% of conscious aged rats (30 months old) showed spontaneous 
contractions during the bladder-filling phase, only 25% of young adult rats (10 
months old) showed spontaneous contractions. Micturition pressure and duration of 
micturition were significantly higher by approximately 40% to 50% in aged rats. 
Contrarily, bladder capacity, bladder compliance, micturition volume, and residual 
volume were not changed with age. In addition, in vitro studies have revealed that 
while contractile responses of the bladder body to KCl, carbachol, arecoline, and α,β-
mATP were similar in tissues from young and aged rats, maximum responses to 
noradrenaline were increased by two-fold in the aged rats. The potency of 
isoprenaline in relaxing KCl-precontracted bladder body was similar in both age 
groups. Furthermore, a significant increase in the mean thickness of the muscularis 
layer with age was observed, while the collagen density significantly decreased in the 
muscularis and in the lamina propria layers with age. 
A recent study using male rats has also demonstrated significant age related 
differences in bladder function. An increase in bladder capacity, post-void residual 
volume, micturition volume and frequency, baseline and intermicturition pressure, 
and spontaneous activity, and a decrease in micturition pressure were observed in 
aged rats (28 to 30 months old) compared to young rats (4 to 6 months old). The 
study also reported significantly lower responses of bladder strips to carbachol and 
electrical field stimulation in aged rats and histological examination revealed 
urothelial thinning, lower muscle mass and higher collagen contents in the bladders 
of aged rats compared to young rats (Zhao et al., 2010). 
Alterations in bladder function have been also observed with ageing in human. An 
urodynamic study of 436 patients (253 men and 183 women, 40 years of age or older) 
has shown that, in both sexes, postvoid residual urine volume increased, and peak 
flow rate, average flow rate, voided volume and bladder capacity decreased with age 
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(Madersbacher et al., 1998). Hence, it raises concern that elderly patients with 
reduced function of organs may develop severe side effects after chemotherapeutic 
treatment. There is a study supporting this view which reported an increased 
incidence of side effects in elderly cancer patients treated with chemotherapy 
compared to younger subjects (Goto et al., 2012).  
 
Aims 
Despite the large number of patients receiving doxorubicin intravesically and the 
high percentage of those suffering urological adverse effects, there have been no 
investigations of the actions of this agent on the non-malignant tissues of the bladder.  
Thus, the aim of the present study was to investigate the effects of doxorubicin 
treatment on (1) basal and stretch-induced release of mediators (ACh, ATP and PGE2) 
from strips of urothelium/LP, (2) tissue responsiveness and sensitivity of bladder 
tissues (intact bladder, detrusor muscle and urothelium/LP) to cholinergic and 
adrenergic stimulation, (3) neurogenic response of detrusor muscle strips to electrical 
field stimulation, and (4) integrity of the urothelium, LP and detrusor muscle. These 
studies aimed to determine whether changes in the local bladder mechanisms may 
provide an explanation for the bladder dysfunction noted by patients following 
intravesical treatment with doxorubicin. Experiments were performed on both young 
and aged porcine bladders to also identify the effects of ageing on the bladder 
function and response to doxorubicin treatment.  
Some of the experiments on young pigs in the following chapter were included in my 
Honours thesis.  These included contractile responses of detrusor muscle strips to 
carbachol and mediator release from urothelial/LP strips. However, the experiments 
were repeated during my PhD project to provide contemporary controls to compare 
with the aged animals and to increase N values, thus allowing a more accurate 
comparison of tissues from young and aged pigs. 
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Materials and Methods 
(Refer to “Porcine tissue experiments” and “Assays for urothelial mediators, NO and 
inflammatory cytokines” sections of Chapter 2 for full details) 
Fresh bladders from two groups of pigs were used in this study: 
(1) Young pigs (4 to 6 months old; approx. 80kg)  
(2) Aged pigs (2 to 3 years old; approx. 250kg) 
Throughout the thesis, bladders from young pigs will be named “Young bladders” 
and bladders from aged pigs will be named “Aged bladders”. 
A clinically used concentration (1mg/ml diluted in fresh Krebs-bicarbonate solution) 
of intravesical doxorubicin was applied to the luminal surface of full thickness sheets 
of bladder wall by using double-chamber treatment apparatus for 1 hour (clinical 
duration).  
Following this pretreatment, strips of intact bladder, detrusor muscle and the 
urothelium/LP were isolated to assess the effects of doxorubicin on tissue responses, 
and mediator release, and whole bladder sections were also isolated to evaluate the 
bladder morphology after treatment. The release of mediators (ATP, ACh, and PGE2) 
from the urothelium/LP was measured using commercially available kits.  
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Results  
Contractile responses to carbachol 
Influence of age on responses of untreated (control) tissues 
All tissue strips (intact bladder, detrusor muscle and urothelium/LP) from control 
incubated young and aged bladders contracted to carbachol (Figure 3.1).  
In both young and aged control tissues, when expressed as the force developed per 
gram of tissue, the largest contractions to carbachol were produced by the 
urothelium/LP tissues, which produced responses significantly (P<0.01) greater than 
the detrusor muscle tissues, which in turn produced contractions significantly (young 
P<0.01; aged P<0.001) greater than the intact bladder tissues (Table 3.1). 
The potency (pEC50 values) of carbachol was simular on detrusor muscle tissues 
from both young and aged control bladders but the potency was higher in intact 
bladder and urothelial/LP tissues from young control bladders compared to aged 
control bladders (Table 3.1).  
The maximum responses to carbachol on all tissues types were significantly greater 
(5-fold) in control tissues from young bladders compared to control tissues from 
aged bladders. Thus, with increasing age, there is reduction in the contractions 
produced by the various tissue types within the bladder.  
Effect of doxorubicin pretreatment (Young & Aged) 
All tissue strips from doxorubicin pretreated young and aged bladders contracted to 
carbachol (Figure 3.1) and doxorubicin pretreatment did not affect the potency 
(pEC50 values) of carbachol on any of the tissues from either young or aged bladders 
(Table 3.1). 
Pretreatment with doxorubicin (1mg/ml) for 1 hour did not alter subsequent 
responses of the detrusor muscle tissues or intact bladder tissues from young 
bladders to carbachol (Figure 3.1; Table 3.1).  However, doxorubicin pretreatment 
did enhance subsequent responses of the urothelium/LP tissues from young bladders 
to carbachol (Figure 3.1). 
In contrast, in all three tissue types of aged bladders, doxorubicin pretreatment 
significantly enhanced subsequent responses to carbachol (Figure 3.1; Table 3.1).  
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Figure 3.1: Cumulative concentration-response curves to carbachol of tissues from control 
and doxorubicin pretreated bladders from young and aged animals. Responses of intact 
bladder [A & B], detrusor muscle [C & D] and urothelium/LP [E & F]. Data are expressed as 
means ± SEM. *P<0.05 and **P<0.01 compared to maximum response of control tissue. 
Note differences in scales between tissues from young and aged bladders. 
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Table 3.1: Potency (pEC50) values and maximum responses (mN/mg tissue) to carbachol of 
intact bladder strips, detrusor muscle strips and strips of urothelium/LP from the bladders of 
young and aged animals.  Data are expressed as means ± SEM. 
Young bladders 
Tissue Control (untreated) bladders  Doxorubicin-pretreated bladders 
 Potency Maximum N  Potency Maximum N 
Intact bladder 4.81±0.35 1.08±0.25 6  5.23±0.26 1.02±0.15 5 
Detrusor muscle 5.07±0.29 1.89±0.34 6  5.14±0.26 1.88±0.29 6 
Urothelium/LP 5.33±0.14 3.39±0.27 4  5.39±0.09 5.45±0.28 5 
 
Aged bladders 
Intact bladder 5.69±0.08a 0.23±0.01b 6  5.61±0.09 0.28±0.01 6 
Detrusor muscle 5.59±0.17 0.33±0.03b 6  5.81±0.14 0.49±0.03 6 
Urothelium/LP 6.07±0.11b 0.65±0.03c 6  5.94±0.14 0.79±0.05 6 
 
 
N number of bladders examined 
a P<0.05 compared to young control tissue 
b P<0.01 compared to young control tissue 
c P<0.001 compared to young control tissue 
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Relaxation responses to isoprenaline 
Influence of age on responses of untreated (control) tissues 
All tissues from the control young and aged bladders relaxed to isoprenaline (Figure 
3.2). The potency (pEC50 values) of isoprenaline was similar on intact bladder tissues 
and detrusor muscle tissues. However, the potency was significantly (P<0.01) higher 
in control urothelial/LP tissues from young bladders compared to aged bladders 
(Table 3.2). In addition, there was no difference in the maximum relaxation to 
isoprenaline (expressed as percentage of pre-contraction to carbachol) between 
young and aged bladders on intact bladder tissues or detrusor muscle tissues, but the 
maximum relaxation to isoprenaline was significantly (P<0.05) greater in control 
urothelial/LP tissues from aged bladders compared to young bladders (Table 3.2).  
Effect of doxorubicin pretreatment (Young & Aged) 
All tissue strips from doxorubicin pretreated young and aged bladders relaxed to 
isoprenaline (Figure 3.2). Although, it seems doxorubicin pretreatment greatly 
reduced relaxation responses of detrusor muscle from aged animals at low 
concentrations of isoprenaline (but not high), statistical analysis of individual points 
as shown in Figure 3.2d demonstrated that they are not significantly different. Also, 
potency of isoprenaline in detrusor muscle from aged bladders was not affected by 
doxorubicin pretreatment (Table 3.2).  In young bladders, doxorubicin pretreatment 
did not affect either the potency of isoprenaline or the maximum relaxation to 
isoprenaline in any of tissue (Figure 3.2; Table 3.2). 
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Figure 3.2: Cumulative concentration-response curves to isoprenaline in tissues from control 
and doxorubicin pretreated bladders from young and aged animals. Responses expressed as a 
percentage of the pre-contraction to carbachol (27.4µM). Responses of intact bladder [A & 
B], detrusor muscle [C & D], and urothelium/LP [E & F]. ns P>0.05 compared to 
corresponding responses of control tissue. 
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Table 3.2: Potency (pEC50) values and maximum relaxation (%) to isoprenaline of intact 
bladder strips, detrusor muscle strips and strips of urothelium/LP. Data are expressed as 
means ± SEM. 
Young bladders 
Tissue Control (untreated) bladders  Doxorubicin-pretreated bladders 
 Potency Maximum N  Potency Maximum N 
Intact bladder 6.69±0.12 64.26±1.78 5  6.79±0.24 62.03±3.64 5 
Detrusor muscle 7.56±0.29 63.66±3.20 5  7.55±0.18 62.10±2.25 5 
Urothelium/LP 7.43±0.21 60.47±2.67 5  7.62±0.33 63.41±3.49 5 
 
Aged bladders 
Intact bladder 6.55±0.11 68.01±1.65 5  6.37±0.11 62.09±2.07 5 
Detrusor muscle 7.50±0.45 59.57±5.54 5  6.51±0.09c 63.67±1.66 5 
Urothelium/LP 6.23±0.12a 51.35±2.84b 5  6.23±0.11 56.80±2.41 5 
 
 
N number of bladders examined 
a P<0.01 potency compared to control urothelium/LP from young bladders 
b P<0.05 maximum relaxation compared to control urothelium/LP from young bladders 
c P=0.0631 potency compared to control detrusor muscle 
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Detrusor responses to electrical field stimulation 
Influence of age on responses of untreated (control) tissues 
Electrical field stimulation (EFS) induced frequency-dependent contractions of 
detrusor muscle strips from control incubated young and aged bladders that in 
preliminary experiments were abolished by the neurotoxin tetrodotoxin (1µM), thus 
confirming their neurogenic origin (data not presented).   
At the lowest stimulation frequency of 1Hz, the responses of control tissues from 
young bladders small (0.003±0.003mN/mg) (Figure 3.3a) but responses of tissues 
from aged bladders were greater (0.015±0.005mN/mg) (Figure 3.3b).  With 
increasing stimulation frequency, responses increased, but at every frequency tested 
(1, 5, 10 and 20Hz), responses were significantly (P<0.01) greater in tissues from 
aged bladders compared to young bladders (Figure 3.3a and b). 
The presence of N(ω)-Nitro-L-Arginine (L-NNA; 100µM) failed to potentiate the 
response in control tissues from young and aged bladders. However, atropine (1µM) 
decreased the detrusor contraction at every frequency and this was similar in both 
young and aged control tissues (Figure 3.3c and d; Table 3.3). The detrusor 
contractions were not further reduced by the presence of α,β-mATP (10µM) (Figure 
3.3c and d). 
Effect of doxorubicin pretreatment (Young & Aged) 
In detrusor muscle tissues from young and aged bladders that had received 
doxorubicin pretreatment, a frequency-dependant contraction was observed in 
response to EFS. Following doxorubicin pretreatment, while the responses to EFS of 
detrusor strips from young bladders were significantly enhanced at all frequency 
(Figure 3.3a), responses of tissues from aged bladders were significantly depressed at 
the higher frequencies of 10 and 20Hz (Figure 3.3b). 
The presence of L-NNA (100µM) did not potentiate the detrusor contractions to EFS 
in either young or aged bladders that had received doxorubicin pretreatment, but the 
responses were depressed by atropine in both age groups (Figure 3.3e and f). The 
inhibition of responses to EFS by the muscarinic antagonist in doxorubicin pretreated 
tissues from young bladders and aged bladders were 68.2±4.0% (average of all 
frequencies) and 52.6±7.8% (average of all frequencies), respectively and these 
inhibition of responses were not different to those observed in control tissues from 
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young and aged bladders (Figure 3.3e and f; Table 3.3). The responses were not 
depressed further by α,β-mATP (Figure 3.3e and f).  
 
 
Figure 3.3: Detrusor muscle response to electrical field stimulation (EFS) in tissues from 
control and doxorubicin pretreated young [A] and aged [B] bladders. Effect of L-NNA, 
atropine and α,β-mATP on control [C] and pretreated [E] tissues from young animals and 
control [D] and pretreated [F] tissues from aged animals. Data are expressed as means ± 
SEM. *P<0.05 and **P<0.01 compared to control incubated tissues.  
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Table 3.3: Reduction (%) in detrusor response to EFS in the presence of atropine (1µM). 
Data are expressed as means ± SEM. 
Young bladders 
Frequency (Hz) Control (untreated) bladders  Doxorubicin-pretreated bladders 
 Reduction (%) N  Reduction (%) N 
1 7.69±7.69 4  41.71±18.99a 4 
5 55.13±6.17 4  40.66±6.13 4 
10 67.62±3.71 4  62.85±2.34 4 
20 68.07±4.32 4  68.20±4.01 4 
Average 49.63±14.30   68.20±4.01  
Aged bladders 
1 46.76±9.11 7  42.19±11.81 7 
5 52.11±18.04 7  37.37±21.27 7 
10 69.40±17.27 7  59.72±17.92 7 
20 77.28±17.42 7  71.11±21.1 7 
Average 61.39±7.17   52.60±7.82  
 
N number of bladders examined 
a P=0.1479 reduction (%) at 1Hz compared to control bladders.  
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Urothelial mediators 
Influence of age on responses of untreated (control) tissues  
Urothelial/LP strips from young and aged bladders that received control incubation 
released all three mediators (ATP, ACh and PGE2) (Figure 3.4 and 3.5).  
The release of urothelial/LP mediators was measured at 2, 3 and 7 minute time points 
in tissues from young bladders but in tissues from aged bladders mediator release 
was measured at four different time points including 1, 2, 3 and 7 minutes. The 
difference in time points was due to the fact that only three time points were selected 
for measuring mediator release from young bladders during my Honours study whilst 
for my PhD study, the 1 minute time point was also included to provide additional 
information. Thus, when comparing the release between young and aged bladders, 
only 2, 3 and 7 minute time points will be considered.  
Stretching the control tissues from young bladders increased ATP release at 2, 3 and 
7 minute time points, but the increases were not statistically different (Figure 3.4a 
and b). Stretch of the tissues from aged bladders failed to increase any of the 
mediators at any time point (Figure 3.5a and b).   
In control tissues, basal release of ATP from aged bladders was significantly 
enhanced compared to young bladders at 2, 3 and 7 minute time points (Figure 3.6a). 
Stretch-induced ATP release from aged bladders was also increased significantly 
compared to aged bladders but only at 3 and 7 minutes (Figure 3.6b). Both basal and 
stretch-induced release of ACh and PGE2 from aged bladders were significantly 
enhanced compared to young bladders at 2, 3 and 7 minutes (Figure 3.6c, d, e and f). 
The average values of basal ATP, ACh and PGE2 release at 2, 3 and 7 minute time 
points in control tissues from aged bladders were increased by 9-fold, 9-fold and 4-
fold compared to the values from young bladders (Table 3.4). The average values of 
stretch-induced ATP, ACh and PGE2 release at the same time points from aged 
bladders were increased by 2-fold, 8-fold and 4-fold compared to the values from 
young bladders (Table 3.4). 
Effect of doxorubicin pretreatment (Young & Aged) 
Doxorubicin pretreated tissues from both young and aged bladders also released all 
three mediators and stretching the tissues only produced increase in ATP release at 2, 
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3 and 7 minutes in young bladders and at 7 minutes in aged bladders (Figure 3.4 and 
3.5).  
In doxorubicin-pretreated tissues from young bladders, basal release of ACh and 
PGE2 was similar to control tissues (Figure 3.4c, d, e and f).  However, basal release 
of ATP in pretreated tissues was significantly increased at 2, 3 and 7 minutes 
compared to control tissues (Figure 3.4a). The release of stretch-induced ATP was 
also significantly increased at 3 and 7 minutes (Figure 3.4b). 
In tissues that received doxorubicin pretreatment from aged bladders, basal release of 
all three mediators was similar to control tissues (Figure 3.5), but stretch-induced 
ATP release was significantly increased compared to control tissues at 7 minutes 
(Figure 3.5b). 
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Figure 3.4: Mediator release from the urothelium/LP of young bladders. Effects of 
doxorubicin pretreatment on basal ATP [A], acetylcholine [C] and prostaglandin E2 [E] 
concentrations after 7 minute incubation, and ATP [B], acetylcholine [D] and prostaglandin 
E2 [F] concentrations after 7 minute incubation that included stretching over the initial 2 
minutes. Data are expressed as means ± SEM. *P<0.05 compared to control incubated 
tissues. 
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Figure 3.5: Mediator release from the urothelium/LP of aged bladders. Effect of doxorubicin 
pretreatment on basal ATP [A], acetylcholine [C] and prostaglandin E2 [E] concentrations 
after 7 minute incubation, and ATP [B], acetylcholine [D] and prostaglandin E2 [F] 
concentrations after 7 minute incubation that included stretching over the initial 2 minutes. 
Data are expressed as means ± SEM. *P<0.05 compared to control incubated tissues.  
 
0 2 4 6 8
0
5
10
15
20
Time (minutes)
[A
TP
] (
nM
)
Control
Doxorubicin pretreated 
A N=5
Time (minutes)
[A
ce
ty
lc
ho
lin
e]
 (µ
M
)
0 2 4 6 8
0
5
10
15
20
C N=6
0 2 4 6 8
0
5
10
15
20
25
Time (minutes)
[P
ro
st
ag
la
nd
in
 E
2] 
(n
M
)
E N≥5
Time (minutes)
[A
TP
] (
nM
)
0 2 4 6 8
0
5
10
15
20
B
*
N=6
Time (minutes)
[A
ce
ty
lc
ho
lin
e]
 (µ
M
)
0 2 4 6 8
0
5
10
15
20
D N=6
0 2 4 6 8
0
5
10
15
20
25
Time (minutes)
[P
ro
st
ag
la
nd
in
 E
2] 
(n
M
)
F N=6
A
TP
A
ce
ty
lc
ho
lin
e
Pr
os
ta
gl
an
di
n 
E 2
 
Basal Stretch-induced
 88 
 
Figure 3.6: Comparison of urothelial/LP mediator release in control tissues from young and 
aged bladders. Basal and stretch-induced release of ATP [A & B], acetylcholine [C & D], 
and prostaglandin E2 [E & F] concentrations after 7 minute incubation. Data are expressed as 
means ± SEM. *P<0.05 compared to young bladders.  
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Table 3.4: Mean (± SEM) urothelial/LP mediator concentrations at 2, 3 and 7 minute time 
points from control incubated tissues. 
Young bladders 
Mediator  Basal release  Stretch-induced release 
 Concentration   Concentration  
ATP (nM) 0.67±0.11   2.32±0.8  
ACh (µM) 1.02±0.12   1.03±0.11  
PGE2 (nM) 1.28±0.5   1.63±0.59  
Aged bladders 
ATP (nM) 6.09±0.25   4.29±0.36  
ACh (µM) 9.42±4.23   8.37±3.49  
PGE2 (nM) 5.35±3.01   6.48±3.83  
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Inhibition of detrusor contraction by the urothelium 
Influence of age on responses of untreated (control) tissues  
The presence of an intact urothelium/LP on strips of detrusor muscle inhibited 
contractions to carbachol in control tissues from both young and aged bladders 
(Figure 3.7a and b). While the potency of carbachol was similar in intact bladder and 
detrusor muscle tissues, maximum responses were significantly depressed (P<0.01; 
21.9±11.7%) in aged bladders. In contrast, whilst maximum responses of young 
bladders look significantly depressed (32.9±15.8%) in tissues with intact 
urothelium/LP compared to tissues without the urothelium/LP, statistical analysis 
revealed that it was not the case. The degree of inhibitions was similar in young and 
aged bladders.   
Effect of doxorubicin pretreatment (Young & Aged) 
The presence of urothelium/LP on detrusor muscle that had received doxorubicin 
pretreatment from young and aged bladders also inhibited contractions to carbachol 
(Figure 3.7c and d). The potency of carbachol was again similar in intact bladder and 
detrusor muscle tissues, but the maximum responses were significantly reduced 
(P<0.01 for young bladders; P<0.001 for aged bladders) in tissues with an intact 
urothelium/LP. The inhibition was similar in tissues from both young (30.1±21.9%) 
and aged (36.1±12.8%) bladders and the amount of inhibition was not affected by 
doxorubicin pretreatment in both young (P=0.9178) and aged (P=0.432) bladders. 
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Figure 3.7: Inhibitory effects of the urothelium/LP on detrusor responses to carbachol in 
intact bladder and detrusor muscle tissues from control [A & B] and doxorubicin pretreated 
[C & D] bladders. Data are expressed as means ± SEM. *P<0.05, **P<0.01 and ***P<0.001 
compared to maximum response of detrusor muscle.  
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Bladder histology 
Influence of age on responses of untreated (control) tissues  
Typical histological features were clearly identifiable in sections of control incubated 
young and aged bladders, with the urothelium and lamina propria thrown into folds 
and overlying a deeper detrusor muscle layer (Figure 3.8 and 3.9). Urothelial 
thickness of young bladders (35.04±2.21µm, N=4) was significantly thicker (P<0.05) 
than the aged bladder (27.81±1.94µm, N=4). 
Effect of doxorubicin pretreatment (Young & Aged) 
In sections of doxorubicin pretreated young and aged bladders, typical histological 
features were also clearly observed (Figure 3.8 and 3.9). Doxorubicin treatment did 
not affect urothelial integrity with the urothelial thickness of pretreated young (33.18 
± 3.03µm, N=4) and aged (27.48±2.62µm, N=4) bladders being similar to those of 
control incubated young and aged bladders.  
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Figure 3.8: Haematological examination of young bladder section. Haematoxylin 
and eosin (H and E) staining of control [A & C], and doxorubicin pretreated [B & D] 
bladders. H and E staining at x10 [A & B] and x40 [C & D] showing the urothelium 
(U) and lamina propria (LP). 
 
 
 
 
 
 
 
 
Control Doxorubicin pretreated 
A B 
C D 
  
  
Urothelium 
Lamina propria 
400µm 
Urothelium 
Lamina propria 
400µm 
U 
LP 
U 
LP 
100µm 100µm 
 94 
 
Figure 3.9: Haematological examination of aged bladder section. Haematoxylin and 
eosin (H and E) staining of control [A & C], and doxorubicin pretreated [B & D] 
bladders. H and E staining at x10 [A & B] and x40 [C & D] showing the urothelium 
(U) and lamina propria (LP). 
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Discussion  
Mediator release from the urothelium/LP 
ATP, ACh and PGE2 
In this study, a basal release of ATP was observed in control and doxorubicin 
pretreated urothelium/LP tissues from both young and aged bladders. In young 
bladders, basal ATP release was enhanced in tissues that received doxorubicin 
pretreatment compared to control tissues. Stretching the tissues increased ATP 
release over basal levels in both control and pretreated tissues and this stretch-
induced ATP release was increased following doxorubicin pretreatment. In aged 
bladders, while doxorubicin pretreatment did not affect basal ATP release, stretch-
induced ATP release was significantly enhanced in pretreated tissues.  
It is well established that in normal bladder, the urothelial ATP initiates a mechanism 
by which low threshold sensory nerves are stimulated via P2X3 receptors on the 
urothelium and lamina propria and thereby activates the micturition reflex 
(Burnstock, 2011). Stretch-induced ATP release is increased in the bladders of 
patients with idiopathic or neurogenic OAB (Kumar et al., 2010). Various in vitro 
studies using animal models of OAB and IC have also suggested that increased 
urothelial ATP release from damaged or sensitised cells in response to injury or 
inflammation might be the contributing factor for triggering increased bladder 
activity and painful sensations via excitation of purinergic (P2X) receptors on 
sensory fibers (Khera et al., 2004; Munoz et al., 2011; Smith et al., 2005; Sun et al., 
2001). In addition, reduced ecto-ATPase activity was observed in OAB (Nishiguchi 
et al., 2005), which suggests that intravesical doxorubicin treatment could possibly 
increase ATP levels by acting on ecto-ATPase (Moore et al., 1992). Thus, elevated 
ATP release from both young and aged bladders in this study may provide an 
explanation for the increased urgency and frequency observed in patients treated with 
intravesical doxorubicin. In addition, ATP can also activate high threshold, 
nociceptive (pain) nerve fibres and ATP release is also greatly increased in patients 
with painful bladder syndrome (Kumar et al., 2007).  Thus, the dysuria observed 
after intravesical treatment with doxorubicin may be related to the enhancement of 
urothelial ATP release. 
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There was also basal release of ACh and PGE2 from the urothelium/LP, but unlike 
ATP, stretch did not increase release.  The role of these urothelial mediators is not 
completely elucidated yet, but ACh appears to influence sensory nerve activity (Daly 
et al., 2010; Yu and de Groat, 2010) and urothelial contractile activity (Akino et al., 
2008; Moro et al., 2012; Moro et al., 2011), while PGE2 influences bladder 
contractions (de Jongh et al., 2007) and sensitizes some capsaicin-sensitive afferent 
neurons (Maggi et al., 1988a).  A stretch-independent release of this prostaglandin 
from the urothelium has also been reported (Nile et al., 2010). Doxorubicin 
pretreatment altered neither the basal nor the stretch-induced release of ACh and 
PGE2 in either young or aged bladders and it is therefore unlikely that these 
mediators are involved in the adverse effects induced by intravesical administration 
of this cytotoxic drug.  
The finding that doxorubicin affected the mediators differently is not surprising since 
the release mechanisms for these mediators is very different. Prostaglandins 
including PGE2 are synthesised and released fresh by cyclooxygenase (COX)-1 and 
COX-2 in the bladder during detrusor contraction (Bultitude et al., 1976; Khalaf et 
al., 1980; Klarskov, 1987) and under basal physiological conditions (Brown et al., 
1980; Poggesi et al., 1980). The expression of COX-1 by the basal layer of the 
urothelium indicates that prostaglandins are synthesised and released from these sites 
(de Jongh et al., 2009; Rahnama'i et al., 2010). Many potential mechanisms for 
urothelial-derived ATP release have been proposed including vesicular release 
(Birder et al., 2003; McLatchie and Fry, 2014; Sui et al., 2014; Wang et al., 2005), 
connexin or pannexin hemichannels (McLatchie and Fry, 2014; Timoteo et al., 2014; 
Wang et al., 2005), transient receptor potential channels (RRPV) 1 or 4 (Mochizuki 
et al., 2009; Wang et al., 2005), ATP-binding cassette (ABC) transporters (Wang et 
al., 2005) and mechanosensitive channels (Birder et al., 2003; Dunning-Davies et al., 
2013). A recent study by McLatchie et al. (2014) has suggested the potential 
involvement of the cystic fibrosis transmembrane conductance regulator (CFTR) and 
intracellular calcium in urothelial-derived ACh release and it appears to be 
independent of extracellular calcium, connexins and pannexins, vesicular 
acetylcholine transporter (VAChT) or the organic cation transporter (OCTs) 1 and 3 
(Lips et al., 2007; McLatchie et al., 2014). 
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The amount of all three mediators, both basal and stretch-induced release was greater 
in tissues from aged bladders compared to tissues from young bladders. The 
observation of age-related increase in mediators from the urothelium/LP in this study 
was consistent with some previous studies, although other studies are contradictory. 
A study by Yoshida et al. (2006) using human bladder strips with or without 
urothelium has shown that the tetrodotoxin-insensitive non-nerve-evoked ACh 
release was significantly greater in strips with urothelium than without urothelium 
and this non-nerve-evoked ACh release from strips with urothelium increased with 
age. Also, an age-related increase in the stretch-induced release of non-nerve-evoked 
ACh was observed. Similarly for ATP, a recent study with mice, Daly et al. (2014) 
demonstrated significantly increased ATP levels in the lumen of aged bladder (24 
months) preparations compared to young bladders (3-4 months) when the whole 
intact bladder was distended and also significantly reduced ACh levels were reported 
in aged bladders in comparison to young bladders. Furthermore, the PGE2 levels in 
urine samples collected from young boys (aged less than 15 years old) with OAB 
was negatively correlated with age (N=38, r = -0.379, P<0.05) (Aoki et al., 2009). 
The results of these studies suggest that ageing may alter the release of mediators 
from the bladder including the urothelium.  
Urothelium-Derived Inhibitory Factor  
The urothelium/LP from healthy bladder also releases unidentified substances during 
muscarinic receptor stimulation that inhibits contraction of the underlying detrusor 
smooth muscle in the pig and human bladder. As a result of these unknown 
substances, bladder overactivity and consequent involuntary urine loss may be 
prevented (Chaiyaprasithi et al., 2003; Hawthorn et al., 2000; Templeman et al., 
2002). This urothelium-derived inhibitory factor (UDIF) is not NO or a prostaglandin 
and it remains unidentified.  
The influence of this factor was noticeable in the present study, where the presence 
of an intact urothelium/LP significantly depressed maximum contractions of the 
detrusor muscle to carbachol in both young and aged bladders.  
After doxorubicin pretreatment the responses of intact bladder and detrusor muscle 
tissues to carbachol and the degree of inhibition by the urothelium/LP was similar to 
the tissues from untreated bladders.  Thus, doxorubicin did not appear to alter either 
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the release or the actions of UDIF and its effects on mediator release from the 
urothelium/LP were limited to an action on ATP release.   
 
Tissue responses 
Muscarinic-mediated contractile response  
In all tissues examined (in both young and aged bladders), the muscarinic agonist 
carbachol induced contraction. These were greater in urothelial/LP strips than those 
produced by strips of detrusor muscle and intact bladder when responses were 
expressed relative to weight (mN/mg tissue). This finding is similar to what was 
observed in a previous study by Sadananda et al. (2008) where strips of urothelium 
containing lamina propria but no detrusor muscle from pig bladder produced 
significantly greater contractile response to carbachol compared to the response 
produced by intact bladder strips. However, the magnitude of responses in 
urothelial/LP strips was not significantly different from responses in detrusor muscle 
strips.   
Following pretreatment with doxorubicin, contractile responses of urothelial/LP 
strips from both young and aged bladders were enhanced. The potency of carbachol 
was unaltered, but the responsiveness of the tissues was increased and the maximum 
responses were significantly greater following doxorubicin pretreatment. However, 
the relevance of this finding to the development of OAB is currently unclear. In a 
report by Kanai et al. (2007), it was demonstrated that spontaneous membrane 
potential transients induced by stretch can originate in the urothelium/LP. Also, in 
feline IC cat bladders, there was increased calcium transient in the urothelium/LP 
which spread to the detrusor muscle in tissues from animals with IC (Ikeda et al., 
2009). These findings suggest that it is possible that contractions generated 
spontaneously in the urothelium/LP can cause spontaneous contractions of detrusor 
smooth muscle. Thus, it is possible that the increase in contractile activity of this 
layer (urothelium/LP) after doxorubicin pretreatment may contribute to the bladder 
overactivity observed in patients following treatment. This idea is supported by the 
finding that gap junction density is increased in patients with urge symptoms. A 
previous study by Neuhaus et al. (2005) compared the expression of connexin (Cx)40, 
Cx43 and Cx45 in bladder biopsies from a control group and an incontinence group. 
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Control tissues were collected from bladder cancer patients without previous history 
of LUTS who underwent cystectomies or TUR. Control tissue samples isolated from 
the bladder were free from bladder carcinoma. The incontinence group consisted of 
patients with urge urinary incontinence, mixed urinary incontinence and painful 
bladder syndrome. The study demonstrated significantly higher Cx43 expression in 
the detrusor muscle, and a tendency to higher Cx45 expression in the LP layer 
associated with urge symptoms, while Cx40 expression was unaffected. 
The effects of doxorubicin on detrusor muscle contraction were also examined. It 
was reported that less than 1% of doxorubicin penetrates this far into the bladder wall 
(Wientjes et al., 1996) and not surprisingly the responses of the muscle itself to 
muscarinic stimulation from young bladders were unaltered by doxorubicin 
pretreatment. However, the response was enhanced in aged bladders following 
doxorubicin pretreatment.  The potency of carbachol was unaltered, but the 
responsiveness of the detrusor muscle tissue was increased and the maximum 
responses were significantly greater following doxorubicin pretreatment. The 
enhanced detrusor contractile responses to carbachol observed in aged bladders 
following doxorubicin treatment may be due to upregulation of the calcium 
sensitisation pathway such as Rho kinase (ROK) and protein kinase C (PKC). The 
mechanisms responsible for initiation and maintenance of smooth muscle 
contractions, induced by stimulation of G protein-coupled receptors (GPCRs) are 
thought to be an increase in cytosolic calcium produced by calcium entry through 
voltage sensitive calcium channels, or calcium release from the sarcoplasmic 
reticulum (SR) (Durlu-Kandilci and Brading, 2006). Muscarinic receptor stimulation 
in detrusor smooth muscle has been reported to increase intracellular calcium 
through release of intracellular calcium from IP3 or ryanodine sensitive stores as well 
as from influx of extracellular calcium (Ma et al., 2002; Visser and van Mastrigt, 
2000). Activation of GPCRs by agonists increases force in smooth muscle via 
calcium-dependent myosin light chain phosphorylation. The level of myosin light 
chain phosphorylation and the activation of smooth muscle are determined by the 
ratio of activities of calcium/calmodulin dependent myosin light chain kinase 
(MLCK) and myosin light chain phosphatase (MLCP). However, there are 
mechanisms that can cause muscle contractions without any necessary change in 
intracellular calcium. When intracellular calcium and MLCK activity are constant, 
agonist activating GPCRs may cause a leftward shift of the calcium/force response 
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curve which is known as calcium sensitisation (Durlu-Kandilci and Brading, 2006). 
There are two major pathways known to be responsible for calcium sensitisation 
which includes ROK and PKC (Horowitz et al., 1996; Somlyo and Somlyo, 2000) 
and they are thought be involved in inhibition of myosin phosphatase activity at 
constant calcium and therefore enhance myosin light chain phosphorylation and 
induce an increase in contractile force (Somlyo and Somlyo, 2003). A study by 
Rajasekaran et al. (2005) has demonstrated that bladder hyperactivity in 
spontaneously hypertensive rats (SHR) is attenuated by inhibition of RhoA/Rho-
kinase with Y-27632 and also reported increased bladder expression of RhoA in 
SHR, suggesting that bladder contractions and tone in SHR are modulated in part by 
RhoA/Rho-kinase calcium sensitizing pathway. Thus, it is possible that the increase 
in contractile activity of both urothelium/LP and the detrusor muscle after 
doxorubicin pretreatment may contribute to the overactivity observed in patients 
treated intravesically with doxorubicin.  
There is no study in the literature demonstrating the difference in the severity of 
adverse effects induced by intravesical chemotherapy including doxorubicin in aged 
versus young. While the effect of ageing on drug permeability into the bladder layers 
is unknown, at least in this study, doxorubicin pretreatment seems to be exerting 
greater toxicity in aged bladders since not only the contractile response of the 
urothelium/LP to muscarinic stimulation was enhanced but also the response of the 
deeper underlying detrusor muscle was increased in the aged bladders following 
doxorubicin pretreatment. It seems that doxorubicin has greater cytotoxic effects on 
aged bladders, possibly due to the declining barrier function of the bladder with age 
as previously discussed in the introduction of this chapter. There are several studies 
reporting greater severity of side-effects in aged patients in other physiological 
systems resulting from systemic use of chemotherapeutic drugs. A regression 
analysis study by Begg, Elson & Carbone (1989), which calculated the odds ratio 
(OR) of cytotoxic drug doxorubicin for grade 3-4 hematological toxicity in elderly 
patients (8787 patients aged <60 years, 5584 aged 60-69 years and 2209 aged ≥70 
years), demonstrated a higher risk of severe hematological toxicity for patients at the 
age of ≥70 years (OR=1.4). A recent study by Goto et al. (2012) also reported an 
increased incidence of side-effects in elderly (aged 65 years or older) caner patients 
treated with chemotherapy compared to younger patients (younger than 65 years). 
Myelosuppresion of grade 3 or more severe adverse effects in the elderly patients and 
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younger subjects was 22.5% and 16.3%, respectively. Cardiotoxicity is a major 
limiting factor with the use of doxorubicin and age is one of the established risk 
factors for doxorubicin-induced cardiotoxicity (Von Hoff et al., 1979).  
In this study, an age-related decrease in contractile response to muscarinic 
stimulation was observed. The maximum contractions to carbachol in all control 
tissues were significantly smaller in aged bladders compared to young bladders. In 
addition, potency of carbachol was lower in intact bladder and urothelium/LP tissues 
from aged bladders compared to young bladders. These findings may indicate that 
tissue responsiveness and sensitiveness to muscarinic stimulation diminish with age. 
A study by Toyoshima et al. (1990) also supports the view of reduced responsiveness 
of the bladder tissues to muscarinic stimulation with age since maximal response in 
intravesical pressure during bladder contraction induced by ACh was lower in aged 
rats (2 years old) compared to younger adult rats (11-23 weeks old). In contrast, there 
are studies reporting increased contractile response to muscarinic stimulation in aged 
bladders compared to young bladders. A study by Kolta, Wallace & Gerald (1984) 
has shown that the maximum contractile responses to ACh were 64% and 15% 
greater in isolated bladders from 29 months and 17 months rats, respectively, as 
compared to 7 months rats and the density of [3H] quinuclidinyl benzilate 
(muscarinic antagonist) bound to membrane preparations were 46% and 7% greater. 
This study suggests that urinary bladder of aged rats appears to develop increased 
responsiveness to cholinergic stimuli and increase in the number of muscarinic 
cholinergic receptors. Another study has also demonstrated an age-dependent 
increase in the maximum contractions elicited by muscarinic agonists where the 
maximum contraction values for strips of bladder base from rats 27 months of age 
were 44%, 58% and 76% greater than those from rats 7 months of age for ACh, 
bethanechol and oxotremorine, respectively (Ordway et al., 1986). In addition, a 
recent study by Daly et al. (2014) reported significantly increased (P<0.001) 
contractile responses of detrusor muscle strips from aged mice (24 months old) to 
bethanechol compared to muscle strips from control mice (3 months old). In contrast, 
there are studies that found no change in contractile responses of the bladder body 
(Lluel et al., 2000) and base (Longhurst et al., 1992) to carbachol between young and 
aged rats. Whilst there are contrasting reports in the literature about the effects of age 
in rats and mice, this study was first to report an aged-related changes in contractile 
response to muscarinic stimulation in pig which may be more relevant to human. 
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Nerve-mediated contractile response 
Both young and aged detrusor muscle tissues responded to EFS at all frequencies 
tested and these neurogenic responses were found to be significantly greater in 
tissues from the aged bladders when compared to the responses in young bladders. 
These findings, which suggest an aged-associated increase in contractile response of 
detrusor muscle to efferent nerve stimulation, are consistent with the previous studies. 
In a report by Longhurst et al. (1992), EFS produced a greater contractile response in 
the bladder body of old rats (24 months old) compared to young rats (6 months old). 
Another study also demonstrated significantly larger contractile responses in circular 
detrusor fibers evoked by EFS in old (27 months old) rats compared with those of 
young (6 months old) rats (Pagala et al., 2001). However, a study by Munro & 
Wendt (1993) using longitudinal smooth muscle strips from bladders of rats reported 
no significant difference in contractile response to EFS between adult (6 months old) 
and aged (24 months old) bladders. In addition, Yoshida et al. reported similar 
finding in their study in which EFS-induced contractions in detrusor muscle from 
human bladder were not significantly different among the three age groups they 
examined (G1, <50 years old; G2, 51-70 years old; G3, >70 years old) (Yoshida et 
al., 2001).  
Following doxorubicin pretreatment, contractile responses of detrusor muscle to EFS 
were enhanced in young bladders. It can be suggested that in young bladders, 
doxorubicin treatment does not affect the detrusor muscle directly, but does affect the 
efferent nerves, increasing transmitter release and thus enhancing neurogenic 
detrusor contractions. Therefore, it can be postulated that the mechanism by which 
doxorubicin enhances transmitter release may induce detrusor contractions during 
bladder filling and contribute to bladder overactivity. In contrast, in the aged 
bladders, doxorubicin treatment depressed neurogenic responses of detrusor muscle 
in addition to an enhanced contractile responsiveness of detrusor muscle. It appears 
that doxorubicin causes a greater cytotoxicity in the aged bladders compared young 
bladders since both the muscle and efferent nerves are affected by the treatment. In 
addition, it appears that in the aged bladders, doxorubicin treatment may cause 
overactivity of the bladder via directly acting on detrusor muscle contractility rather 
than enhancing neurotransmitter release as in young bladders since the depressed 
neurogenic responses observed in aged bladders after the treatment may indicate 
toxic damage on efferent nerves. The neurotoxicity observed in this study may be 
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due to the effects of ageing on the bladder function which can lead to greater 
susceptibility of aged bladders to doxorubicin toxicity. There is a study by Gottlieb et 
al. (1987) which supports this view where he claimed that neurotoxicity is age 
related. In the study, fifteen patients with acute myeloid leukemia were given a total 
of 17 courses of high-dose cytosine arabinoside (Ara-C) and of five patients over the 
age of 55 years, four developed severe, irreversible neurotoxicity, but there were no 
severe episodes in patients aged 55 years or less (P<0.01), suggesting that 
administration of high dose chemotherapy Ara-C carries a risk of severe irreversible 
cerebellar toxicity that increases with age. 
In both pig and human bladder, the cholinergic component plays a major role in 
nerve-mediated detrusor muscle contraction (Yoshida et al., 2004; Yoshida et al., 
2002). Although, less pronounced compared to cholinergic responses, purinergic 
neurotransmitters are also involved in detrusor muscle contraction (Burnstock, 1986; 
Hoyle et al., 1989). Our study also agree that the cholinergic neurotransmission is the 
major pathway for detrusor muscle contraction, as contractile response of detrusor 
muscle to EFS in both young and the aged bladders were reduced in the presence of 
atropine, but did not abolish responses which is consistent with a finding by Sibley 
(1984) that observed inhibition of contractile response of pig intact bladder tissue to 
EFS by 22% in the presence of atropine (0.01-1nM). However, when P2-
purinoceptors were desensitised with α,β-mATP in the present study, neurogenic 
responses were not affected. A study by Brading & Williams (1990) using rat 
detrusor muscle strips also found a small but not significant reduction in response to 
stimulation at 1Hz and 25% reduction in the responses were observed at 20Hz in the 
presence of atropine. Their study also reported completely abolished responses at 
1Hz and 75% reduction at 10 and 20Hz in the presence of α,β-mATP. In addition, 
combination of both drugs eliminated the nerve-mediated responses. The differences 
observed may be attributed to species-dependent neurotransmitter responses.  
The effects of atropine were not affected by doxorubicin treatment in either young or 
aged, suggesting that doxorubicin affects cholinergic and purinergic 
neurotransmission equally when neurotransmission is enhanced in young pigs 
following treatment with doxorubicin. In addition, no differences were observed in 
cholinergic transmission between young and the aged bladders. This is different to 
what was observed in a study by Yoshida et al. (2001), which measured the release 
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of neurotransmitters, ACh and ATP from isolated human detrusor tissue, and 
demonstrated a significant negative correlation (r= -0.91) between age and the 
amount of ACh released by electrical field stimulation (EFS), and a significant 
positive correlation (r= 0.83) between age and the amount of ATP released, 
suggesting that purinergic and cholinergic neurotransmission increases and decreases, 
respectively with age.  
The effect of L-NNA on neurogenic responses was also examined but the responses 
were not enhanced in the presence of L-NNA in this study which is consistent with a 
previous study using rats that did not reveal any alteration of the contractile 
responses to EFS in normal tissues by L-NNA but significantly increased contractile 
responses in the bladders from the cyclophosphamide (CYP)-induced cystic rats 
(Vesela et al., 2012). Thus, it appears that NO does not influence contractile 
responses of detrusor muscle to efferent nerve stimulation in the healthy bladder or 
following cytotoxic drugs in the short-term (my study), but may in the longer term. A 
previous study supports this idea. The study evaluated the effects of nitric oxide 
synthase (NOS) on detrusor overactivity after removal of bladder outlet obstruction 
in rats. Rats were divided into a control group and an experimental group. The 
bladders in the experimental group were partially obstructed for 3 weeks. After 
removal of obstruction, the experimental group was subdivided into ‘normalised’ and 
‘overactive’ groups, on the basis of cytometrogram results. Expression of neuronal, 
inducible, and endothelial NOS (nNOS, iNOS and eNOS, respectively) mRNA in 
bladders of each group was analysed by RT-PCR. Significantly decreased (P<0.05) 
expression of nNOS and iNOS mRNA was demonstrated in the normalised group 
compared to the control group, and nNOS levels were increased (P<0.05) in the 
overactive group compared to the normalised group. In addition, a significant 
increase (P<0.05) in eNOS mRNA expression was shown in the normalised and 
overactive group compared to the control group. The findings of the study suggest 
that increases in nNOS and eNOS expression may be related to OAB conditions 
(Kim et al., 2008). 
 
β-adrenoceptor-mediated relaxation 
Pre-contractions induced by carbachol in all tissues from both young (≈63%) and the 
aged (≈62%) bladders were relaxed by isoprenaline. This finding is consistent with a 
previous study by Murakami et al. (2007) which also reported relaxation (≈75%) of 
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carbachol pre-contracted pig tissues including intact bladder and detrusor muscle in 
response to isoprenaline.  A study by Moro and his colleagues (2013) has also 
demonstrated relaxation and slowing of spontaneous phasic contraction of porcine 
urothelial/LP strips by isoprenaline.   
The potency and maximum relaxation in intact bladder and detrusor muscle tissues 
were similar between young and the aged bladders. Similar observations were made 
in a previous study by Kolta et al. (1984) in which there was no difference in 
isoprenaline-induced relaxations of isolated whole bladders from rats aged between 
7-month and 29-month. Also, another study reported no-aged related changes in 
contractile response of isolated whole rat bladder to isoprenaline (ages 5-7, 16-18 
and 22-24 months) (Chun et al., 1989).  
In contrast, isoprenaline was found to be more potent in urothelial/LP tissues from 
the aged pig bladders compared to young bladders. In addition, maximum relaxation 
in the urothelium/LP was also demonstrated to be greater in the aged bladders in 
comparison to young bladders. It can be suggested that the ability of urothelial/LP 
tissues to relax as well as sensitivity to β-adrenergic stimulation may increase with 
age.  
Following doxorubicin treatment, the potency and maximum relaxation were similar 
to control incubated tissues in both young and the aged bladders, suggesting that the 
ability of tissues to relax in response to β-adrenergic stimulation are not affected by 
doxorubicin treatment.  
 
Integrity of bladder morphology 
Histological examination of cross-section of the bladder revealed that urothelial 
thickness of the aged bladders was significantly thinner than those of young bladders.  
Urothelial thinning was also reported in a study by Zhao et al. (2010) which found 
significantly decreased urothelial thickness in old (28-30 months) compared to young 
(4-6 months) rat bladders. There were also other age-related changes in anatomy of 
the bladder reported by the same study. These include a decrease in muscle mass and 
an increase in collagen deposition in the bladders of old rats compared to young rats. 
In addition, old rats had higher bladder weight than young rats. No studies have 
reported age-associated changes in urothelial thickness in human and it is also 
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unclear from the histological image taken from this study to determine whether 
decreased thickness of the urothelium is due to a change in cell number or volume. 
The finding of urothelial thinning with ageing could provide an explanation to why 
doxorubicin was found to be more cytotoxic in the aged bladders compared to young 
bladders in this study, potentially leading greater doxorubicin penetration into the 
deeper layer of the bladder, thus affecting not only the urothelium but also the 
detrusor muscle. In addition, the present study found no change in urothelial 
thickness in either young or aged bladders following doxorubicin treatment. 
 
Conclusions  
Here we demonstrated the effects of ageing on various function of the bladder. 
Contractile response to muscarinic stimulation were reduced, neurogenic responses 
were greater, mediator release from the urothelium/LP were greater, relaxation 
responses of the urothelium/LP were enhanced and lastly urothelial thickness was 
reduced in the aged bladders compared to young bladders.  
It can be concluded that doxorubicin treatment may exerts its adverse effects in 
patients through enhancing ATP release from the urothelium/LP and increasing 
urothelial/LP contractile response to muscarinic stimulation in both young and the 
aged bladders. In the aged bladders, however, doxorubicin appears to have greater 
toxic effects on bladder function affecting deeper layer, detrusor muscle and this 
appears to be due to urothelial thinning observed in the aged bladders. Such toxic 
effects caused an increase in contractile activity of detrusor muscle to muscarinic 
stimulation as well as depression of neurogenic detrusor contractility (via damage on 
the efferent nerves) in which the former may also provide an explanation to the 
mechanism by which doxorubicin treatment may exert overactive activity in elderly 
patients following treatment. Whilst in young bladders, doxorubicin treatment may 
also contribute to overactivity of the bladder via increasing the release of 
neurotransmitters as observed by an enhanced neurogenic response following 
treatment.   
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Chapter 4 - The effects of mitomycin C and 
epirubicin on aged porcine bladder tissue 
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Introduction 
The previous chapter demonstrated changes in tissue responses and mediator release 
with ageing and also doxorubicin pretreatment. Apart from doxorubicin, intravesical 
chemotherapeutic treatment with mitomycin C (MMC) and epirubicin are also 
widely practiced by clinicians to reduce progression and recurrence of bladder cancer. 
General introduction about these two cytotoxic drugs in addition to their detailed 
antitumor and cytotoxic mechanisms have been mentioned previously in Chapter 1. 
Thus, in this chapter, the following introduction for each agent will specifically focus 
on the efficacy and incidence of urinary adverse effects. 
 
Intravesical mitomycin C (MMC) 
A randomised clinical trial study by Trolley et al. (1996) involving 502 patients with 
newly diagnosed superficial bladder cancer has revealed the positive benefit of MMC 
to decrease the number of subsequent recurrences and increase the recurrence-free 
interval. In that trial, after resection of tumor, the patients were randomised into 1 of 
3 treatment groups; no further treatment, 1 instillation of MMC at resection, and 1 
instillation at resection and at 3-month interval for 1 year (total 5 instillations). A 40-
mg dose of MMC in 40ml water was administered intravesically. The study found 
that 1 and 5 instillations of MMC resulted in decreased recurrence rates and 
increased recurrence-free interval compared to no treatment group and there was 
suggestive but not conclusive evidence that 5 instillations of MMC offered a slightly 
higher advantage over 1 instillation. 
Shelley et al. (2003) conducted a meta analysis study and reported that 2% to 21% of 
patients developed cystitis, while allergy occurred in 7% to 16% of patients treated 
with intravesical MMC (Krege et al., 1996; Lamm et al., 1995; Rintala et al., 1991; 
Witjes et al., 1998; Witjes et al., 1996). Overall, approximately 30% of those patients 
receiving intravesical MMC were found to be developing local toxicities (dysuria, 
cystitis, frequency and haematuria). Also, in another study, contracted bladder was 
reported in three out of 125 patients treated with MMC (Malmstrom et al., 1999). 
Mangiarotti et al. (2008) reported that 11 out of 46 patients with low grade recurrent 
superficial bladder cancer developed grade 1-2 toxicity (mild or moderate cystitis in 
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6 patients and mild or moderate hypersensitivity reactions in 5) and grade 3 toxicity 
in 11 patients (severe cystitis in 4, gross haematuria in 2 and severe hypersensitivity 
in 5 cases) after MMC treatment. Intravesical treatment had to be terminated in 11 
patients.  
Also, increased urinary frequency occurred in 40.7% of patients (31 of the 76 
patients) with Ta, T1 and TIS transitional cell carcinoma of the bladder after 
receiving eight weekly instillations of intravesical MMC (Heney et al., 1988). 
A study by Au et al. (2001) randomised 217 patients with histologically proven 
transitional cell carcinoma and at high risk for recurrence into two groups to test 
whether enhancing the concentration of MMC in urine would improve its efficacy. 
Patients in the optimised-treatment group (N=119) received a 40-mg dose of MMC, 
pharmacokinetic manipulations to increase drug concentration by decreasing urine 
volume, and urine alkalinisation to stabilize the drug. Patients in the standard-
treatment group (N=111) received a 20-mg dose without pharmacokinetic 
manipulations or urine alkalinisation. Patients in both groups received six weekly 
treatments with intravesical MMC dissolved in 20 mL of sterile water for 2 hour. In 
the study, patients in the optimised group showed a longer median time to recurrence 
(29.1 months) and a greater recurrence-free fraction (41%) at 5 years than patients in 
the standard group (11.8 months and 25%, respectively). Minimal differences in 
toxicity were observed in the two treatment groups. The incidence of urinary 
frequency/urgency in the optimised and standard groups were 31%/26% and 
24%/22%, respectively. Cystitis occurred in 23% of patients in the optimised group 
and in 16% of patients in standard group. 18% and 19% of patients experienced 
fatigue in the optimised and normal groups, respectively. Dysuria was the only toxic 
effect that occurred more frequently in the optimised group (33%) compared to the 
standard group (18%), but did not result in more frequent termination of treatment 
(1.8% and 1.9%, respectively). Grade 3 dysuria (painful urination not controlled by 
pyridium) occurred in four patients in the optimised group but in no patients in the 
standard group. Twelve patients who complained of dysuria or cystitis (two in the 
standard group and 10 in the optimised group) were treated with antibiotics for 
possible urinary-tract infection. The study suggests that a higher dose of intravesical 
MMC (2mg/ml) compared to normal dose (1mg/ml) can enhance efficacy of the drug 
without seeing a significant increase in bladder toxicity.  
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Intravesical epirubicin 
A study by Sengor et al. (1996) which included 45 patients with Ta-Tl superficial 
bladder cancer has found that intravesical epirubicin therapy is effective in the 
prophylaxis of superficial bladder cancer, reducing the recurrence rate and 
prolonging time to recurrence. Fourteen patients who had transurethral resection 
(TUR) of the tumour alone were assigned to the control group and the rest of the 
patients received 8 weekly instillations of intravesical epirubicin (50mg diluted in 
50ml saline) two weeks after complete TUR of the tumour (the epirubicin group). 
The study found a higher recurrence rate in the control group (64% versus 32%) 
which was not statistically significant, but importantly also demonstrated that 
tumour-free intervals in patients with recurrent disease were significantly longer in 
the epirubicin group.  
In a report by Ali-el-Dein et al. (1997), epirubicin has been demonstrated to be more 
efficacious and less toxic than doxorubicin when used as an intravesical agent. In 
that study, a total of 253 patients with superficial bladder cancer were randomly 
allocated to 4 study arms:  
(1) 50mg epirubicin after TUR 
(2) 80mg epirubicin after TUR 
(3) 50mg doxorubicin after TUR 
(4) TUR alone 
Instillation was repeated weekly for 8 weeks, and monthly thereafter, to complete 1 
year of treatment. The study found that rates of recurrence were significantly lower 
in the chemotherapy groups than in controls (P<0.001) and lower in the epirubicin 
groups than in the doxorubicin group (P<0.05). Recurrence rates were 25%, 18%, 37% 
and 66% in arms 1 to 4, respectively. Also, mean interval to first recurrence was 16, 
15.4, 18.9 and 6.3 months, respectively, with a significant difference (P<0.05) 
between the chemotherapy and control groups. Local toxicity developed in 10 (16%), 
16 (24%) and 25 (42%) patients in chemotherapy arms 1 to 3, respectively. 
Significantly lower toxicity rates in arms 1 and 2 than in 3 (P<0.01) was reported, 
and a marginal insignificant difference was demonstrated between low and high dose 
epirubicin (P=0.3). It appears that intravesical treatment with epirubicin is more 
efficacious on bladder cancer and also less cytotoxic than intravesical doxorubicin. 
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However, the results of the study suggest that the efficacy of epirubicin is not 
concentration-dependent.  
In another study by Hendricksen et al. (2008), the effects of either an early 
instillation or maintenance instillations of adjuvant intravesical epirubicin (50mg in 
50ml NaCl for 1 hour), as compared to the epirubicin standard treatment schedule 
only were evaluated, in patients with non-muscle invasive bladder cancer. The 
patients were randomised into 3 groups: 
(1) 4 weekly and 5 monthly instillations (standard schedule) 
(2) The same schedule as group 1, but with an additional instillation less than 
48 hour after TUR 
(3) The same scheme as group 1, but with additional instillations at 9 and 12 
months (maintenance schedule).  
Standard follow-up was 5 year and consisted of cystoscopy, cytology, and 
registration of adverse events. The study showed that out of a total of 731 patients, 
44%, 43%, and 45% of the patients, respectively, in groups 1, 2, and 3 were 
recurrence free, and 90%, 88%, and 88% of the patients, respectively, were 
progression free. Also, 23%, 30%, 15% and 9% of patients who received at least one 
instillation of epirubicin developed bacterial cystitis, chemical cystitis, haematuria 
and other local side effects, respectively. While side effects were not significantly 
different between treatment groups, haematuria occurred significantly more in the 
immediate instillation group (2) (19%) compared to group 1 (14%) and group 3 
(11%). Thirteen percent of the patients reported systemic side effects which included 
tiredness, fever, nausea, headache, and abdominal pain. Seven percent of the patients 
discontinued the instillations due to local (6%) or systemic (1%) side effects.  
It can be seen that both MMC and epirubicin can effectively reduce recurrence of 
bladder cancer if used intravesically after TUR compared to TUR alone. However, 
despite the advantage of direct exposure of cytotoxic drugs to tumours with minimal 
systemic introduction, various bladder toxicities occur in patients. Both cytotoxic 
agents commonly reported chemical cystitis such as increased urinary urgency and 
frequency, and dysuria.  
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Aims 
Since, bladder cancer is a disease of senior adults and the differences in bladder 
functions were observed between young and aged pigs, bladders from the aged pigs 
were used in this study. Thus, the aim of this study was to investigate the effects of 
two other commonly used intravesical chemotherapeutic agents MMC and epirubicin 
on normal bladder functions including mediator release, integrity of bladder 
morphology, tissue responsiveness and sensitivity, and neurogenic responses. 
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Materials and Methods 
(Refer to “Porcine tissue experiments” and “Assays for urothelial mediators, NO and 
inflammatory cytokines” sections of Chapter 2 for full detail) 
Full thickness sheets of bladder wall from aged pigs (2 to 3 years old; approx. 250kg) 
were set up in treatment chambers and therapeutic concentration of either MMC 
(2mg/ml) or epirubicin (1mg/ml) was exposed to the urothelial surface for 2 hour or 
1 hour, respectively. Both cytotoxic drugs were diluted in fresh Krebs-bicarbonate 
solutions. 
Following pretreatment with either MMC or epirubicin, tissue responses, 
urothelial/LP mediator release, and bladder morphology were evaluated. The release 
of mediators was measured using commercially available kits. 
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Results  
Contractile responses to carbachol 
All tissues contracted to carbachol again as it was already demonstrated in 
doxorubicin study previously (Figure 3.1). The potency (pEC50 values) of all tissues 
in each control group was similar to each other, but the maximum responses varied 
among each control groups. While the maximum responses of intact bladder and 
detrusor muscle tissues in controls from epirubicin and doxorubicin studies were 
similar, the maximum response of these tissues in controls from MMC study was 
significantly smaller compared to controls from other two studies (Table 4.1 and 
Table 3.1 from doxorubicin study). Also, the maximum responses of urothelial/LP 
tissues in controls from MMC and doxorubicin studies were similar, but the 
maximum response of this tissue in control from epirubicin study was significantly 
smaller compared to controls from other two studies (Table 4.1 and Table 3.1 from 
doxorubicin study).  
MMC pretreatment did not affect the maximum contraction of intact bladder tissues 
to carbachol, but the maximum contractions of pretreated detrusor muscle and 
urothelial/LP tissues to carbachol were significantly reduced (P<0.05 and P<0.01, 
respectively) by 15.9% and 23.6%, respectively, compared to control tissues (Figure 
4.1; Table 4.1).  
Epirubicin pretreatment did not affect any of the tissue responses to carbachol except 
the maximum contraction of detrusor muscle was significantly reduced (P<0.05) by 
26.7% compared to control tissues following treatment (Figure 4.1; Table 4.1). 
 115 
 
Figure 4.1: Cumulative concentration-response curves to carbachol of tissues from control 
and pretreated bladders by MMC or epirubicin. Responses of intact bladder [A & B], 
detrusor muscle [C & D] and urothelium/LP [E & F]. Data are expressed as means ± SEM. 
*P<0.05 and **P<0.01 compared to maximum response of control tissue. 
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Table 4.1: Potency (pEC50) values and maximum responses (mN/mg tissue) to carbachol of 
intact bladder strips, detrusor muscle strips and strips of urothelium/LP.  Data are expressed 
as means ± SEM. 
MMC 
Tissue Control (untreated) bladders  Pretreated bladders 
 Potency Maximum N  Potency Maximum N 
Intact bladder 5.62±0.18 0.14±0.001b 8  5.84±0.26 0.17±0.02 8 
Detrusor muscle 5.64±0.15 0.22±0.01c 8  5.53±0.14 0.18±0.01a 8 
Urothelium/LP 6.13±0.24 0.57±0.04 7  5.89±0.11 0.43±0.02a 8 
 
Epirubicin 
Intact bladder 5.90±0.20 0.24±0.02 7  5.85±0.29 0.25±0.03 7 
Detrusor muscle 6.04±0.15 0.33±0.02 6  6.07±0.16 0.24±0.01a 6 
Urothelium/LP 6.31±0.13 0.36±0.02d 8  5.85±0.20 0.36±0.03 8 
 
 
N number of bladders examined 
a P<0.05 and P<0.01 compared to corresponding control tissue.  
b P<0.001 compared to corresponding control tissues from epirubicin and doxorubicin (aged 
bladders from Table 3.1).  
c P<0.01 compared to corresponding control tissues from epirubicin and doxorubicin (aged 
bladders from Table 3.1).  
d P<0.001 compared to corresponding control tissues from MMC and doxorubicin (aged 
bladders from Table 3.1). 
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Relaxation responses to isoprenaline 
All tissues relaxed to isoprenaline (Figure 4.2) and the potency (pEC50) values were 
similar on all three tissues from both MMC and epirubicin studies (Table 4.2).  
For MMC pretreated bladders, there was no difference in the maximum relaxation to 
isoprenaline (expressed as percentage of pre-contraction to carbachol) between 
control and pretreated intact bladder tissues, and also between control and pretreated 
urothelial/LP tissues. However, the maximum relaxation of pretreated detrusor 
muscle tissues to isoprenaline was significantly greater (P<0.05) than control 
detrusor muscle tissues (Figure 4.2; Table 4.2).  
Following epirubicin pretreatment, the maximum relaxation of all three tissues to 
isoprenaline was similar to control tissues (Figure 4.2; Table 4.2). 
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Figure 4.2: Cumulative concentration-response curves to isoprenaline in tissues from control 
and pretreated bladders by MMC or epirubicin. Responses expressed as a percentage of the 
pre-contraction to carbachol (27.4µM). Responses of intact bladder [A & B], detrusor muscle 
[C & D] and urothelium/LP [E & F]. Data are expressed as means ± SEM. *P<0.05 
compared to control tissue. 
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Table 4.2: Potency (pEC50) values and maximum relaxation (%) to isoprenaline of intact 
bladder strips, detrusor muscle strips and strips of urothelium/LP. Data are expressed as 
means ± SEM. 
MMC 
Tissue Control (untreated) bladders  Pretreated bladders 
 Potency Maximum N  Potency Maximum N 
Intact bladder 7.04±0.19 59.42±2.89 8  7.16±0.20 59.70±2.91 8 
Detrusor muscle 7.48±0.21 47.68±3.68 8  7.19±0.14 58.16±2.08a 8 
Urothelium/LP 6.48±0.46 69.60±6.23 7  6.97±0.33 71.25±3.92 6 
 
Epirubicin 
Intact bladder 7.48±0.25 67.08±2.66 6  7.59±0.26 66.66±2.63 6 
Detrusor muscle 7.59±0.35 65.47±3.71 5  7.99±0.28 67.13±2.39 5 
Urothelium/LP 6.43±0.23 64.93±3.61 6  6.33±0.18 65.57±3.01 5 
 
 
N number of bladders examined 
a P<0.05 compared to control denuded detrusor.  
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Detrusor responses to electrical field stimulation 
The detrusor responses to electrical field stimulation (EFS) increased with increasing 
stimulation frequency and the responses were depressed in the MMC pretreated 
tissues compared to control tissues with a statistically significant depression (P<0.05) 
at the lower stimulation frequencies of 1Hz and 5Hz (Figure 4.3a). The responses of 
both control and epirubicin pretreated detrusor strips to EFS also increased with 
increasing stimulation frequency, however there was no difference in the responses 
between the control and the epirubicin pretreated tissues (Figure 4.3b).  
The detrusor muscle responses to EFS did not change in the presence of the nitric 
oxide synthase inhibitor (L-NNA, 100µM) when compared to the normal responses 
without L-NNA (Figure 4.3c, d, e and f).  
The effect of atropine on detrusor responses was also examined. A cholinergic 
neurotransmission was observed in all tissues (control, MMC pretreated & epirubicin 
pretreated tissues), however there was no difference in the cholinergic component 
(atropine sensitive) between control and pretreated tissues (Figure 4.3c, d, e and f; 
Table 4.3).  
In addition, desensitisation of P2-purinoceptor with α,β-mATP had no effect on 
responses to EFS in either control or pretreated tissues (Figure 4.3c, d, e and f).   
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Figure 4.3: Detrusor muscle responses to electrical field stimulation (EFS) in tissues from 
control bladders and bladders pretreated with MMC [A] or epirubicin [B]. Effect of L-NNA, 
atropine and α,β-mATP on tissues from control [C & D] bladders and bladders pretreated 
with MMC [E] or epirubicin [F]. Data are expressed as means ± SEM. *P<0.05 compared to 
control incubated tissues. 
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Table 4.3: Reduction (%) in detrusor response to EFS in the presence of atropine (1µM). 
Data are expressed as means ± SEM. 
MMC 
Frequency (Hz) Control (untreated) bladders  Pretreated bladders 
 Reduction (%) N  Reduction (%) N 
1 64.8±12.2 8  50.1±20.8 8 
5 49.2±16.6 8  47.0±13.3 8 
10 59.7±14.9 8  53.1±11.4 8 
20 73.0±9.9 8  65.0±10.3 8 
Average 61.68±13.4   53.8±13.95  
Epirubicin 
1 63.7±16.3 5  60.6±15.7 5 
5 56.0±14.9 5  61.7±9.4 5 
10 68.9±9.8 5  64.1±8.5 5 
20 77.9±6.1 5  76.5±4.2 5 
Average 66.63±11.78   65.73±9.45  
 
N number of bladders examined 
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Urothelial mediators 
Isolated strips of urothelium/LP from the control incubated bladders of the MMC 
study released all three mediators, but the basal release of ACh was on average 270-
fold greater than that of ATP, and the basal release of ATP was approximately 2-fold 
greater than that of PGE2. Stretching the tissues produced on average a 3-fold 
increase in ATP release, but had no effect on either ACh or PGE2 release (Figure 4.4). 
In tissues from bladders pretreated with MMC, the basal release of ATP and ACh 
was similar to control tissues at all time points. However, the basal release of PGE2 
in pretreated tissues was significantly (P<0.05) increased (2-fold) at 7 minutes 
compared to tissues from control bladders. Unlike tissues from control bladders, 
stretching MMC-pretreated tissues did not affect any mediator release. The stretch-
induced release of PGE2 from pretreated tissues was similar to control tissues at all 
times. Also, the stretch-induced ACh release was similar to the control at all time 
points except at 3 minutes where a significant increase was observed.  However, the 
stretch-induced release of ATP in MMC pretreated tissues was significantly (P<0.05 
and P<0.01) reduced (on average 80%) at 2, 3 and 7 minutes compared to control 
tissues (Figure 4.4).  
Urothelial/LP strips from the control incubated bladders for the epirubicin 
experiment released all three mediators but the basal release of ACh was on average 
1470-fold greater than that of ATP, and the basal release of ATP was approximately 
2-fold greater than that of PGE2. In this series of experiments, stretching the control 
tissues did not increase release of ACh and PGE2. It appeared to produce an increase 
in ATP release, but the difference was not statistically significant (Figure 4.5). In 
tissues from epirubicin pretreated bladders, the basal release of ATP, ACh and PGE2 
was similar to control tissues at all time points, except a significant increase was 
observed at 7 minutes for basal release of ACh compared to control. Stretching 
urothelial/LP tissues from epirubicin pretreated bladders produced on average a 2-
fold increase (P<0.05) in PGE2 release, but had no effect on either ATP or ACh 
release. The stretch-induced release of ACh and PGE2 from pretreated tissues was 
similar to control tissues at all time points. However, the stretch-induced release of 
ATP in epirubicin pretreated tissues was significantly (P<0.05) reduced (halved) at 7 
minutes compared to control tissues (Figure 4.5). 
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Figure 4.4: Mediator release from urothelial/LP tissues. Effects of MMC pretreatment on 
ATP [A], acetylcholine [C] and prostaglandin E2 [E] concentrations after 7 minute 
incubation, and ATP [B], acetylcholine [D] and prostaglandin E2 [F] concentrations after 7 
minute incubation that included stretching over the initial 2 minutes. Data are expressed as 
means ± SEM. *P<0.05 and **P<0.01 compared to control incubated tissues. 
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Figure 4.5: Mediator release from urothelial/LP tissues. Effects of epirubicin pretreatment 
on ATP [A], acetylcholine [C] and prostaglandin E2 [E] concentrations after 7 minute 
incubation, and ATP [B], acetylcholine [D] and prostaglandin E2 [F] concentrations after 7 
minute incubation that included stretching over the initial 2 minutes. Data are expressed as 
means ± SEM. *P<0.05 compared to control incubated tissues. 
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Inhibition of detrusor contraction by the urothelium 
The presence of an intact urothelium/LP on strips of detrusor muscle inhibited 
contractions to carbachol in control tissues but not in MMC pretreated bladders 
(Figure 4.6). In control tissues the potency of carbachol was similar in intact bladder 
and detrusor muscle tissues, but the maximum responses were significantly (P<0.001) 
depressed (27±12%) in intact bladder compared to detrusor muscle tissues.  However, 
different results were obtained in tissues from MMC pretreated bladders, with both 
the potency of carbachol and the maximum responses being similar in intact bladder 
and detrusor muscle tissues (Table 4.1).  
Similarly, the presence of an intact urothelium/LP on strips of detrusor muscle 
inhibited contractions to carbachol in control tissues but not in epirubicin pretreated 
bladders (Figure 4.6). The potency of carbachol in control tissues was similar in 
intact bladder and detrusor muscle tissues, but the maximum responses were again 
significantly (P<0.01) depressed (33±14%) in intact bladder compared to detrusor 
muscle tissues. In contrast, both the potency of carbachol and the maximum 
responses of epirubicin pretreated bladders were similar in intact bladder and 
detrusor muscle tissues (Table 4.1). 
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Figure 4.6: Inhibitory effects of the urothelium/LP on detrusor responses to carbachol in 
intact bladder and detrusor muscle tissues from control [A & B], MMC [C] and epirubicin 
[D] pretreated bladders. Data are expressed as means ± SEM. **P<0.01 and ***P<0.001 
compared to maximum response of detrusor muscle.  
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Bladder histology  
As in the doxorubicin study, tissue sections from untreated bladder demonstrated 
typical histological features such as the urothelium and lamina propria thrown into 
many folds and also a layer of detrusor smooth muscle underneath these layers 
(Figure 3.7 and 3.8).  
Histologically, the bladder structure was affected by both MMC and epirubicin 
pretreatment. Urothelial thickness of MMC pretreated bladders (22.93±2.91µm, N=4) 
was significantly (P<0.05) thinner compared to control incubated bladders 
(32.77±2.05µm, N=4) (Figure 3.7). In addition, urothelial thickness of epirubicin 
pretreated bladders (24.79±3.08µm, N=4) was also significantly (P<0.05) thinner 
compared to control (40.16±5.08µm, N=4) (Figure 3.8). 
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Figure 4.7: Haematological examination of bladder section. Haematoxylin and eosin 
(H and E) staining of control [A & C], and MMC pretreated [B & D] bladders. H and 
E staining at x10 [A & B] and x40 [C & D] showing the urothelium (U) and lamina 
propria (LP). 
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Figure 4.8: Haematological examination of bladder section. Haematoxylin and eosin 
(H and E) staining of control [A & C], and epirubicin pretreated [B & D] bladders. H 
and E staining at x10 [A & B] and x40 [C & D] showing the urothelium (U) and 
lamina propria (LP). 
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Discussion 
Tissue responses  
As in the doxorubicin study, in all tissues carbachol induced contraction. These 
contractions, when expressed relative to weight (mN/mg), were greater in 
urothelial/LP strips compared to those produced by detrusor muscle and intact 
bladder strips, which is consistent with a report by Sadananda et al. (2008). 
Following pretreatment with MMC and epirubicin, the potency of carbachol was 
unaltered, but the maximum responses of detrusor muscle were significantly 
decreased compared to control tissues. Decreased detrusor contractility is generally 
associated with under activity of the bladder and the finding is surprising since 
intravesical MMC and epirubicin treatment is characterised by increased urinary 
urgency and frequency (Duque and Loughlin, 2000; Hendricksen et al., 2008; Kim 
and Lee, 1989; Onrust et al., 1999). Thus, the decreased detrusor contractility 
observed in this study is unlikely to explain the increased urinary urgency and 
frequency reported in patients following intravesical epirubicin treatment, but it may 
indicate direct muscle damage by MMC and epirubicin toxicity.  
In addition, the neurogenic detrusor contractions elicited by nerve depolarisation 
during EFS was not affected by epirubicin, but was significantly depressed by MMC. 
The decrease in detrusor neurogenic responses by MMC was expected since the 
muscle responses to carbachol were also depressed after treatment. Similar to the 
observations made in the doxorubicin study, neither L-NNA nor α,β-mATP affected 
neurogenic responses but the responses were reduced in the presence of atropine, 
indicating a cholinergic component to detrusor contraction of porcine which was not 
affected by pretreatment with either MMC or epirubicin (discussed in detail in 
doxorubicin study).  
Since, the decrease in neurogenic response (32%) was significantly greater than the 
decrease in muscle response (18%), it can be postulated that efferent nerves in 
detrusor muscle in addition to the detrusor muscle itself are potentially damaged by 
the toxic effect of MMC. The decreased detrusor contractility to exogenous agonist 
and to nerve stimulation following MMC treatment may possibly result from a 
maintained tonic contraction of the detrusor. Such a persistent contracted bladder has 
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been reported to occur in patients following intravesical MMC treatment (Kim and 
Lee, 1989).  
Furthermore, the maximum responses of urothelial/LP tissues were also significantly 
decreased following MMC treatment and it is currently unclear what relevance the 
depressed urothelial/LP contractility may have to the development of OAB (see 
discussion Chapter 3).  
The non-selective β-AR agonist isoprenaline induced relaxation in all tissues and 
these responses were not affected by pretreatment with epirubicin. However, while 
the potency of isoprenaline was unaffected by MMC, the maximum relaxation of 
detrusor muscle to isoprenaline was significantly reduced. This may also be due to a 
toxic effect of MMC on detrusor muscle and was evident by both a decreased 
detrusor contractility to exogenous agonist and to nerve stimulation. Activation of β-
ARs is involved in relaxation of the bladder induced by sympathetic nerve activation 
during the filling phase. β-ARs are classified into three different subtypes, β1-, β2- 
and β3-ARs (Igawa et al., 2010), and the functional involvement of β-AR subtypes in 
bladder relaxation has been demonstrated to be species dependent (Morita et al., 
2000; Takeda et al., 2003; Yamazaki et al., 1998). There is evidence suggesting that 
the relaxation induced by β-AR agonists in detrusor muscle may be mediated mainly 
via β2-AR and possibly β3-AR in pigs (Yamanishi et al., 2002b). In the human 
detrusor, a study by Igawa et al. (1998) has shown that the relaxation induced by 
adrenergic stimulation is mediated mainly by β3-AR, rather than β1- or β2-AR, since 
a non-selective β-AR antagonist bupranolol that is known to have antagonistic action 
only on β1- and β2-AR at a low concentration (10nM) did not inhibit isoprenaline-
induced relaxation but at higher concentrations (0.1-10µM), which is known to also 
affect the β3-AR, the drug caused a rightward shift of the concentration-relaxation 
curve for isoprenaline in a dose-dependent manner. In addition, while neither a β1-
AR agonist dobutamine nor a β2-AR agonist procaterol produced significant 
relaxation in human detrusor (Igawa et al., 1998; Igawa et al., 1999), the selective β3-
AR agonists including BLR37,344, CL316,243, and CGP12,177A all produced 
concentration-dependent relaxation (Igawa et al., 1999; Takeda et al., 1999). Thus, 
an oral β3-AR agonist such as mirabegron is the newest option for treatment of OAB. 
In a two 12-week, randomised, double-blind, placebo-controlled Phase 3 studies, 
mirabegron has been reported to significantly reduce the number of incontinence 
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episodes and also micturitions per 24 hours were reduced from baseline values 
(Bridgeman et al., 2013). Several animal studies have revealed the in vivo function of 
β-AR agonists on bladder function. In a study by H. Takeda et al. (2000) using 
urethane-anaesthetised rats, isoprenaline, procaterol, and CL316,243 dose-
dependently decreased intravesical pressure under isovolumetric conditions, and in 
cystometry experiments, CL316,243 significantly prolonged the micturition interval 
and increased bladder capacity. A further study by H. Takeda et al (2003) 
demonstrated reduced intravesical pressure in urethane-anaesthetised rats by both 
procaterol and CL316,243. In addition, whilst intravenous administration of 
procaterol did not affect voiding pressure relative to vehicle and had little effect on 
bladder capacity in conscious, unrestrained rats, CL316,243 had no effect on bladder 
capacity but reduced voiding pressure (Kaidoh et al., 2002).  
Compliance is defined as the increase in pressure per unit increase in volume. 
Healthy bladder is very compliant and may be filled with large volumes with little 
increase in detrusor pressure (Sand and Ostergard, 1995), but a reduced maximum 
bladder capacity has been reported in patients following MMC treatment (Kim and 
Lee, 1989). Michielsen et al. (2005) has also reported decreased maximum volume 
and compliance of the bladder in mice treated with MMC. This decreased bladder 
compliance can result in greater pressure increases during filling. Therefore, the 
finding of reduced detrusor relaxation to β-AR stimulation observed in this study 
may provide a mechanism by which MMC could cause decreased bladder capacity in 
patients. Furthermore, decreased maximum bladder volume caused by low bladder 
compliance may be correlated to overactivity of the bladder  (increased urinary 
urgency and frequency) reported in patients following MMC treatment because a 
decreased bladder volume would result in the bladder needing to be voided more 
frequently and thus urge to urinate will also be subsequently increased.  
 
Integrity of bladder morphology 
The effects of chemotherapeutic agents on urothelial integrity are unknown, but it 
was found that doxorubicin pretreatment does not affect urothelial thickness (Chapter 
3). However, histological examination of the bladder sections that received MMC 
and epirubicin pretreatment, revealed that urothelial thickness was significantly 
thinner compared to those of control bladder sections, suggesting that these two 
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agents may cause an urothelial thinning in patients after intravesical treatment. 
Reduced urothelial thickness may indicate that the protective components of the 
urothelium such as uroplakins, tight junctions and GAGs are damaged. This can 
potentially compromise the protective function of the urothelium, which in a healthy 
bladder effectively prevents penetration of harmful solutions into the layers 
underneath the urothelium. The loss of barrier function may lead to increased 
susceptibility of chemotherapeutic agents to be absorbed by the urothelium itself as 
well as deeper layers of the bladder such lamina propria and detrusor muscle. This 
finding may explain why contractile responses of the urothelium/LP and the ability 
of detrusor muscle to relax were reduced by MMC in addition to depressed 
contractile responses of the detrusor muscle by both cytotoxic drugs.  
 
Mediator release from the urothelium/LP 
In this study, a basal release of ATP, ACh and PGE2 were observed in all tissues. 
Unlike the control tissues from the epirubicin and doxorubicin (aged) experiments, 
stretching the tissues resulted in increased ATP release over basal level in control 
bladders from the MMC experiments. This highlights the importance of running 
matched controls with each experiment as was done in this study so that changes 
caused by drug treatment can be clearly identified. Stretching the control tissues did 
not lead to an increase in ACh or PGE2 in any of three experiments. Pretreatment 
with MMC and epirubicin has demonstrated various changes in these urothelial 
mediators. 
The role of urothelial-derived ACh is still being identified but it has been suggested 
that once released in response to mechanical and chemical stimulation, urothelial-
derived ACh may act in a paracrine manner to stimulate the detrusor muscle and 
sensory nerves, or in an autocrine manner to stimulate urothelial associated 
muscarinic receptors (Birder, 2010; Hanna-Mitchell et al., 2007). Kanai et al. (2007) 
applied muscarinic receptor agonist to rat bladder tissues and subsequently induced 
membrane-potential transients and Ca2+ transients that begin near the urothelial-
lamina propria interface and then spread to the detrusor muscle. The study suggests 
the possibility that the urothelium may regulate the generation of spontaneous, non-
voiding contraction in the bladder. Patients with OAB can be effectively treated with 
muscarinic receptor antagonists which enhance the storage phase of micturition by 
 135 
inhibiting the binding of ACh at muscarinic receptors (M2 & M3) on the detrusor 
smooth muscle as well as pre-junctional muscarinic receptors in the bladder on 
cholinergic and adrenergic nerve terminals (Abrams and Andersson, 2007; Chess-
Williams, 2002; Pathak and Aboseif, 2005; Staskin and MacDiarmid, 2006). Since, 
the full complement of muscarinic receptors are also expressed by the urothelium, 
this may indicated that urothelial-derived ACh can play a role in the OAB (Yoshida 
et al., 2006). In patients with OAB, increased cholinergic afferent effects, 
specifically sensitisation of ACh-evoked signalling in the urothelium have been 
reported (Yoshida et al., 2010). The results of this study revealed that in 
urothelial/LP tissues, basal and stretch-induced ACh release was elevated at the 
majority of time points by both cytotoxic drugs. However, this effect was only 
statistically significant at the 3 minute time point for stretch-induced ACh release 
after MMC and at the 7 minute time point for basal release after epirubicin. It 
appears that ACh release overall is increased by both cytotoxic drugs. Thus, 
enhanced release of ACh from the urothelium/LP following MMC and epirubicin 
pretreatment may contribute to overactivity of the bladder (increased urinary urgency 
and frequency) reported in patients following intravesical treatment with these two 
agents.  
As it was discussed previously in doxorubicin study, it is well accepted that an 
augmented urothelial ATP release is associated with pathophysiology of bladder 
disorders such as OAB and IC/PBS. These conditions are characterised by increased 
bladder activity and painful sensations and it has been suggested that excitation of 
purinergic receptors on sensory fibers may be a contributing factor (Khera et al., 
2004; Munoz et al., 2011; Smith et al., 2005; Sun et al., 2001). Therefore, depressed 
stretch-induced ATP release from the urothelium/LP following MMC and epirubicin 
treatment was surprising. Thus, urological adverse effects caused by intravesical 
MMC and epirubicin treatment such as dysuria, increased urinary urgency and 
frequency which are similar to those symptoms seen in OAB and PBS cannot be 
explained by reduced ATP release following MMC and epirubicin treatment.  
However, there is some evidence suggesting that P2Y receptors might also be 
contributing to hyperexcitablity and increased firing of bladder afferents that are 
associated with urinary urgency and pain, all of which are adverse effects 
experienced by patients treated with MMC and epirubicin. It has been reported that 
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P2Y1, P2Y2, P2Y4 and P2Y11 are expressed on urothelial cells (Birder et al., 2004; 
Chopra et al., 2008; Shabir et al., 2013) and respond to endogenous purine and 
pyrimidine nucleotides (ATP, ADP, AMP, adenosine, UTP and UDP) released into 
the extracellular environment from various tissues (Lazarowski and Boucher, 2001; 
Lazarowski and Harden, 1999; von Kugelgen, 2006). The function of these receptors 
in the bladder is not well studied, but there is a growing evidence to support the 
involvement of P2Y receptors in mechanosensation and or/ nociception under normal 
and pathological conditions. A recent study by Fry et al. (2012) has demonstrated 
enhanced spontaneous activity in rat bladder sheets after exogenous application of 
P2Y receptor agonist (ADP and UTP). Chen et al. (2010) has reported increased 
excitability of mouse bladder sensory neurons by UTP (a P2Y2 and P2Y4 agonist) via 
a depolarisation of the resting membrane potential, increasing action potential firing, 
and facilitating purinergic (P2X) currents. Also, a study by Timoteo et al. (2014) has 
shown that intravesical instillation of a P2Y6 selective agonist in a rat cystometry 
model induced bladder overactivity characterised by increased urinary frequency, 
and also increased ATP release in the voided fluid. The urothelium expresses ecto-
ATPase enzymes (Stella et al., 2010) and so is able to hydrolyse ATP to breakdown 
products such as ADP, AMP, and adenosine. The function of these enzymes is to 
limit the availability of ATP (Mansfield and Hughes, 2014e). It can be postulated 
that MMC and epirubicin treatment may increase the activity of ecto-ATPase activity 
in the urothelium, which leads to reduced ATP concentrations and increases the 
amount of ATP breakdown products. Thus, an increase in the hydrolysed products of 
ATP such as ADP, AMP and adenosine, which act on P2Y receptors, may be 
contributing to sensitisation of afferent pathway and increased bladder activity.  
PGE2, which is the product of the cyclooxygenase (COX) pathway, is also released 
from the urothelium during bladder filling. The actions of the urothelial-derived 
PGE2 in the bladder are not well understood, but it has been reported to stimulate 
spontaneous bladder contractions (de Jongh et al., 2007), stimulate release of ATP 
from urothelial cells (Tanaka et al., 2011) and sensitize bladder capsaicin-sensitive 
afferent neurons (Maggi et al., 1988a), all actions which suggest PGE2 may play 
important roles in the modulation of nerve and detrusor functions (Apodaca et al., 
2007; Birder, 2005). Previous studies have shown that overexpression of PGE2 in the 
bladder stimulates the micturition reflex through activation of C fibres (Aoki et al., 
2009; Maggi et al., 1988a). Also, cyclooxygenase (COX), when inhibited improved 
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storage function in rats with detrusor overactivity, indicating potential stimulatory 
effect of PGE2 on bladder micturition reflex (Yokoyama, 2010a). In humans, 
intravesical administration of PGE2 caused detrusor overactivity, urgency and 
decreased bladder capacity (Schussler, 1990). In addition, elevated local PGE2 
production was reported in the bladders of animals with overactive detrusor muscle 
(Hu et al., 2003; Park et al., 1999) as well as patients with OAB (Kim et al., 2005; 
Kim et al., 2006a). Thus, enhanced basal PGE2 release from the urothelium/LP 
following MMC pretreatment observed in this study may lead to increased activation 
of the bladder micturition reflex and may contribute to the increased urinary urgency 
and frequency experienced by patients treated intravesically with this drug. Unlike 
MMC treatment, epirubicin had no effect on the release of PGE2. 
The effects of urothelium-derived inhibitory factor (UDIF) on detrusor muscle 
contractility have been mentioned previously (Chapter 3). The influence of this 
factor was also evident in this study, where the presence of an intact urothelium/LP 
in control tissues significantly depressed maximum contractions of the detrusor 
muscle to carbachol. However, after MMC or epirubicin treatment inhibition of 
detrusor muscle responses by the urothelium/LP was absent. These findings suggest 
that MMC and epirubicin may depress the release or the actions of UDIF following 
urothelial damage which was represented by a decreased urothelial thickness as well 
as depressed contractile response of the urothelium/LP to carbachol by MMC. A 
reduction in inhibitory mechanisms of the urothelium on detrusor muscle contraction 
has been observed in the human neurogenic OAB. A study by Chess-Williams, Cross 
& Chapple (2009) demonstrated that inhibition of maximal responses to carbachol 
(42.6±11.5%) in the presence of the urothelium in bladder strips from neurogenic 
OAB patients was less than that seen in control tissues (65±4%). Thus, lack of 
inhibition on detrusor contractility by the urothelium/LP by the cytotoxic drugs 
observed in this study may also be a contributing factor to overactivity of the bladder.  
 
Conclusions 
In conclusion, it appears that MMC treatment is highly toxic on detrusor muscle as 
demonstrated in the present study by depressed contractile responses of the detrusor 
muscle to muscarinic receptor stimulation and neurogenic stimulation along with a 
reduced ability of detrusor muscle to relax to β-AR stimulation. Reduced detrusor 
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compliance may contribute to adverse effects such as decreased bladder capacity. 
Both the lack of UDIF effect on detrusor contractility and enhanced release of ACh 
and PGE2 caused by toxicity of MMC on the urothelium (reduced urothelial 
thickness) would tend to result in bladder overactivity, thus causing increased urinary 
frequency and urgency. Epirubicin treatment, on the other hand, had a lower toxicity 
profile compared to MMC depressing contractile responses of detrusor muscle 
without affecting relaxation or neurogenic response. It appears to cause adverse 
effects through its toxic properties affecting mainly the urothelium (decreased 
urothelial thickness) causing abolition of the UDIF effect and increased ACh release 
both of which would tend to result in bladder overactivity. 
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Chapter 5 - The effects of mitomycin C on RT4 
urothelial cells 
 
 140 
Introduction 
The previous chapters demonstrated that the cytotoxic agents doxorubicin, MMC and 
epirubicin alter porcine bladder function, in terms of muscle contraction, response to 
neurogenic stimulation and release of mediators from the urothelium/LP.  A study 
conducted during my Honours project also demonstrated that doxorubicin alters 
release of urothelial mediators, ATP, ACh and PGE2 from RT4 human urothelial 
cells, with stimulation of inflammatory cytokine release (Kang et al., 2013).  Given 
that multiple cells types in the bladder wall have been reported to release mediators 
such as ATP, this chapter assessed the cell specific changes that occur when human 
urothelial cell cultures are treated with MMC. The work described in this chapter has 
recently been published in Naunyn-Schmiedeberg’s Archives of Pharmacology in a 
paper entitled “Recovery of urothelial mediator release but prolonged elevations in 
interleukin-8 and NO secretion following mitomycin C treatment” by S. Kang, R. 
Chess-Williams, S. Anoopkumar-Dukie and C. McDermott. 
 
Models of Urothelial Function 
The urothelium which lines the luminal surface of the bladder is in close proximity to 
the cytotoxic agents during intravesical treatment. The urothelium was originally 
thought to act as a simple distensible barrier protecting the underlying nerves, 
muscular and vascular tissues from the potentially harmful contents of the urine. 
However, recent studies have shown that the urothelium can release a number of 
chemical mediators and transmitters including ATP (Burnstock, 2011), ACh (Birder, 
2010; Hanna-Mitchell et al., 2007), PGE2 (Aizawa et al., 2010; Apodaca et al., 2007; 
Birder, 2005; Tanaka et al., 2011) and NO (Birder et al., 1998; Giglio et al., 2005) in 
response to chemical and mechanical stimuli during bladder filling to communicate 
with underlying tissues, and regulate sensory mechanisms and bladder contraction 
(Birder et al., 2010f; Cockayne et al., 2000; Maggi et al., 1988a). Urothelial 
mediators have been covered in detail in Chapter 1.  
Despite the urothelium acting as an effective barrier to the movement of substances 
from the bladder lumen to the deeper tissue layers, there is evidence that some 
intravesical chemotherapeutic agents diffuse into the detrusor muscle including 
MMC and doxorubicin, albeit only a fraction of the luminal concentration (Wientjes 
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et al., 1993; Wientjes et al., 1991). It is likely that the urothelium is the layer most 
affected by intravesical chemotherapy given the immediate contact between this 
layer and high concentrations of cytotoxic drugs.  To determine the effects of MMC 
on urothelial function RT4 cells, a human urothelial cell line were used as a model of 
urothelial mediator release in this chapter. 
Human cancer cell lines are widely used in research to examine cancer biology and 
develop anti-cancer drugs. Generally, it is only highly aggressive metastatic cancers 
that have accumulated the genetic changes necessary for unlimited growth in vitro 
that spontaneously become continuous cell lines. Therefore, most primary well-
differentiated cancer cell lines are not mortal but still retain characteristics of normal 
urothelial cells (Masters, 2000). Thus, the RT4 cell line which is a malignant human 
urothelial cell line derived from a recurring papillary tumour of the bladder was used 
in this study, since it is from well-differentiated tumours, still retains features of 
asymmetric unit membrane and the specialised luminal surface of terminally 
differentiated superficial urothelial cells (Masters and Palsson, 1999). The in vitro 
urothelial culture model used in this study has been used previously to assess 
urothelial mediator release by our group and others (Kang et al., 2013; Mansfield and 
Hughes, 2014a, e; McDermott et al., 2012).   
In vivo models are complicated by the presence of structural heterogeneity and do not 
allow for toxic mechanisms to be clearly defined.  Using cultured urothelial cells 
allowed us to investigate the effects of MMC at cellular level and aids in 
identification of urothelial specific effects, in addition to performing repeat 
treatments and investigating the potential for recovery post-treatment.  The 
complexity of bladder tissue is such that multiple cell types in the bladder wall 
release the mediators of interest in this study (Cheng et al., 2011).  Given that our 
aim was to assess the effects of MMC on urothelial function, interpretation of 
changes in mediator release from intact tissue is complicated by multiple sources of 
release. A major limitation of animal studies is difficulty with interpretation based on 
species differences.  Therefore, a significant advantage of the urothelial model used 
here is that it is of human origin and has been shown to release ATP, ACh and PGE2 
under basal and stretch conditions as in the intact bladder.  We must however be 
mindful of the limitations of cell culture models when interpreting results and 
making conclusions that relate to the clinical setting due to possible changes to 
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functional characteristics in cultured cells and the complexity of the whole organism.  
Future pharmacological and physiological studies are therefore necessary to confirm 
if our conclusions regarding the role of inflammation are valid. 
We recently reported that doxorubicin, at clinically relevant concentrations and 
durations of treatments, alters release of ATP, ACh and PGE2 from RT4 urothelial 
cells (Kang et al., 2013). Twenty-four hours following treatment, urothelial mediator 
release was still affected and induction of pro-inflammatory cytokines (IL-8 and IL-
1β) was observed.  Based on the results of this study, we hypothesised that release of 
inflammatory mediators may be a common factor following treatment with 
intravesical chemotherapeutic agents and many play a role in inducing local side 
effects. 
 
Inflammation 
Inflammation is triggered by tissue injury such as physical trauma, intense heat and 
irritating chemicals or when innate immune cells detect infection by viruses and 
bacteria (Khan and Khan, 2010; Newton and Dixit, 2012). Innate immune cells that 
reside in tissues including macrophages, fibroblasts, mast cells and dendritic cells, 
and circulating leukocytes such as monocytes and neutrophils recognise pathogen 
invasion or cell damage. Then, these immune cells as well as injured tissue cells 
release inflammatory mediators such as histamine, prostaglandins, and NO to cause 
vasodilation, which increases blood flow and brings in circulating leukocytes. Also, 
inflammatory mediators including histamine and leukotrienes act on endothelial cells 
to increase vascular permeability and allow plasma proteins and leukocytes to exit 
the circulation (Newton and Dixit, 2012). Cytokines, which is another inflammatory 
mediator, attract leukocytes to the site of inflammation and lastly, activated innate 
immune cells at the site of infection or injury, such as dendritic cells, macrophages 
and neutrophils, remove foreign particles by phagocytosis (Newton and Dixit, 2012).   
Inflammation is reported in many bladder pathologies including IC/PBS and OAB. 
These disorders of the bladder have symptoms common to those reported by bladder 
cancer patients treated with intravesical chemotherapy such as cystitis including 
urinary urgency, together with frequency and dysuria (Macdiarmid and Sand, 2007; 
Thrasher and Crawford, 1992). There is much evidence demonstrating the 
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relationship between the inflammation of the bladder and the symptoms of urinary 
bladder diseases. Studies using cyclophosphamide (CYP)-induced cystitis model, 
which assessed cytokine expression, have detected enhanced IL-6, IL-1α and IL-4, 
among others, protein and mRNA levels in the urine and urinary bladder (Eichel et 
al., 2001; Smaldone et al., 2009). Cystitis in rats has shown to increase bladder 
afferent excitability and is believed to contribute to bladder overactivity and pain 
(Hayashi et al., 2009). Increased transcription and expression of cytokine was 
observed in the urinary bladder of patients with ulcerative IC/PBS (Corcoran et al., 
2013; Lotz et al., 1994; Ogawa et al., 2010). Also, several studies reported elevated 
IL-6 in the urine of patients with ulcerative IC/PBS (Erickson et al., 1997; Erickson 
et al., 2002; Lotz et al., 1994). Additionally, a recent study by Liu and her colleagues 
(2013) has demonstrated significantly increased serum cytokine (IL-1β, IL-6, IL-8 
and TNF-α) levels in OAB patients compared to the controls.  
Cytokines are small proteins secreted by cells of the immune system that act in an 
autocrine, paracrine or endocrine manner to have a specific effect on the interactions 
and communications between cells to modulate inflammatory response. Cytokines 
include lymphokine (cytokines made by lymphocytes), monokine (cytokines made 
by monocytes), chemokine (cytokines with chemotactic activities), and interleukin 
(cytokines made by one leukocytes and acting on other leukocytes).  Cytokines are 
redundant in their activity which means similar functions can be stimulated by 
different cytokines. Many cell types produce cytokines, but they are predominantly 
made by helper T cells and macrophages. Cytokines such as tumour necrosis factor 
(TNF) and interleukin-1 (IL-1) promotes recruitment of leukocytes at the site of 
inflammation through the process called “extravasation” by increasing the levels of 
leukocyte adhesion molecules on endothelial cells (Newton and Dixit, 2012; Sciacca 
et al., 1994). Interleukin-6 (IL-6) is also produced at the site of inflammation and 
plays a crucial role in inflammatory response. IL-6 is responsible for the transition 
from acute to chronic inflammation by altering the nature of leucocyte infiltrate 
(from polymorphonuclear neutrophils to monocyte/macrophages) and also favours 
chronic inflammatory responses by exerting stimulatory effects on T and B cells 
(Gabay, 2006). Interleukin-8 (IL-8) is also known for its role in inflammation and its 
main function is chemotaxis and activation of neutrophils and T cells in 
inflammatory region (Baggiolini, 1998). Other cytokines that plays a crucial role in 
inflammatory response include interleukin-10 (IL-10) and interleukin-12 (IL-12). IL-
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10 is a potent anti-inflammatory cytokine that limits host immune response to 
pathogens, thereby preventing damage to the host and maintaining normal tissue 
homeostasis (Iyer and Cheng, 2012). IL-12, which is produced mostly by phagocytic 
cells and to some degree by B-cells, induces cytokine production, primarily of 
interferon-gamma (IFN-γ), from natural killer (NK) and T cells, acts as a growth 
factor for activated NK and T cells, enhances the cytotoxic activity of NK cells, and 
favours cytotoxic T cell generation (Trinchieri, 1995). Hence, BD Cytometric Bead 
Array (CBA) Human Inflammatory Cytokine Kit, which can simultaneously quantify 
six cytokines (IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70 are actively involved in 
inflammatory response as mentioned above), was used in this study to evaluate the 
effects of the three cytotoxic drugs on inflammation of the urothelium. Certain 
cytokines are involved in not only the initiation but also the persistence of pathologic 
pain by directly acting on nociceptive sensory neurons (Zhang and An, 2007). There 
are studies showing that inflammatory cytokines are released after intravesical 
treatment with immunotherapeutic agent, BCG (de Boer et al., 1997) and the 
chemotherapeutic agent, doxorubicin (Abou El Hassan et al., 2003). In addition, 
MMC has been shown to induce IL-8 release in human fibroblasts (Chou et al., 
2007).  
 
Nitric Oxide 
NO, which is one of the non-adrenergic, non-cholinergic (NANC) transmitters 
affecting the bladder, is a small gaseous free radical with a half-life of less than 6 
seconds (Andersson and Persson, 1994). 
NO is an important cellular signalling molecule produced by nitric oxide synthase 
(NOS). There are three distinctive isoforms of NOS including endothelial nitric 
oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric 
oxide synthase (iNOS) (Winder et al., 2014). It has been reported in several studies 
that NO formation occurs in urothelial cells via either iNOS or eNOS, with some 
reports also indicating the presence of nNOS mainly in species other than human 
(Birder et al., 2002; Chuang et al., 2013; Gillespie et al., 2005; Theobald, 2003). 
NO activates soluble guanylate cyclase (sGC), a key enzyme of the NO-cyclic GMP 
(cGMP) signalling pathway which induces smooth muscle relaxation.  Activation of 
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sGC results in formation of a second messenger, cGMP which activates protein 
kinase G. This causes reuptake of Ca2+ and opening of calcium-activated potassium 
channels. The decrease in intracellular concentration of Ca2+ activates myosin light-
chain phosphatise (MLCP) which dephosphorylates the myosin light-chains, leading 
to smooth muscle relaxation (Bryan et al., 2009). The role of the NO-cGMP 
signalling pathway in regulating bladder smooth muscle (detrusor) relaxation is still 
unclear, however it appears to be the above mechanism (cGMP signalling pathway) 
which modulates high voltage Ca2+ channels, thereby affecting the firing threshold 
(Yoshimura et al., 2001). 
NO is released from the urothelium in response to mechanical and chemical 
stimulation such as noradrenaline (NA), capsaicin and isoproterenol. It is a 
potentially important soluble factor which modulates bladder functions (Andersson 
and Persson, 1995; Apodaca et al., 2007; Birder et al., 2002; Birder et al., 2010g; 
Murakami et al., 2007). The role of NO in regulating bladder activity is still being 
evaluated but it may have several functions including relaxation of detrusor muscle, 
modulation of afferent and efferent nerve functions and regulation of urothelium 
barrier function (Birder et al., 2002).  
The mechanical stimuli such as bladder filling will stimulate the release of NA which 
directly relaxes detrusor muscle. It also elicits release of NO which will enhance 
relaxation further. Also, stimulation of cholinergic receptors induces NO release 
from the urothelium which results in relaxation of the bladder outlet, allowing 
bladder emptying to occur with little increase in intravesical pressure (Apodaca et al., 
2007; Chess-Williams, 2002). There is growing evidence which support the 
inhibitory effects of NO on the bladder reflex pathway. It has been reported that 
intravesical administration of oxyhemoglobin (NO scavenger) results in a bladder 
hyperactivity and also decreased bladder capacity inducing bladder contraction via 
modulation of the threshold for afferent nerve firing, indicating an inhibitory role for 
NO in the control of bladder reflexes (Pandita et al., 2000). In addition, an 
intravesically administered NO donor (S-nitroso-N-acetylpenicillamine) 
demonstrated decreased overactivity induced by chemical irritants in rats, further 
supporting the idea of NO partly exerting its effect on afferent nerve terminals 
(Ozawa et al., 1999). Furthermore, bladder overactivity of rat cystitis model induced 
by cyclophosphomide was further increased with an unselective NOS-inhibitor 
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(N(ω)-nitro-L-arginine methyl ester; L-NAME) (Andersson et al., 2011; Ozawa et al., 
1999). These findings suggest that NO depresses activity of the bladder reflex by 
suppressing the excitability of and/or the release of transmitters from bladder afferent 
nerves (Masuda et al., 2007).  
Contrarily, an excitatory effect of NO on bladder contractility has also been observed 
during electrical field stimulation (Liu and Lin-Shiau, 1997), possibly by aiding 
intracellular Ca2+ release in myocytes (Wei et al., 2008; Yanai et al., 2008). Also, 
some studies have discussed the role of NO in facilitating vesicular release of ACh 
and ATP which has been suggested to be responsible for the contractile effects of 
NO in the bladder (Bal-Price et al., 2002; Mothet et al., 1996).  
In addition to the effects of NO on smooth muscle contractility in pathological 
conditions, studies in various tissues have suggested important immunomodulatory 
effects of NO on development of inflammation as well as necrosis/apoptosis and the 
subsequent loss of barrier function (Andersson et al., 2011; Chuang et al., 2013; 
Jezernik et al., 2003; Xu et al., 2002). Increased levels of NO in urine have been 
reported in patients with IC (Logadottir et al., 2004). The Ca2+ independent isoform, 
iNOS has been discussed by many studies as the key for the formation of urothelial 
NO in the acute phase of cell damage and early inflammatory response (Jezernik et 
al., 2003; Moncada et al., 1991; Persson et al., 1999). It has been shown that 
lipopolysaccharide (LPS) treatment can cause upregulation of iNOS in the 
urothelium (Persson et al., 1999). Hence, it can be postulated that subsequent 
apoptosis and disrupted barrier function is due to high levels of NO produced as a 
result of iNOS (Jezernik et al., 2003). This is further supported, since a decrease in 
urothelial damage and subsequent inflammation have been observed by preventing 
the formation of NO with a NOS-inhibitor (Souza-Fiho et al., 1997). Furthermore, 
the expression of another isoform, eNOS is increased in the urothelium and 
suburothelium of rats 60 hours following treatment with the anti-cancer agent 
cyclophosphamide when the inflammatory response was at its peak (Giglio et al., 
2005).  
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Aims 
Generally, intravesical treatments are received at weekly intervals. To our knowledge, 
recovery of urothelial function over longer periods such as this has not been assessed 
to date. The aim of this study was to investigate the effects of MMC on basal and 
stretch-induced release of urothelial mediators (ATP, ACh and PGE2) from human 
urothelial cells and determine whether changes in urothelial function may provide an 
explanation for the urological adverse effects experienced by patients treated with 
intravesical MMC. The release of inflammatory cytokines and NO from urothelial 
cells after MMC treatment was also assessed to determine if inflammation may play 
a role in the adverse effects associated with treatment. In addition, recovery of 
urothelial function was assessed 1 week post-treatment and repeat treatments 
conducted. 
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Materials and Methods 
Cell culture 
The RT4 cell line is an immortalised human urothelial cell line derived from explants 
of a recurring papillary tumour of the bladder supplied by European Collection of 
Cell Cultures (ECACC). RT4 cells were routinely cultured in 75cm2 culture flasks 
(T75) using McCoy’s 5A culture medium supplemented with additional 2mM L-
glutamine, 1% v/v penicillin-streptomycin and 10% v/v Fetal Bovine Serum (FBS). 
Cells were maintained at 37°C in 5% CO2. The doubling time of RT4 cells is 
approximately 36 hours and confluent cells (approx. 90%) were subcultured at a 1:4 
ratio by detaching cells from the flask using a trypsin/EDTA solution. 
 
Seeding densities of cell treatments 
Cell viability was assessed using trypan blue exclusion prior to seeding plates for 
treatment with mitomycin C (MMC). Only cells with viability ≥ 95% were used for 
experiments. RT4 cells were seeded in 24 or 96 well plates or T25 flasks at a density 
determined in initial optimisation experiments, see Table 5.1 below. Cells were 
incubated overnight at 37ºC to allow cells to adhere.   Seeding density was also 
dependent on the timing of endpoint measurement following initial or repeat 
treatment. 
Table 5.1: Optimum seeding density used for experiments with RT4  
Timing of Endpoint 
Measurement 
Seeding Density in 
96 well plates 
Seeding Density in 
24 well plates 
Seeding Density in 
T25 flasks 
Immediate 0.05 x 106 per well 0.3 x 106 per well 4.0 x 106 per well 
24 hours after 1st 
treatment 0.015 x 10
6 per well 0.1 x 106 per well 1.3 x 106 per well 
1 week after 1st 
treatment 0.085 x 10
5 per well 0.05 x 106 per well 0.65 x 106 per well 
1 week after 2nd 
treatment 0.05 x 10
5 per well 0.03 x 106 per well 0.4 x 106 per well 
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MMC treatment of urothelial cells 
Krebs-bicarbonate solution was added to the first column of the plate serving as a 
vehicle control (untreated) (Figure 5.1). The next 5 columns were treated with 
increasing concentrations of MMC (0.0002, 0.002, 0.02, 0.2 and 2mg/ml). MMC was 
diluted in Krebs-bicarbonate solution and was allowed to equilibrate for 30 minutes 
at 37°C immediately before use. The plate was then incubated for two hours at 37°C 
in 5% CO2. Cell viability and urothelial mediator release was then assessed 
immediately post-treatment. 
Control 
(Krebs) 
MMC 
(0.0002mg/ml) 
MMC 
(0.002mg/ml) 
MMC 
(0.02mg/ml) 
MMC 
(0.2mg/ml) 
MMC 
(2mg/ml) 
      
      
      
      
 
Figure 5.1: Illustration of 24 well plate containing control and MMC treated wells.  
 
To assess the late effects (24 hour post 1st treatment) of MMC on urothelial function, 
cell viability, NO and cytokine release, after treatment with MMC concentration of 
0.0002 or 0.02 mg/ml for 2 hour, all solutions on the plate were aspirated, cells were 
washed twice with PBS.  McCoy’s 5A culture medium was added into each well 
seeded. The plate was then incubated at 37°C for a further 24 hours prior to analysis 
of endpoints.  
To assess effects of MMC on treated cells 1 week after 1st treatment with 0.002 
mg/ml MMC, plates/flask were handled as just described but incubated at 37°C for 1 
week. The culture medium was changed every two days during this period.  
Urothelial cells were treated with lower concentrations of MMC for 24 hour (0.0002 
or 0.02 mg/ml) and 1 week (0.002 mg/ml) post-treatment experiments as a previous 
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study showed that the concentration of MMC that reaches the urothelial cells is 
approximately 3% of intravesical treatment (Wientjes et al., 1993). They also report 
that the amount of MMC penetrating the normal bladder tissue is lower than the 
levels penetrating the superficial tumours of the bladder. In addition, often the dose 
used clinically is half of that used here (Colombo et al., 2012). Therefore, these 
lower concentrations are more likely to reflect the concentration reached in urothelial 
cells in vivo. In addition, higher concentrations of MMC left cell viability too low to 
allow for measurement of urothelial mediator release as would be expected with such 
a high concentration. Since cultured urothelial cells are actively proliferating unlike 
urothelial cells in situ, they are likely to be more vulnerable to the cell death 
mechanisms of chemotherapeutic agents such as MMC that tend to be more specific 
for proliferating cells. Hence, it is more appropriate to assess the drug at 
concentrations that have little effect on cell viability. 
 
Repeat MMC treatment of urothelial cells 
To assess the effects of repeated treatment on urothelial cells, cells received a 2nd 
treatment with the same concentration of MMC 1 week following initial treatment.  
Cells were initially handled in the same way as those just described for analysis of 
endpoints following 1 week with culture medium being changed every two days. 
After 1 week incubation, treatment wells were again exposed to 0.002 mg/ml of 
MMC (2nd treatment) for two hours, while control wells were exposed to normal 
Krebs-bicarbonate solution. After second treatment, incubation medium was 
aspirated and cells were washed with PBS.  Fresh McCoy’s 5A culture medium was 
then added into each well. The plate was then incubated at 37°C for further 1 week. 
The culture medium was again changed every two days. After 1 week incubation, 
endpoint analysis was carried out as described in the following sections. 
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Assessment of urothelial cell viability - resazurin reduction assay 
Cells were seeded in 96-well microtiter plates as previously described and treated 
with MMC (0-2mg/ml) for 2 hour at 37°C. Immediately, 24 hour and 1 week after 1st 
MMC treatment, and also 1 week after 2nd MMC treatment, fresh medium containing 
44 µM resazurin was added to each well. After 2 hour incubation at 37°C, the 
quantity of resorufin was determined by fluorescence (excitation 530 nm; emission 
590 nm) using a Modulus microplate reader. Appropriate cell free controls were also 
included. Under all conditions tested, the extent of resazurin reduction was directly 
proportional to viable cell counts (data not shown). No change in cell number was 
observed immediately after 2 hour MMC treatment. Viability was also assessed 7 
days after repeat MMC treatment.  
 
Mediator release from treated cells 
Basal release 
Immediately, 24-hour, or 1-week following 2 hour incubation with MMC, all 
solutions on the plate were aspirated and cells were washed twice with phosphate 
buffered saline (PBS) solution.  
Preparation of samples for analysis of mediator release from RT4 cells was 
previously described by Kang et al (2013). Krebs-bicarbonate solution (150µl) was 
added into each well (Figure 5.2). The plate was then incubated at 37°C. After 15 
minutes, the solutions in each well were collected into microfuge tubes and these are 
representative of basal release of urothelial mediators from MMC treated and control 
cells.  
Hypo-osmotically stimulated release  
Hypotonic Krebs-bicarbonate solution was added into each well (150µl) (Figure 5.3). 
The use of hypotonic Krebs-bicarbonate solution (50% of normal NaCl content; 180 
mOsm/L) causes the cells to swell, mimicking stretching of the cells (Hanna-
Mitchell et al., 2007; Kang et al., 2013). After 15 minutes incubation at 37°C, the 
solutions in each well were collected into microfuge tubes. 
Samples collected from each row were used for measuring each of the urothelial 
mediators (ACh, ATP and PGE2) (Figure 5.2 and 5.3). This collection of samples 
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containing urothelial mediators from basal and stimulated conditions equals one 
independent experiment (N=1) and samples from each experiment were frozen at       
-80°C for later assay of urothelial mediators.  
 
Control 
(Krebs) 
MMC 
(0.0002mg/ml) 
MMC 
(0.002mg/ml) 
MMC 
(0.02mg/ml) 
MMC 
(0.2mg/ml) 
MMC 
(2mg/ml) 
Samples for 
ACh assay 
      
Samples for 
ATP assay 
      
Samples for 
PGE2 assay 
      
 
Figure 5.2: Illustration of control and mitomycin C treated plate exposed to Krebs-
bicarbonate solution (or isotonic solution) for measurement of basal mediator release. 
 
Control 
(Krebs) 
MMC 
(0.0002mg/ml) 
MMC 
(0.002mg/ml) 
MMC 
(0.02mg/ml) 
MMC 
(0.2mg/ml) 
MMC 
(2mg/ml) 
Samples for 
ACh assay 
      
Samples for 
ATP assay 
      
Samples for 
PGE2 assay 
      
 
Figure 5.3: Illustration of control and mitomycin C treated plate exposed to hypotonic 
Krebs-bicarbonate solution (or hypotonic solution) for measurement of hypo-osmotically 
stimulated mediator release. 
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Inflammatory cytokine and NO release from treated cells 
To assess the late effects (24 hour post 1st treatment) of MMC on release of 
inflammatory cytokines and urothelial NO, cells were seeded in 25cm2 flasks at 
density and treated with MMC concentrations (and duration), as described above. 
Control flasks were exposed to normal Krebs-bicarbonate solution (untreated). The 
flasks were then incubated for 2 hour at 37°C in 5% CO2.  
After treatment, solutions on each flask were washed off. McCoy’s 5A culture 
medium was added into each flask. The flasks were then incubated at 37°C for 24 
hours. 
After 24 hour incubation, samples of cell free incubation medium for analysis of 
cytokines (IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70) and NO metabolites (nitrate 
and nitrite) were collected. The samples were frozen at -80°C until analysis.   In 
additional experiments, samples were also collected 1 week following 1st and 2nd 
treatment, with media changes performed every 2 days during the incubation period.  
 
(The release of various mediators was measured using commercially available kits as 
described in “Assays for urothelial mediators, NO and inflammatory cytokines” 
section in Chapter 2) 
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Results 
Immediate effects of MMC on urothelial mediator release 
Immediately following treatment, no significant change was observed in basal 
release of ATP from human urothelial cells at all concentrations of MMC tested 
(Figure 5.4a).  Stimulated release of ATP was observed in vehicle treated control 
urothelial cells and cells treated with MMC (0.0002-0.2mg/ml), with significant 
increase above basal levels of ATP release in response to hypotonic stimulation; 
except at 2mg/ml where stimulated release of ATP was completely abolished (95% 
decrease) (Figure 5.4b).  
Immediately following MMC treatment, whilst basal release of ACh from urothelial 
cells exposed to 2mg/ml was significantly increased (2-fold) compared to vehicle 
treated control cells; stimulated release of ACh was not significantly affected by 
MMC in comparison to control (Figure 5.4c and d). 
Basal release of PGE2 from cells treated with 2mg/ml of MMC was significantly 
decreased (7-fold) immediately following 2 hour drug exposure compared to control 
(Figure 5.4e). A significant decrease in release of PGE2 in response to hypotonic 
stimulation was observed in cells treated with MMC (0.0002-0.2mg/ml) (Figure 5.4f). 
In contrast, there was a significant increase in stimulated release of PGE2 from cells 
treated with 2mg/ml of MMC. 
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Figure 5.4: Immediate effects of 2 hour mitomycin C (MMC) treatment on basal 
extracellular ATP [A], acetylcholine [C] and prostaglandin E2 [E] concentrations, and ATP 
[B], acetylcholine [D] and prostaglandin E2 [F] response to hypo-osmotic stimulation. Data 
are expressed as means ± SEM. *P<0.05 and **P<0.01 compared to vehicle control. 
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Effects of MMC on urothelial cell viability and mediator release 
24h post-treatment 
Twenty-four hours following MMC pre-treatment a concentration-dependent 
decrease in urothelial cell viability was observed, with significant changes detected 
in cells treated with MMC ≥ 0.0002mg/ml (Figure 5.5a).  
Since urothelial mediator release is affected immediately after MMC treatment, the 
ability of the urothelium to recover was assessed. Release of urothelial mediators was 
measured 24 hour after MMC pre-treatment with lower MMC concentrations, as 
these are more likely to reflect the concentration reached in urothelial cells in vivo, 
which has been estimated to be 3% of intravesical concentration (Wientjes et al., 
1993). Both basal and stimulated release of ATP from MMC pretreated urothelial 
cells remained unchanged compared to vehicle-treated controls 24 hour following 
treatment (Figure 5.6a and b). In contrast, 24 hour after MMC treatment, 
concentration-dependent increase in basal ACh release was observed with significant 
increases at both 0.0002 and 0.02mg/ml (Figure 5.6c) but stimulated ACh remained 
unchanged compared to controls (Figure 5.6d). In addition, basal release of PGE2 
was significantly increased in urothelial cells pre-treated with 0.02mg/ml MMC 
compared to control cells (Figure 5.6e) and PGE2 response to stretch was not 
observed in both controls and MMC pretreated cells 24 hour following treatment 
with basal release being significantly higher than stimulated release at 0.02mg/ml 
MMC (Figure 5.6f).  
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Figure 5.5: Effect of 2 hour mitomycin C (MMC) treatment on urothelial cell viability 
assessed by resazurin reduction 24 hour [A] and 1 week [B] after first treatment. Data are 
expressed as means ± SEM. **P<0.01 compared to vehicle treated control cultures. 
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Figure 5.6: Twenty-four hour post-treatment effects of mitomycin C (MMC) on basal 
extracellular ATP [A], acetylcholine [C], prostaglandin E2 [E] concentrations, and ATP [B], 
acetylcholine [D] and prostaglandin E2 [F] response to hypo-osmotic stimulation. Data are 
expressed as means ± SEM. **P<0.01 and ***P<0.001 compared to vehicle control. 
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Effects of first and repeat MMC treatments on urothelial cell 
viability and mediator release at 1 week 
One week following MMC pre-treatment urothelial cell viability was not affected in 
cells treated with MMC ≤ 0.02mg/ml, however complete cell death were observed in 
cells treated with 0.2 and 2mg/ml MMC (Figure 5.5b).  One week after MMC pre-
treatment with 0.002mg/ml MMC concentration, stimulated release of ATP was 
significantly decreased in pre-treated cells compared to control cells (Figure 5.7a and 
b). While basal release of ACh was significantly decreased, stimulated release of 
Ach was significantly increased in pre-treated cells (Figure 5.7c and d). Also, in 
MMC pre-treated cells, basal release of PGE2 was significantly increased compared 
to control cells (Figure 5.7e and f).  
To assess the long-term (1 week) and repeat treatment effects of MMC, urothelial 
mediator release from cells treated with 0.002mg/ml MMC was assessed.  This 
treatment concentration was selected to ensure adequate viable cell numbers for 
endpoint experiments.  Urothelial cell viability was reduced to 86.64 ± 5.7% 1 week 
after repeat MMC treatment with 0.002mg/ml. No significant change in ATP (Figure 
5.8a and b) and ACh release (Figure 5.8c and d) was observed one-week after repeat 
MMC treatment (0.002mg/ml), but stimulated release of PGE2 was significantly 
increased in cells pre-treated with 0.002mg/ml MMC compared to control cells 
(Figure 5.8e and f). Response of all three mediators to stretch was not observed in 
control cells. 
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Figure 5.7: One week post-first treatment effects of mitomycin C (MMC) on basal 
extracellular [A] ATP, [C] acetylcholine, [E] prostaglandin E2 concentrations, and [B] ATP, 
[D] acetylcholine and [F] prostaglandin E2 response to hypo-osmotic stimulation. Data are 
expressed as means ± SEM (N=6). *P<0.05, **P<0.01 and ***P<0.001 compared to vehicle 
control. 
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Figure 5.8: One week post-repeat treatment effects of mitomycin C (MMC) on basal 
extracellular [A] ATP, [C] acetylcholine, [E] prostaglandin E2 concentrations, and [B] ATP, 
[D] acetylcholine and [F] prostaglandin E2 response to hypo-osmotic stimulation. Data are 
expressed as means ± SEM (N=6). *P<0.05 and **P<0.01 compared to vehicle control. 
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Effects of MMC on inflammatory cytokine and NO release 
The presence of inflammatory cytokines (Interleukin (IL)-8, -1β, -6, -10, -12p70 and 
tumour necrosis factor) in urothelial cell incubation medium was tested 24 hour and 
1 week after 1st MMC treatment and also 1 week after 2nd MMC treatment as a 
measure of urothelial inflammation. IL-8 was secreted by untreated urothelial cells at 
24 hour, while urothelial cells treated with MMC (0.02mg/ml) showed a 326-fold 
increase in release (25.52 ± 2.53 pg/ml control vs. 8321 ± 654 pg/ml treated, P < 0.01) 
(Figure 5.9a). IL-1β, -6, -10, -12p70 and tumour necrosis factor were not detected in 
control or treated samples at any timepoint tested. Increased IL-8 secretion was also 
detected 1 week after 1st (13-fold increase from) and repeat (7-fold increase 
compared to) MMC treatment (Figure 5.9b and c).  
Metabolites of NO (nitrate and nitrite) were measured in incubation medium to 
determine the effects of MMC on urothelial NO release. NO was released by 
untreated urothelial cells at 24 hour, with a significant increase observed from cells 
treated with MMC (0.02mg/mL) (Figure 5.10a). A significant increase in urothelial 
release of NO was also evident 1 week after the 1st MMC treatment (Figure 5.10b), 
but 1 week after 2nd MMC treatment no significant differences could be detected 
compared to control (Figure 5.10c). 
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Figure 5.9: Interleuken-8 secreted from control and mitomycin C (MMC) treated urothelial 
cells [A] 24 hour, [B] 1 week after first treatment and [C] 1 week after repeat treatment. Data 
are expressed as means ± SEM (N=6). **P<0.01 and ***P<0.001 compared to vehicle 
control. 
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Figure 5.10: Effect of mitomycin C (MMC) on metabolites of nitric oxide (nitrate and nitrite) 
24 hour [A], 1 week [B] after first treatment and 1 week [C] after repeat treatment. Data are 
expressed as means ± SEM. *P<0.05 compared to vehicle control. 
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Discussion  
We previously reported that doxorubicin treatment results in alterations in the release 
of urothelial mediators (ATP, ACh and PGE2) immediately and 24 hour following 
treatment (Kang et al. 2013).  In addition, there are strong links between 
development of bladder symptoms and inflammation in other conditions (Nomiya et 
al., 2012; Yoshimura et al., 2002) and the cytotoxic agent doxorubicin has been 
shown to increase urothelial secretion of interleukin -8 and -1β (Kang et al., 2013). 
Thus, we investigated the effects of the commonly used intravesical 
chemotherapeutic agent MMC on urothelial function, markers of inflammation and 
the ability to recover following first and repeat treatments.  
 
ATP 
As discussed previously in Chapter 3, an increase in ATP release is closely 
associated with disorders of the bladder such as OAB and IC/PBS that share 
symptoms similar to those local adverse effects experienced by patients treated with 
intravesical MMC. Therefore, in this study, enhanced release of ATP from the 
urothelial cells was expected by MMC treatment. Surprisingly, MMC had an 
inhibitory effect on stimulated release of ATP at the clinical concentration (2mg/ml) 
immediately after treatment. Twenty-four hours following MMC treatment, 
stimulated release of ATP was recovered back to control level but after 1 week 
recovery period, MMC had again inhibitory effect on stimulated release of ATP at 
MMC concentration 1000-fold lower (0.002mg/ml) than the clinical concentration. 
However, repeat MMC treatment had no effect on stimulated ATP release following 
another 1 week recovery period, suggesting that ATP release is unlikely to play a 
major role in the adverse effects induced by MMC treatment in the long-term. 
Similarly, doxorubicin has inhibitory effects on urothelial ATP release (Kang et al., 
2013). The urological side effects experienced by patients following intravesical 
MMC treatment cannot be explained by inhibition in stimulated ATP release 
reported here. The discrepancy may be addressed by various factors. One is that the 
pain induced by MMC treatment may be due to increased sensitivity of afferent C 
fibers rather than the increase in ATP release that is observed in other bladder 
disorders mentioned previously. Decreased ATP release reported here may not 
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directly take part in causing urinary symptoms but may impact on the release of other 
urothelial mediators, potentially leading to abnormal communication between the 
urothelium and underlying layers such as myofibroblasts, nerves and detrusor muscle. 
Another possibility is that there may be enhanced release of ATP from other cells in 
the bladder wall resulting in symptoms of pain. Both interstitial cells and smooth 
muscle cells from the bladder have been shown to release ATP during stretch (Cheng 
et al., 2011). Furthermore, the decrease in urothelial ATP release may be due to 
MMC acting on the ecto-ATPase enzyme to enhance ATP breakdown, which in turn 
the hydrolysed products of ATP and itself can act on P2Y purinergic receptors 
present on the urothelium (Lazarowski and Boucher, 2001; Lazarowski and Harden, 
1999; von Kugelgen, 2006). As discussed in Chapter 4, activation of P2Y 
purinoceptors is associated with overactivity and increase firing of bladder afferents 
that can cause urinary urgency and pain (Chen et al., 2010; Fry et al., 2012; Timoteo 
et al., 2014). 
 
Acetylcholine 
Unlike, unaltered ACh release from MMC pretreated porcine urothelial/LP strips 
discussed in Chapter 4, MMC treatment affected release of ACh from human 
urothelial cells. The potential excitatory role of urothelial-derived ACh in bladder 
micturition reflex as well as its association with bladder pathologies such as OAB 
was reviewed in detail from the previous chapter (4). Thus, increased release of basal 
ACh from the urothelial cells immediately and 24 hour following MMC treatment as 
well as increased release of stimulated ACh release one week following MMC 
treatment may activate cholinergic transmission in the bladder, possibly leading to 
the bladder overactivity observed in patients treated with intravesical MMC. The 
implication of inhibited release of basal ACh one week following MMC treatment in 
causing overactivity of the bladder is unknown. However, it may be postulated that a 
decrease in ACh release from the urothelium could cause an imbalance in cholinergic 
systems in the bladder, possibly leading to urinary dysfunction. However, since 
repeat MMC treatment had no effect on ACh release after a recovery period of one 
week, it is unlikely that ACh release like ATP is involved in adverse effects of MMC 
treatment in the long-term. 
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Prostaglandin E2 
In this study, MMC had an inhibitory effect on basal release of PGE2 immediately 
following treatment with the clinical dose. This may be due to changes in ATP 
release that were observed immediately after treatment as these two mediators are 
reported to be co-related (Tanaka et al., 2011). In contrast, 24 hour following 
treatment with a 100-fold lower MMC concentration, an excitatory effect of MMC 
on basal release of PGE2 was observed. Also, one week following treatment with a 
1000-fold lower MMC concentration, MMC had an excitatory effect again on basal 
release of PGE2. Doxorubicin has also been shown to increase basal but also 
stimulated release of PGE2 from urothelial cells (Kang et al., 2013). In addition, 
stimulated release of PGE2 was enhanced one week following repeat treatment. Since 
there is growing evidence indicating potential stimulatory effects of PGE2 on bladder 
micturition reflex and its association with bladder pathology such as OAB as 
mentioned in Chapter 4, these findings suggest that unlike ATP and ACh, PGE2 
release is affected long-term and that sustained enhancement of PGE2 release by 
MMC may lead to a sensitisation of the micturition reflex, possibly causing increased 
urinary frequency as well as perception of pain which are side effects commonly 
experienced by patients treated with MMC. Therefore, while less ATP release was 
observed here following MMC treatment, sensitisation of nerves due to the enhanced 
PGE2 release reported would mean that less ATP is required to stimulate sensory 
activity. 
 
Inflammatory cytokine 
Release of inflammatory mediators is associated with intravesical Bacillus Calmette-
Guerin (BCG) treatment (de Boer et al., 1997) and has also been linked to 
chemotherapeutic agents such as doxorubicin (Abou El Hassan et al., 2003). 
Previous studies have also shown that MMC induces release of IL-8 in human 
fibroblasts (Chou et al., 2007).  We have also recently reported that the 
chemotherapeutic agent doxorubicin induces release of IL-8 and IL-1β from treated 
urothelial cells (Kang et al., 2013). Here we assessed the effects on MMC on release 
of a number of human inflammatory cytokines from urothelial cells but only IL-8 
was detected, with a 326-fold increase 24 hours after treatment.  IL-8 was still 
elevated 1-week after treatment and again following repeat MMC treatment, while 
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release of urothelial ATP and ACh had recovered after repeat treatment.  It was 
reported by Mansfield and Hughes (2014a) that exposure of human urothelial cells to 
inflammatory mediators (histamine and serotonin) resulted in decreased release of 
stretch-induced ATP, suggesting that decreased ATP release observed here is 
possibly due to the effects of elevated IL-8 (inflammatory cytokine) release by MMC 
treatment. Inflammation has been shown to increase bladder afferent excitability and 
is believed to contribute to bladder overactivity and pain (Hayashi et al., 2009; 
Wyndaele and De Wachter, 2003). Cytokines are thought to alter cell-cell 
communication by affecting gap-junctions in bladder smooth muscle and 
suburothelial myofibroblasts, in addition to altering voltage-gated K+ channel 
expression in bladder afferents (Hayashi et al., 2009; Heinrich et al., 2011; Wyndaele 
and De Wachter, 2003). IL-8 is a member of the chemokine family that plays an 
important role in attracting granulocytes, predominantly neutrophils to the site of 
inflammation (Petering et al., 1999). The biological action of IL-8 (also known as 
CXCL8) is activated when it binds to seven-membrane G-protein-coupled receptors 
named CXCR1 and CXCR2. IL-1β is a potent mediator in response to infection and 
injury, and plays a vital role in a number of chronic and acute inflammatory diseases 
(Dinarello, 1998; Li et al., 2008). Majority of IL-1β is synthesised by blood 
monocytes, but it is also produced by macrophages, dendritic cells and a variety of 
other cells in the body (Dinarello, 1996; Sasaki et al., 2002). A small amount of IL-
1β in vivo can cause fever, hypotension, release of adrenocorticotrophic hormone and 
production of cytokines which in turn lead to a number of inflammatory and immune 
responses (Li et al., 2008). 
A recent study has suggested that inflammation may be a key factor in the 
development of bladder overactivity in chronic bladder ischemia detecting increased 
levels of pro-inflammatory cytokines including IL-8, IL-6 and TNF-α (Nomiya et al., 
2012). Our data suggests that sustained release of inflammatory cytokines may be 
important in the development of the bladder overactivity and pain experienced by 
patients following intravesical treatment. 
 
Nitric oxide 
NO plays a major role in the bladder outlet region during micturition, inducing 
relaxation and preventing large increases in pressure during bladder contraction 
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(Bustamante et al., 2010). Along with acetylcholine, NO is released as a co-
transmitter from parasympathetic nerves and exerts an inhibitory effect on 
contraction (Dokita et al., 1991). Recently the urothelium has been shown to be an 
alternative source of NO in the bladder; endothelial NO synthase (eNOS) has been 
identified in umbrella cells of the rat urothelium and stretch or muscarinic receptor 
stimulation has been shown to release NO from these cells in culture (Birder et al., 
1998; Giglio et al., 2005).  The function of urothelial NO is uncertain, but indirect 
evidence suggests a role in modulating sensory nerve activity (Birder et al., 1998; 
Giglio et al., 2005) and NO donors have recently been shown to inhibit afferent 
nerve activity (Aizawa et al., 2011). NO donors have been shown to inhibit urothelial 
contraction and inhibit pacemaker activity (Moro et al., 2012). There is also some 
evidence to suggest that NO can exert excitatory effects, such as in isolated mouse 
bladder it has been shown that NO can increase phasic contractile activity (Gillespie 
and Drake, 2004) and in precontracted human detrusor strips both relaxation and 
contraction responses to NO donors have been observed (Moon, 2002).  Elevated 
levels of NO have been reported with inflammatory disease of the bladder including 
bacterial cystitis, IC and after BCG treatment for bladder cancer, and is thought to 
play a role in inflammation progression (Ehren et al., 1999; Logadottir et al., 2004; 
Lundberg et al., 1996).  iNOS expression was shown to be localised in the 
urothelium of bladder cancer patients following BCG treatment (Koskela et al., 
2008), while increased NOS expression and enhanced NO release from the bladder 
mucosa is also associated with cyclophosphamide-induced cystitis (Andersson et al., 
2008). A recent study reported that inhibition of NOS prevents muscarinic and 
purinergic dysfunction and development of cyclophosphamide-induced cystitis in the 
rat (Aronsson et al., 2014).  Elevated bladder wall NO production has been reported 
in patients with IC, with a concurrent increase in IL-6, -10 and -17A mRNA 
(Logadottir et al., 2014).  Here we show an increase in NO release from urothelial 
cells 24 hours following MMC treatment which persists 1 week following first 
treatment but returns to normal 1 week following repeat treatment. These findings 
suggest that elevated NO release may temporarily contribute to the pain and 
alterations in bladder function experienced in patients following intravesical MMC 
treatment but persist the adverse effects by playing a role in inflammation 
progression which can be supported by observation of sustained inflammatory 
cytokine release even after repeat treatment in the present study. 
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Conclusions 
Here we show that MMC treatment alters urothelial release of ATP, ACh and PGE2 
immediately, 24 hours and 1 week following treatment, but that release of these 
mediators except PGE2 returns to normal 1 week following repeat treatment. In 
addition, enhancement in urothelial NO release 24 hours and 1 week following 
treatment was demonstrated without sustained release observed one week following 
repeat treatment. The results of this study therefore suggest that alterations in 
urothelial ATP (decrease), ACh (increase) and NO (increase) may directly contribute 
to adverse effects of MMC in the short-term but enhanced NO and induction of IL-8 
which persist even after repeat treatment along with sustained increase in PGE2 
throughout the recovery period and following repeat treatment may contribute 
significantly in causing the pain and bladder dysfunction experienced by patients 
following intravesical MMC. 
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Chapter 6 - The effects of epirubicin on UROtsa 
urothelial cells 
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Introduction 
In Chapter 5, the effects of MMC treatment on release of urothelial mediators, 
markers of inflammation and cell viability were assessed using the human urothelial 
cancer cell line, RT4.  I previously used this cell line as a model of urothelial 
function to assess the effects of the cytotoxic drug doxorubicin during my Honours 
project (Kang et al., 2013). The results of these studies indicated that release of 
inflammatory cytokines was common to both drug treatments (doxorubicin and 
MMC) and may potentially play an important role in causing the side effects reported 
by patients.  Interestingly, we found that while these agents alter release of urothelial 
mediators initially, there was partial or full recovery with time.  
The RT4 cell line, while a useful model of urothelial mediator release is derived from 
malignant urothelial tissue, and so when a cell culture model derived from 
normal/non-cancer urothelial tissue (UROtsa cell line) became available we chose to 
use it for the study detailed in this chapter. In this study, UROtsa was used to assess 
the effects of epirubicin on normal urothelial function.  
 
UROtsa cell line 
The UROtsa cell line originated from a primary culture of normal human urothelium 
and was immortalised by SV-40 large T antigen.  Following immortalisation, 
UROtsa cells did not acquire characteristics of neoplastic transformation (Petzoldt et 
al., 1995). UROtsa cells proliferate in serum-containing growth medium as a 
monolayer of cells with little evidence of uroepithelial differentiation. Under serum-
free growth conditions, UROtsa cells exhibit raised, three-dimensional structures 
consisting of a stratified layer of cells that strongly resemble in situ urothelium 
(Rossi et al., 2001). An immunofluorescence study revealed expression of 
cytokeratin 7, which is normally expressed in a urothelial subtypes (e.g., umbrella, 
intermediate, and basal cells), confirming the urothelial origin of UROtsa cell line 
(Bakali et al., 2014). UROtsa have been used extensively to study mechanisms of 
carcinogenesis (Eblin et al., 2008; Johnen et al., 2013) and more recently as a model 
of urothelial function to assess release of urothelial mediators, regulation of release 
as well as studies to assess receptor expression (Bakali et al., 2014; Mansfield and 
Hughes, 2014e; Save et al., 2011; Save and Persson, 2010; Tyagi et al., 2006). 
 173 
It has been demonstrated that UROtsa cells express the machinery for ACh synthesis 
(ChAT and CarAT) and muscarinic receptors with the rank order of 
M3>M2>M5>M1=M4 (Arrighi et al., 2011). A study by Save & Persson (2010) 
demonstrated release of ATP and inflammatory cytokines (IL-8) from UROtsa cells 
and RT-PCR studies confirmed the presence of mRNA for P2Y1, P2Y2 and P2Y11 
purinoceptors in these cells. A further RT-PCR study by Save et al. (2011) reported 
transcriptions of adenosine receptor subtypes including A1, A2A, A2B but not A3 in 
UROtsa cells. Stretch-induced ATP release was demonstrated when UROtsa cells 
were treated with hypotonic Krebs solution and also an increase in ATP was 
observed with the P2Y agonists ADP and UTP (Mansfield and Hughes, 2014e). In 
addition, a recent study by Bakali et al. (2014) has shown expression of GPR55 
cannabinoid receptor and also purinoceptors including P2X1, P2X2, P2Y2 and P2Y4 
on UROtsa cells. When purinoceptors were activated with ATP, intracellular calcium 
increased significantly. Furthermore, radioligand binding study by Harmon, Porter & 
Porter (2005) has demonstrated β-adrenergic receptors (ARs) on UROtsa cells and 
when activated by the selective β-AR agonist isoprenaline enhanced protein levels 
for COX-2 and iNOS which are associated with inflammation. Hence, UROtsa may 
be a valuable in vitro model for studying the effect of chemotherapeutic agents on 
the function of ‘normal’ urothelium. 
 
Aims 
The aim of this study was to investigate the effects of epirubicin on basal and stretch-
induced release of urothelial mediators (ATP, ACh and PGE2) from UROtsa human 
urothelial cells and determine whether changes in urothelial function may provide an 
explanation for the urological adverse effects experienced by patients treated with 
intravesical epirubicin. The release of inflammatory cytokines and NO from 
urothelial cells after epirubicin treatment was also assessed to determine if 
inflammation may play a role in the adverse effects associated with treatment. In 
addition, recovery of urothelial function was assessed 1 week post-treatment. It was 
hypothesised, that while urothelial mediator release may change initially, there 
would be recovery over time but that a sustained increased in inflammatory cytokine 
release would be observed following epirubicin treatment, as seen in Chapter 5 with 
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MMC.  This sequence of events was hypothesised to be common to 
chemotherapeutic drugs regardless of the in vitro model used. 
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Materials and Methods 
Cell culture 
The UROtsa cell line was received as a gift from Dr. Scott Garret at University of 
North Dakota. UROtsa were routinely cultured in 75cm2 culture flasks (T75) using 
Dulbecco’s modified eagle medium (DMEM) - low glucose culture medium 
supplemented with additional 1mg/ml glucose, 1% v/v penicillin-streptomycin and 5% 
v/v Fetal Bovine Serum (FBS). Cells were maintained at 37°C in 5% CO2 and 
confluent cells (approx. 90%) were subcultured at a 1:4 ratio by detaching cells from 
the flask using a trypsin/EDTA solution.  
 
Seeding densities of cell treatments 
UROtsa cells were seeded in 24 or 96 well plates or T25 flasks at a density 
determined in initial optimisation experiments, see Table 6.1 below. Cells were 
incubated overnight at 37ºC to allow cells to adhere.    
Table 6.1: Optimum seeding density used for experiments with UROtsa  
Timing of Endpoint 
Measurement 
Seeding Density in 
96 well plates 
Seeding Density in 
24 well plates 
Seeding Density in 
T25 flasks 
Immediate 0.2 x 105 per well 1.2 x 105 per well 1.6 x 106 per well 
24 hours after 1st 
treatment 0.2 x 10
5 per well 1.2 x 105 per well 1.6 x 106 per well 
1 week after 1st 
treatment 0.17 x 10
5 per well 1.0 x 105 per well 1.3 x 106 per well 
1 week after 2nd 
treatment 0.13 x 10
5 per well  0.8 x 105 per well 1.1 x 106 per well 
 
Following attachment of UROtsa cells, culture medium was changed to serum-free 
DMEM-low glucose (supplemented with 1mg/ml glucose and 1% v/v 
penicillin/streptomycin) and incubated for further 24 hours to allow cells to 
differentiate. UROtsa were treated with epirubicin following 24 hour incubation in 
serum free medium. 
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Epirubicin treatment of urothelial cells 
UROtsa cells were treated with epirubicin (0.0001, 0.001, 0.01, 0.1 and 1mg/ml) as 
described previously in MMC cell study. Epirubicin was diluted in serum-free 
DMEM culture medium and was allowed to equilibrate for 30 minutes at 37°C 
immediately before use. Serum-free DMEM culture medium was added to control 
cells. The plate was then incubated for one hour at 37°C in 5% CO2.  
To assess 24 hour and 1 week post-treatment effects of epirubicin on urothelial 
function, the same protocols were followed as described in the previous chapter, 
except for the following: 
(1) Concentration and duration of epirubicin treatment 
- 0.0001 or 0.01 mg/ml for 1 hour (24 hour post-treatment) 
- 0.001 mg/ml for 1 hour (1 week post-treatment) 
- epirubicin diluted in serum-free DMEM 
(2) After aspiration of drug, serum-free DMEM culture medium was 
added into each well.  
(3) During 1 week recovery period, culture medium was changed every 
three days. 
(4) Repeat treatments were also attempted in UROtsa, however cells did 
not survive repeat treatment and therefore endpoint analysis could not 
be conducted. 
 
Assessment of cell viability - resazurin reduction assay 
Cells were seeded in 96-well microtiter plates as previously described and treated 
with epirubicin (0-1 mg/ml) for 1 hour at 37°C. Then, resazurin reduction cell 
viability assay was performed immediately, 24 hour or 1 week after epirubicin 
treatment as described in Chapter 5, except the incubation period with resazurin was 
1 hour at 37°C. 
 
 177 
Mediator release from urothelial cells 
Basal release 
Immediately, 24-hour, or 1-week following 1 hour incubation with epirubicin, all 
solutions on the plate were aspirated and cells were washed twice with phosphate 
buffered saline (PBS) solution.  
UROtsa cells were first incubated with serum-free DMEM culture medium for 15 
minute incubation. After that, culture medium were aspirated and the cells were 
incubated for 15 minutes with isotonic solution (composition, mM: NaCl 130, KCl 5, 
CaCl2 1.5, MgCl2 1, NaHEPES 25, BSA 0.015 and glucose 5) at 37°C in 5% CO2. 
Then, the solutions on the plate were aspirated and fresh isotonic solution was added 
into each well. After 10 minutes, the solutions in each well were collected into 
microfuge tubes and these are representative of basal release of urothelial mediators 
from epirubicin treated and control cells. 
Hypo-osmotically stimulated release  
Hypotonic solution (isotonic solution without NaCl) was added into each well. After 
10 minutes incubation at 37°C, the solutions in each well were collected into 
microfuge tubes and these are representative of stimulated release of urothelial 
mediators from epirubicin treated and control cells. 
 
Inflammatory cytokine and NO release from cell lines 
To assess the late effects (24 hour post 1st treatment) of epirubicin on release of 
inflammatory cytokines and urothelial NO, cells were seeded in 25cm2 flasks using 
conditions described above. 
Then, procedures were followed by the same protocol used in the previous chapter, 
except for the following: 
(1) After treatment, serum-free DMEM culture medium was added 
(2) In additional experiments, where samples were also collected 1 week 
following treatment, media changes were performed every 3 days 
during the incubation period.  
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(The release of various mediators was measured using commercially available kits as 
described in “Assays for urothelial mediators, NO and inflammatory cytokines” 
section in Chapter 2) 
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Results 
Effects of epirubicin on urothelial cell viability 
Urothelial cell viability was significantly decreased in UROtsa cells treated with 
epirubicin ≥ 0.01mg/ml at all time points tested post-treatment. Complete cell death 
was observed in cells treated with 1mg/ml epirubicin compared to control cells at all 
time points (Figure 6.1a, b and c). 
 
Figure 6.1: Effect of 1 hour epirubicin treatment on urothelial cell viability assessed by 
resazurin reduction immediately [A], 24 hour [B] and 1 week [C] after treatment. Data are 
expressed as means ± SEM (N=6). **P<0.01 and ***P<0.001 compared to vehicle control 
cultures. 
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Effects of epirubicin on mediator release immediately post-
treatment 
Since, there was complete cell death observed at the clinical dose (1mg/ml) 
immediately following treatment, urothelial mediator release could not be measured 
in cells treated with this concentration.  
UROtsa cells released ATP under basal and stimulated conditions, with a significant 
increase above basal levels of ATP in response to hypotonic stimulation observed in 
both vehicle treated control cells and cells treated with epirubicin (Figure 6.2a and b). 
Immediately following treatment, a significant increase (2-fold) in basal release of 
ATP from cells treated with 0.1mg/ml epirubicin was observed (Figure 6.2a). A 
significant increase (2-fold) in stimulated release of ATP was also observed from 
cells treated with the same concentration of epirubicin (Figure 6.2b). 
Basal and stimulated release of ACh and PGE2 were observed in both control and 
epirubicin treated UROtsa cells immediately following treatment (Figure 6.2c, d, e 
and f).   There was a significant increase in release of both mediators in response to 
stretch when compared to basal levels.  However, there was no significant change in 
release of ACh or PGE2 from UROtsa cells immediately following treatment with 
epirubicin (Figure 6.2c, d, e and f).  
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Figure 6.2: Immediate effects of 1 hour epirubicin treatment on basal extracellular ATP [A], 
acetylcholine [C] and prostaglandin E2 [E] concentrations, and ATP [B], acetylcholine [D] 
and prostaglandin E2 [F] response to hypo-osmotic stimulation. Data are expressed as means 
± SEM (N=6). **P<0.01 compared to vehicle control. 
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Effects of epirubicin on mediator release 24 hour post-treatment 
Since urothelial ATP release was affected immediately after epirubicin treatment, the 
ability of the urothelium to recover was assessed. Release of urothelial mediators was 
measured 24 hour after epirubicin treatment with low epirubicin concentrations (≤ 
0.01 mg/ml).  As detailed in Chapter 5 previous studies have shown that only a small 
fraction of intravesical chemotherapeutic agents (doxorubicin and MMC) penetrates 
the urothelium, therefore lower concentrations of epirubicin are also likely to be 
more relevant.  
Both basal and stimulated release of ATP from urothelial cells treated with 
0.01mg/ml epirubicin increased significantly compared to vehicle-treated controls 24 
hour following treatment (Figure 6.3a and b). While, basal release of ACh was 
significantly increased in cells treated with 0.01mg/ml epirubicin, stimulated release 
of ACh was significantly reduced at the same concentration in comparison to control, 
although stimulated ACh release was still greater than basal levels (Figure 6.3c and 
d). In contrast, both basal and stimulated release of PGE2 remained unchanged 
compared to control cells 24 hour following epirubicin treatment (Figure 6.3e and f). 
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Figure 6.3: Twenty-four hour post-treatment effects of epirubicin on basal extracellular ATP 
[A], acetylcholine [C], prostaglandin E2 [E] concentrations, and ATP [B], acetylcholine [D] 
and prostaglandin E2 [F] response to hypo-osmotic stimulation. Data are expressed as means 
± SEM (N=6). *P<0.05 and **P<0.01 compared to vehicle control. 
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Effects of epirubicin on mediator release 1 week post-treatment 
One week after treatment with 0.001mg/ml epirubicin, stimulated release of ATP 
was significantly decreased (Figure 6.4a and b), while stimulated release of ACh was 
significantly increased (Figure 6.4c and d) in treated cells compared to control cells. 
Both basal and stimulated release of PGE2 remained unchanged compared to control 
cells 1 week following epirubicin treatment (Figure 6.4e and f). However, it must be 
noted that the PGE2 increase over basal in response to stretch was no longer present 
at this timepoint, and likely reflects changes due to the prolonged period of serum 
starvation. 
 
 
Figure 6.4: One week post-treatment effects of epirubicin on basal extracellular ATP [A], 
acetylcholine [C], prostaglandin E2 [E] concentrations, and ATP [B], acetylcholine [D] and 
prostaglandin E2 [F] response to hypo-osmotic stimulation. Data are expressed as means ± 
SEM. *P<0.05 compared to vehicle control. 
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The effects of epirubicin on cell viability one week following repeat epirubicin 
treatment were assessed in this study. One week following repeat treatment, almost 
complete cell death (8.2±1.2%, N=6) was observed in cells treated with 0.001mg/ml 
epirubicin. Therefore, it was not possible to measure the effects of epirubicin on 
urothelial mediator release following repeat treatment. 
 
Effects of epirubicin on inflammatory cytokine and NO release 
The presence of inflammatory cytokines IL-8, IL-1β, IL-6, IL-10, IL-12p70 and TNF 
in urothelial cell incubation medium was tested 24 hour and 1 week after epirubicin 
treatment as a measure of urothelial inflammation. IL-1β, IL-6, IL-10, IL-12p70 and 
TNF were not detected in control or treated samples at any timepoint tested. IL-6 was 
secreted by untreated urothelial cells at 24 hour, while urothelial cells treated with 
epirubicin (0.01mg/ml) showed a 70-fold increase in release (53.24 ± 5.02 pg/ml 
control vs. 3511 ± 494 pg/ml treated, P<0.01) (Figure 6.5a). IL-8 was also secreted 
by untreated urothelial cells at 24 hour, while urothelial cells treated with epirubicin 
(0.01mg/ml) showed a 5-fold increase in release of IL-8 (292 ± 23 pg/ml control vs. 
1519 ± 89 pg/ml treated, P<0.01) (Figure 6.5c). IL-6 (8-fold increase, P<0.001) and -
8 (3-fold increase, P<0.001) secretions were also significantly increased compared to 
controls 1 week after epirubicin treatment (Figure 6.5b and d). 
Metabolites of NO (nitrate and nitrite) were measured in incubation medium to 
determine the effects of epirubicin on urothelial NO release. NO was released by 
untreated UROtsa cells at 24 hour, with a significant increase observed from UROtsa 
cells treated with epirubicin (0.01mg/ml) (Figure 6.6a), but 1 week after epirubicin 
treatment no significant differences could be detected compared to control (Figure 
6.6b). 
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Figure 6.5: Interleuken-6 secreted from control and epirubicin treated urothelial cells 24 
hour [A] and 1 week [B] after treatment. Interleuken-8 secreted from control and epirubicin 
treated urothelial cells 24 hour [C] and 1 week [D] after treatment. Data are expressed as 
means ± SEM (N=6). **P<0.01 and ***P<0.001 compared to vehicle control. 
 
 
Figure 6.6: Effect of epirubicin on metabolites of nitric oxide (nitrate and nitrite) 24 hour [A] 
and 1 week [B] post-treatment. Data are expressed as means ± SEM (N=6). **P<0.01 
compared to vehicle control. 
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Discussion 
ATP 
Here we report enhanced release of both basal and stimulated ATP immediately after 
epirubicin treatment at 0.1mg/ml, which was still evident 24 hours following 
treatment. In Chapter 3, the close association of enhanced ATP release with bladder 
disorders such as OAB and IC/PBS, which are also characterised by symptoms 
common in patients treated with intravesical epirubicin, has been discussed in detail. 
Therefore, increased urothelial ATP release observed in this study could directly 
contribute to the pain and bladder overactivity reported in patients treated with 
intravesical epirubicin. In contrast, doxorubicin has been shown to have inhibitory 
effects on urothelial ATP release (Kang et al., 2013) as did MMC (see Chapter 5).  
Interestingly, a decrease in stimulated ATP release was observed one week following 
epirubicin treatment.  This may indicate time-dependent rather drug specific effects. 
How a decrease in urothelial ATP release could contribute to some of the reported 
side effects has been discussed in detail in Chapter 5. 
 
Acetylcholine 
A recent study reported that UROtsa cells express the cellular machinery required for 
synthesis of ACh, as well as expressing all 5 muscarinic receptors (Arrighi et al. 
2011). Here we found that the cells release ACh under basal conditions with a 
significant increase in release in response to stretch.  The potential excitatory effect 
of urothelial-derived ACh on the micturition reflex has been discussed previously in 
Chapter 4. Thus, enhanced release of basal urothelial ACh 24 hours following 
epirubicin treatment may activate muscarinic receptors in the bladder which can 
potentially cause overactivity of the bladder reported in patients treated with 
intravesical epirubicin. The observed increase in ACh levels may be due to the 
effects of epirubicin influencing the release of other mediators which play a role in 
controlling ACh release (as mentioned previously in this thesis, ACh and ATP are 
co-released from parasympathetic nerves and NO can facilitate vesicular release of 
ACh and ATP) or due to changes in ACh breakdown or reuptake mechanisms. An 
increase in stimulated release of urothelial ACh one week following epirubicin was 
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observed and this may also contribute to bladder overactivity. However, as it was 
mentioned for ATP, this may also be time-dependent rather drug specific effects. 
Since there is a growing consensus that ACh released from the urothelium has a role 
in excitatory mechanism of bladder function, it would be expected that a decrease in 
ACh release may attenuate overactivity of the bladder, thus not explaining the 
adverse effects of intravesical epirubicin. However, the decrease in extracellular ACh 
concentration caused by hypotonic stimulation observed 24 hours following 
epirubicin treatment in this study may cause an imbalance in cholinergic systems in 
the bladder, potentially contributing to bladder dysfunction. Its implication in OAB 
conditions is unknown. This may be due to increased ACh breakdown rather than a 
decrease in release, which is supported by reports that epirubicin has been used to 
differentiate neuroblastoma cells and was shown to increase acetylcholine esterase 
(AChE) activity (Rocchi et al., 1987).  However, a recent study reported that 
systemic chemotherapy for gastric adenocarcinoma which included epirubicin 
resulted in decreased AChE activity in gastric tissue possibly contributing to 
alteration in neuro-muscular gastric function in cancer patients receiving this 
treatment (Sung et al., 2012). The decrease in AChE activity report by Sung et al. 
may also be due to the other chemotherapeutic drugs used as part of the treatment 
regimen rather than a specific effect of epirubicin.  
 
Prostaglandin E2 
Epirubicin had no effect on either basal or stimulated release of PGE2 from UROtsa 
cells immediately, 24 hours and 1 week post-treatment. Therefore, unlike for 
doxorubicin (Kang et al., 2013) and MMC (see Chapter 5), PGE2 does not appear to 
play a role in causing the adverse effects reported in patients treated with intravesical 
epirubicin. In both pretreated and untreated (control) cells, an increase in ATP and 
ACh release over basal levels in response to stretch was observed one week 
following epirubicin treatment. However, increased PGE2 release in response to 
hypotonic stimulation was no long present in control or pretreated cells at this 
timepoint. This may be due to the effects of long-term serum deprivation on cell 
function. It is well established that serum starvation in cells for several days can 
induce G0/G1 cell cycle arrest. A study by Khammanit et al. (2008) using canine 
dermal fibroblast cells has demonstrated that short periods of serum starvation (24 to 
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72 hours) increased the proportion of cells at the G0/G1 phase (88.4 to 90.9%) 
compared to controls (73.6%). Also, a recent study using sheep granulosa cells 
reported significantly increased G0/G1 phase cells after serum starvation for 24, 48 
and 72 hours when compared to normal growing cells (P<0.05). A significant 
apoptosis of granulosa cells occurred when serum starved for 72 hours (P<0.05) 
(Sadeghian-Nodoushan et al., 2014). In addition, a study by Hasan et al. (1999) using 
Chinese hamster V79 cells has demonstrated that serum starvation led to growth 
arrest, rounding up of cells and the appearance of new protein kinase C (PKC)-α and 
p53 bands on Western blots. Prolonged incubation (≥48 hours) in serum-starved 
medium caused cell detachment and death. It is known that serum-starved conditions 
result in expression of structural features of differentiated urothelium (Rossi et al., 
2001). However, the effects of longer period serum starvation such as one week on 
cell function are not well known. However, a study by Zhang et al. (2006) which 
serum starved (0.5% serum) human diploid fibroblasts for about 70 days, has found 
that the cells were transformed (became round and had more than one nucleolus) and 
also led to cell chromosomal instability (such as abnormal karyotype including 
aneuploidy and structural aberrations and high telomerase activities). The serum-
starvation for one week in this study has not resulted in a decrease in cell viability in 
control cells, thus UROtsa cells may not undergo apoptosis during this period, but 
instead may potentially lead to changes in cell function such as affecting stimulated 
PGE2 release. Therefore, determining the effects of long-term serum starvation on 
urothelial function would be beneficial in interpreting the recovery results (1 week 
post-treatment) from studies using UROtsa cells that differentiate in serum-free 
growth conditions.  
 
Nitric oxide 
An increase in NO release from UROtsa cells was observed 24 hours following 
epirubicin treatment.  This is consistent with the effects of MMC on RT4 urothelial 
cells however the levels returned to normal 1 week following epirubicin treatment 
unlike in MMC treated cells where the changes in NO release were still evident 1 
week later.  Changes in NO release did not remain following repeat MMC treatment. 
These finding suggests that an initial increase in NO release is common to MMC and 
epirubicin treatment, but recovery to normal levels is time dependent.  Longer time 
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to recovery may also reflect why side-effects are more commonly reported following 
MMC treatment compared to other intravesical drugs (Shelley et al., 2012). The 
potential for enhanced NO release to contribute to pain and overactivity has been 
discussed in Chapter 5. Several studies have assessed the impact of anthracyclines 
(including doxorubicin and epirubicin) on NO signalling pathways, in particular in 
relation to the cardiotoxicity associated with these agents.  There is evidence that 
exposure to these drugs can increase myocardial iNOS expression resulting in 
enhanced NO production (Pacher et al., 2003; Weinstein et al., 2000). 
 
Inflammatory cytokine 
In the present study, when the effects of epirubicin on release of inflammatory 
cytokines from UROtsa cells were assessed, increases in IL-8 and IL-6 were 
observed 24 hours following treatment and both inflammatory cytokines were still 
elevated 1 week after treatment. These findings are similar to the observation made 
in Chapter 5 where an increase in IL-8 from RT4 urothelial cells 24 hours and 1 
week after initial MMC treatment and also 1 week after repeat MMC treatment were 
demonstrated. A recent study by our group also reported that doxorubicin treatment 
induces release of IL-8 and IL-1β from RT4 cells 24 hours following treatment 
(Kang et al., 2013). Thus, it can be postulated that the induction of inflammatory 
cytokines and their persistent release are common to chemotherapeutic agents 
doxorubicin, MMC and epirubicin and may play a significant role in causing the 
bladder overactivity and pain experienced by patients following intravesical 
chemotherapy (see Chapter 5 for detailed discussion of how enhanced release of 
inflammatory cytokine can lead to overactivity and pain).  
In Chapter 5, the function of IL-8 and IL-1β in immune system has been discussed. 
There is evidence suggesting that IL-6 may play an important role in the generation 
and propagation of chronic inflammation. IL-6 trans-signalling via soluble IL-6 
receptors increases the expression of endothelial leukocyte adhesion molecules 
(VCAM-1, ICAM-1), promoting leukocyte accumulation (Barnes et al., 2011; Hurst 
et al., 2001; Jones et al., 2005; Rose-John, 2012). Also, IL-6 may have a role in 
promoting neutrophil apoptosis and thus the resolution of acute (nonspecific) 
inflammation (Afford et al., 1992; McLoughlin et al., 2003). However, an 
antiapoptotic effect of IL-6 on neutrophils has been also reported (Colotta et al., 
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1992). In addition, IL-6 reportedly rescues T cells from apoptosis, which promotes a 
chronic inflammatory cell infiltrate (Curnow et al., 2004; Narimatsu et al., 2001; 
Takeda et al., 1998; Teague et al., 1997). IL-6 trans-signalling also promotes the 
release of IL-6 from fibroblasts and endothelial cells in a positive autocrine feedback 
system (Barnes et al., 2011). It should be noted that the increase in IL-8 release 
following MMC treatment was much greater (326-fold) compared to that for the 
other agents tested (5-fold for epirubicin and 5.5-fold for doxorubicin) which again 
may reflect the greater incidence of urological adverse effects following MMC 
treatment. 
In addition, decreases in stimulated release of ATP reported here may be due to the 
effects of inflammatory cytokine release by epirubicin treatment, since a study by 
Mansfield & Hughes (2014a) demonstrated that exposing human urothelial cells to 
inflammatory mediators (histamine and serotonin) resulted in reduced stretch-
induced release of ATP.  However, the increased ATP release observed in this study 
could also be due to inflammation since there is a study that demonstrated increased 
(P<0.01) extracellular ATP levels when UROtsa cells were infected with 
uropathogenic Escherichia coli IA2 strain (Save and Persson, 2010). 
Furthermore, when the effects of epirubicin treatment on viability of UROtsa cells 
were assessed, a concentration-dependent decrease in urothelial cell viability was 
observed with significant changes detected in cells treated with epirubicin ≥ 
0.01mg/ml immediately, 24 hours and 1 week following treatment. However, 1 week 
following repeat treatment almost complete cell death (8.2±1.2%) was demonstrated 
in cells treated with a 1000-fold lower than clinical concentration of epirubicin. It 
can be postulated that significant cytotoxicity of epirubicin on the urothelium by 
repeated epirubicin treatment may be due to sustained release of inflammatory 
cytokines observed in this study which can induce inflammation of the bladder, 
causing the urothelium to be more susceptible to the cytotoxic effects of epirubicin or 
may reflect the prolonged period in serum-free culture. 
 
Conclusions 
The present study has shown that epirubicin treatment alters urothelial release of 
ATP and ACh immediately, 24 hours and 1 week following treatment. In addition, 
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enhancement in urothelial NO release 24 hours, but not 1 week, after treatment was 
observed.  
In conclusion, the results of our study suggest that while it is evident that alterations 
in urothelial mediator release (ATP, ACh, and NO) can contribute both temporarily 
and long-term to local adverse effects experienced by patients treated with epirubicin, 
it appears that epirubicin exerts adverse effects primarily through induction of 
urothelial inflammatory cytokine release and their sustained release (one week 
following treatment), which has been reported to be strongly associated with 
development of bladder dysfunction such as pain and overactivity, possibly causing 
the urothelium to be more vulnerable to cytotoxic effects of epirubicin in long-term 
(evident by significant cell death one week following repeat treatment).  
Interestingly, the release of inflammatory cytokines is common to all of the 
chemotherapeutic agents tested. Future pharmacological and physiological studies 
are necessary to confirm if our conclusions regarding the role of inflammation are 
valid and whether interventions to reduce inflammation could potentially improve 
the tolerability of these agents without affecting cytotoxic efficacy on cancer cells. 
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Chapter 7 - General discussion 
 194 
The aim of this thesis was to explain the urinary adverse effects noted by patients 
following intravesical treatment with doxorubicin, MMC and epirubicin. Hence, a 
number of studies, utilising a variety of techniques and in vitro models, were 
conducted. Subsequently, throughout the thesis, various changes in the local bladder 
mechanisms, that are known to be involved in maintaining normal bladder function, 
were identified after treatment with these agents. In addition, age-related changes in 
bladder function were evident when the findings of young and aged porcine tissues 
were compared. They were discussed in detail in Chapter 3, hence will not be further 
mentioned in this final discussion.  
Studies using tissues dissected from bladders of aged pigs demonstrated a number of 
alterations in bladder function following cytotoxic drug treatments and some 
similarities and differences were observed among the three cytotoxic agents (Table 
7.1). While doxorubicin treatment had no effect on integrity of the urothelium, both 
MMC and epirubicin treatment resulted in urothelial thinning. Contractile responses 
of urothelial/LP strips to muscarinic stimulation were not affected by epirubicin 
treatment, however following doxorubicin and MMC treatment the responses were 
enhanced and inhibited, respectively. The effect of UDIF on detrusor contractility 
was unaltered following doxorubicin treatment, where the presence of an intact 
urothelium/LP depressed maximum contractions of the detrusor muscle to carbachol. 
However, this UDIF effect was abolished by both MMC and epirubicin treatment. 
Also, contractile responses of the detrusor muscle strips to muscarinic stimulation 
were enhanced following doxorubicin treatment, while the responses were inhibited 
by both MMC and epirubicin treatment. In addition, relaxation responses of the 
detrusor muscle to isoprenaline were reduced by MMC treatment, however both 
doxorubicin and epirubicin treatment demonstrated no effect on detrusor relaxation. 
Furthermore, neurogenic detrusor contractility was inhibited following doxorubicin 
and MMC treatment, however epirubicin treatment had no effect on neurogenic 
responses of the detrusor muscle. It was demonstrated in tissue studies, that MMC 
showed greater toxicity on bladder functions compared to doxorubicin and epirubicin, 
this is consistent with the high incidence of reported local side effects in patients 
following intravesical MMC. However, it is difficult to conclude whether epirubicin 
demonstrated lesser bladder toxicity than doxorubicin. These changes in bladder 
function appear to drug specific and how they might contribute local side effects in 
patients has been discussed in detail in chapters 3 and 4. 
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Table 7.1: The effects of doxorubicin, MMC and epirubicin on tissue responses of aged 
porcine bladders. 
 DXR MMC EPR 
Urothelial thickness ⇔ ⇓ ⇓ 
Urothelial contractility 
(muscarinic) ⇑ ⇓ ⇔ 
UDIF effect ⇔ Abolished Abolished 
Detrusor contractility 
(muscarinic) ⇑ ⇓ ⇓ 
Detrusor relaxation 
(adrenergic) ⇔ ⇓ ⇔ 
Detrusor neurogenic response 
(EFS) ⇓ ⇓ ⇔ 
 
Doxorubicin (DXR); Epirubicin (EPR) 
Increase ⇑; Decrease ⇓; Unchanged ⇔ 
 
The release of urothelial mediators following cytotoxic drug treatments was 
measured in both tissues and cell cultures, with recovery also assessed in cell culture 
experiments. Immediately following doxorubicin treatment in urothelial/LP strips 
from aged bladders, increase in stretch-induced ATP release was demonstrated, 
while ACh and PGE2 release was not affected. In contrast, immediately following 
doxorubicin treatment in urothelial cells, abolition of stretch-induced ATP release, 
increased basal ACh release, decreased stretch-induced ACh, and increased stretch-
induced PGE2 release were observed. Twenty four hours following doxorubicin 
treatment in urothelial cultures, partial recovery of ATP release was shown, but 
without observing recovery, basal ACh and PGE2 release remained enhanced and 
stretch-induced ACh remained depressed (Table 7.2).  
Epirubicin caused decrease in stretch-induced ATP release and increase in basal ACh 
release, but had no effect on PGE2 release immediately following treatment in 
urothelial/LP strips from aged bladders. Similarly, PGE2 release was also unaffected 
in urothelial cells immediately after epirubicin treatment. However, both basal and 
stretch-induced ATP release were increased and ACh release was unaltered 
immediately following epirubicin treatment in cells. One week following treatment, 
recovery of basal ATP release and decrease in stretch-induced ATP release were 
demonstrated. Recovery of basal ACh release, and increase in stretch-induced ACh 
release were observed 1 week following epirubicin treatment in cells, while release 
of PGE2 was unaffected (Table 7.2).  
 196 
Immediately following MMC treatment, decrease in stretch-induced ATP release 
was demonstrated in both tissues and cells, however the release of ACh and PGE2 
differed when compared between two in vitro models. Increase in basal and stretch-
induced ACh release was observed in tissues and cells. In addition, increase and 
decrease in the release of basal PGE2 was demonstrated in tissues and cells, 
respectively. Recovery of ATP and ACh release, partial recovery of basal PGE2 
release, and increase in stretch-induced PGE2 release were observed one week 
following repeat MMC treatment (Table 7.2). The differences between tissue and cell 
responses in mediator release may be due to the different cell types present. A study 
by Cheng et al. (2011) using porcine bladders demonstrated that cultures of urothelial 
cells, myofibroblasts and also detrusor muscle cells all release ATP in both basal and 
stretched conditions and may account for some of the differences observed here. 
Given that much of the changes in urothelial mediator release recover at least in part 
over time, suggests that in the long-term mediator release may not play a major 
contributing role in the ongoing side-effects experienced by patients.  
 
Table 7.2: The effects of doxorubicin, MMC and epirubicin on urothelial mediator and 
cytokine release from urothelial/LP tissues and urothelial cell cultures. 
 
 Urothelium/LP Urothelial Cultures 
 ATP ACh PGE2 ATP ACh PGE2 Cytokines 
DXR ⇑ ⇔ ⇔ PR ⇑ & ⇓ ⇑ ⇑ 
MMC ⇓ ⇑ ⇑ R R PR & ⇑ ⇑ 
EPR ⇓ ⇑ ⇔ R & ⇓ R & ⇑ ⇔ ⇑ 
 
Doxorubicin (DXR); Epirubicin (EPR) 
Basal release (blue colour); Stretch-induced release (red colour) 
Recovery (R); Partial recovery (PR); Increase ⇑; Decrease ⇓; Unchanged ⇔ 
 
One of the major findings of this study was the evidence of inflammation in the 
urothelium following treatment with all three agents, observed by induction of 
cytokines and their sustained release without recovery while other mediators that 
were also affected by these drugs observed partial or full recoveries (Table 7.2). 
Therefore, this final discussion will focus on how inflammation is associated with 
pathophysiology of various bladder dysfunctions and may explain the local adverse 
effects associated with intravesical chemotherapy.  
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Inflammation and urothelial abnormalities 
The fundamental function of the urothelium is to form a high-resistance barrier to ion, 
solute and water flux, and pathogens (Birder, 2010). Three components that seem to 
be responsible for this property are tight junctions, plaques and the 
glycosaminoglycan (GAG) layer. The urothelial plaques or asymmetric unit 
membrane (AUM) are constructed from uroplakins (UPs), which consist of four 
major forms including UPIa and Ib, UPII and UPIII (Garcia-Espana et al., 2006). 
Tight junctions, which are localised between the umbrella cells, are composed of 
multiple proteins that include occludins and claudins. These proteins, together with 
uroplakins, assemble into hexagonal plaques, contributing to the urothelial barrier 
function (Hicks, 1975; Liang et al., 2001). The GAG layer is composed of negatively 
charged sulfated polysaccharides which are bound to core proteins that also have a 
negative charge and this is believed to be due to N-terminal sialic moieties (Parsons, 
2011). Together they form a proteoglycan layer that binds water into a gel form via a 
process known as electrostatic entrapment. This results in a buffer between irritants 
in urine and the urothelial cell membrane, acting as the first line of defense. The 
GAGs associated with the bladders includes heparan sulfate, chondroitin sulfate, 
dermatan sulfate and hyaluronic acid (Buckley et al., 1996; Hurst and Zebrowski, 
1994; Janssen et al., 2013). Therefore, any disruption to the components of this 
permeability barrier may lead to increased infiltration into the bladder wall and 
exposure of interstitial fluid to the potentially harmful contents of urine (Hurst et al., 
1996; Parsons, 2011; Parsons et al., 2005; Parsons and Hurst, 1990). UPIII gene 
knockout mice in a study by Hu et al. (2000) demonstrated overexpression of UPIa, 
UPIb and UPII, defective glycosylation, and abnormal targeting of UPIb, resulting in 
small plaques and urothelial leakage.  Also, a study by Janssen et al. (2013) reported 
an increased permeability of the urothelium after removing the GAG layer. 
There is a growing body of evidence to support the conclusion that abnormalities in 
the urothelium may be involved in pathophysiology of functional bladder disorders 
such as IC/PBS and OAB, which share LUT symptoms that are also commonly 
reported in patients treated intravesically with three agents (Keay et al., 2014). 
Abnormalities such as an increased permeability of the urothelium are common in 
these bladder conditions (Hauser et al., 2008; Hurst et al., 1996; Parsons, 2011; 
Parsons et al., 1998; Parsons et al., 1991). Especially in patients with IC/PBS, this 
may be due to a perturbation to the components of urothelial barrier function 
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including denudation and tears in the bladder urothelium (Johansson and Fall, 1990; 
Ratliff et al., 1994; Tomaszewski et al., 2001), and/or thinning of the bladder 
urothelium to 1-2 cell layers thick (Tomaszewski et al., 2001). In microscopic studies, 
bladder urothelial abnormalities were confirmed in IC/PBS patients with disruption 
of the AUM and bladder urothelial junctions of the umbrella cells (Elbadawi and 
Light, 1996). Also, the urothelial mucin layer has been shown to be abnormal in 
IC/PBS (Hanno, 2002; Tomaszewski et al., 2001). In addition, a study by Parsons 
(2002) has demonstrated reduced formation of GAGs and one of their metabolite, 
uronic acid in urine of IC patients in comparison to control group. As it was 
mentioned previously in Chapter 5, inflammation is also closely associated with 
these conditions. However, it is unclear whether the compromised barrier function, 
noted by various abnormalities in the urothelium, causes the related inflammation or 
is a subsequent result of inflammation. 
The results in this thesis also demonstrated abnormalities in urothelial thickness 
following MMC or EPI treatment as well as indication of inflammatory responses in 
urothelium cultures after treatment with the three agents. A correlation between 
inflammation and urothelial abnormalities was shown in a study by Shie & Kuo 
(2011). This study revealed significantly decreased cell proliferation, lower 
expression of junction protein E-cadherin and increased number of apoptotic cells in 
bladder urothelial tissues from IC/PBS patients compared to control bladder tissue, 
indicating greater damage level of the urothelium in patients with IC/PBS compared 
to control. Activation of mast cell, which is an important source of several 
inflammatory mediators including proteases and vasoactive amines such as histamine 
(Zhang et al., 2012b), was also significantly increased in tissues from IC/PBS 
patients and this mast cell activation significantly correlated with the apoptotic cell 
numbers. A further study by this group demonstrated that the levels of inflammatory 
molecules and pro-apoptotic proteins were significantly increased in the IC/PBS 
bladder, and phospho-p38 and TUNEL double staining indicated that inflammatory 
and apoptotic events coexisted in these patients. These results were confirmed by 
immunoblotting and suggested that the tissue damage and abnormal urothelium in 
the IC/PBS patients could result from upregulation of inflammatory mediators, 
including p38 mitogen-activated protein kinase and TNF-α. The in vitro analysis also 
showed that the apoptotic process could be induced by TNF-α treatment and 
anisomycin stimulation in normal urothelial cells (Shie et al., 2012). Thus, it can be 
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postulated that the urothelial cell damage caused by the three cytotoxic agents such 
as decreased urothelial thickness and cell viability, may be a secondary effect of 
inflammation where increased release of inflammatory cytokines observed after 
treatment could trigger the damage to the urothelium.  
One of the widely accepted mechanisms of bladder toxicity of the three intravesical 
agents tested here is ROS production, which can be cytocidal to both cancer and 
normal cells and these mechanisms have been discussed in detail in Chapter 1. 
Several enzymes are capable of producing ROS but the most important of these is 
NADPH oxidase (NOX) (Hancock et al., 2001). NOX is predominantly found in 
white blood cells such as neutrophils (Mittal et al., 2014) but has been also found to 
be present in cells that have no role in host defense such as fibroblasts (Meier et al., 
1991), mesangial cells (Radeke et al., 1991), endothelial cells (Jones et al., 1996), 
osteoclasts (Steinbeck et al., 1994) and chondrocytes (Hiran et al., 1997). The ROS 
serve as both a signaling molecule and a mediator of inflammation at low 
concentrations (exact concentrations still remain to be determined) but if excessive 
and unchecked, they are injurious to cells at high concentrations because they can 
oxidize protein and lipid cellular constituents and damage the DNA (Droge, 2002; 
Mittal et al., 2014; Thannickal and Fanburg, 2000).  
There are several studies supporting that inflammation could induce ROS production. 
A previous study by Meier et al. (1989) using primary cell cultures of human 
fibroblasts collected from healthy skin has demonstrated that treatment of these cells 
with cytokines IL-1 and TNF-α released hydrogen peroxide (H2O2) that increased 
with increasing treatment durations and concentrations.  Also, a study using articular 
chondrocyte cells isolated from rabbits has shown that exposure to IL-1, TNF-α and 
interferon-γ (IFN-γ) for a period of 18 to 20 hour increased production of H2O2 
compared to control (Tiku et al., 1990). Treatment of bovine articular chondrocytes 
with TNF-α also induced production of ROS (Lo and Cruz, 1995). A more recent 
study by Yang et al. (2007) demonstrated a time- and dose-dependent increase in 
both intracellular and extracellular ROS production from human RPE (retinal 
pigment epithelium) cells (isolated from donor eyes) in response to IL-1β, TNF-α 
and IFN-γ stimulation. In addition, there is evidence showing that Rac1, which is an 
important cytosolic subunit that is required for activation of one of the NADPH 
oxidase homologs NOX2, can be activated by a variety of inflammatory stimuli 
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including IL-1β (Monaghan-Benson and Burridge, 2009). Furthermore, a study by 
Bulua et al. (2011) has shown that mitochondrial-derived ROS (MtROS) can 
contribute to LPS-mediated production of pro-inflammatory cytokines IL-1β, IL-6, 
and TNF-α, suggesting that the ROS produced in response to inflammation can 
further enhance cytokine release that may lead to much higher production of ROS.  
This may explain the mechanism of bladder toxicity of the three intravesical agents 
whereby doxorubicin, epirubicin and MMC elicit inflammatory response to cause 
urothelial damage via oxidative stress, resulting in loss of the barrier function. The 
loss of barrier function can then lead to exposure of the bladder wall to infiltration of 
urinary constituents like potassium that can depolarize muscle and nerve cells, 
inflame tissues, degranulate mast cells, and cascade to the development of LUT 
symptoms (Parsons, 2011). In addition, disorders in normal glycosylation of UPs 
lead to abnormal epithelial adhesion, leakage of the urinary tract and spread of 
Escherichia coli (E. coli) infection, potentially exacerbating inflammation (Taganna 
et al., 2011). A study by Soler et al. (2008) has demonstrated that damage to 
urothelial barrier function by intravesical instillation of protamine sulfate in rats led 
to inflammation but in rats that underwent bilateral nephrectomy to prohibit urine 
production no inflammation resulted, supporting that the increased permeability of 
the barrier function to noxious substances in the urine can aggravate initial 
inflammation induced by intravesical agents and lead to chronic inflammation which 
is thought to be a potential mechanism of pathogenesis for bladder disorders 
(Erickson et al., 2002; Ogawa et al., 2010; Saini et al., 2008).  
Above, it was proposed that a major mechanism of bladder toxicity by three 
intravesical agents may be their ability to elicit inflammation causing the disruption 
to urothelial barrier function, via excessive production of ROS, which can 
subsequently lead to a cascade of effects on bladder function. This theory was based 
on the findings of this thesis obtained from in vitro models, human urothelial cell 
lines and porcine bladder tissues. Thus, the clinical relevance of this concept needs to 
be considered. The viability of each in vitro model in terms of their physiological 
similarities to in vivo bladders such as receptor expressions and mediator release that 
are pivotal in regulation of storage and voiding function have been discussed in detail 
in respective chapters. However, resemblance in urothelial barrier components of 
these models has not been mentioned previously. Lobban and his colleagues (1998) 
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at the Cancer Medicine Research Unit in St. James’s University Hospital (Leeds, 
United Kingdom) cloned cDNA sequence for human uroplakins UPIa, UPIb, UPII 
and UPIII, and used them to investigate uroplakin transcription by normal and 
neoplastic urothelial cells. It was found that normal human urothelial cell line 
obtained from patients with no history of urothelial dysplasia or malignancy as well 
as neoplastic cell line RT4 expressed mRNA for all four uroplakins. A freeze 
fracture analysis by Rossi et al. (2001) has demonstrated that the normal human 
urothelial UROtsa cell line possessed the tight-junction sealing strands and gap 
junctions.  
A previous study by Wu et al. (1994) reported that the AUMs, which form the apical 
plagues of the urothelium, appear morphologically similar in human and pig urinary 
bladders bearing crystalline, hexagonal arrays of uroplakin and immunoblotting 
confirmed the presence of four uroplakins in AUMs of these species. Also, well 
differentiated superficial cells on the surface of the urothelium and intact tight 
junctions between cells have been reported in pig urinary bladders (Kos et al., 2006). 
In addition, immunohistochemistry experiments by Janssen and his colleagues (2010) 
reported the presence of a GAG layer in the RT4 cell line and GAG isolation 
experiments showed that the GAG layer produced by these cells contains heparan 
sulfate, chondroitin sulfate, dermatan sulfate in respectively decreasing 
concentrations and this distribution of GAGs is similar to those produced by the 
human bladder urothelium. Furthermore, a recent study by the same group has shown 
the presence of GAG in both human and porcine bladder biopsies and no differences 
were observed in GAG expression between these mammalian species.  GAG 
isolation has revealed that the luminal side of the urothelium contained 
predominantly chondroitin sulfate and low amounts of heparan sulfate. Similar 
concentrations of chondroitin sulfate and heparan sulfate were found in the deeper 
urothelial layer and dermatan sulfate was predominantly found in deeper bladder 
layers. The role of GAGs present in the deeper layers remains unidentified. 
Consecutive immunofluorescence assays demonstrated that the GAG distribution on 
the urothelium was comparable between species (Janssen et al., 2013). Both 
urothelial cells and porcine bladder tissues closely mimic barrier components of the 
urothelium, thus urothelial dysfunction and injury observed in this thesis by three 
agents are clinically relevant to the patients and therefore supports the above toxicity 
mechanism.  
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The urothelium is one of the slowest growing epithelial cells in mammals under 
normal conditions, but when stimulated appropriately with growth signals especially 
during wound healing and carcinogenesis, the urothelium can undergo significant 
growth (Cohen and Ellwein, 1993; de Boer et al., 1994; Romih et al., 2001; Varley 
and Southgate, 2008; Walker, 1960). Due to its natural presence in the urine, 
epidermal growth factor (EGF) has been suspected to be one of the key in vivo 
growth signals for the urothelium (Fuse et al., 1991; Messing, 1992). Since 
epidermal growth factor receptors (EGFRs) are predominantly expressed by the basal 
cells of the urothelium, which is situated under the physical barrier imposed by the 
umbrella cells, the interaction between EGF ligand and its urothelial receptors is 
normally prevented (Messing, 1990; Messing et al., 1987; Romih et al., 2001).   
Urothelial damage, resulting in loss of cells following treatment with all of the 
intravesical agents tested has been reported in this thesis. This can expose the basal 
cell layer, leading to urothelial proliferation and also hyperplasia which are 
demonstrated in rats treated with cyclophosphamide (CYP) injections (Romih et al., 
2001; Zupancic et al., 2009) and in rats treated intravesically with the alkylating 
agents methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) 
(Tudor et al., 1983). In a report by Romih et al. (2001), hyperplastic urothelium due 
to CYP-induced cell damage was fully restored to a normal three-layered urothelium 
two weeks after treatment. Therefore, it can be expected that the damaged urothelium 
observed in this thesis may potentially present with hyperplasia within this recovery 
period and subsequently produce higher levels of the stimulatory mediators ATP, 
ACh and PGE2, which can cause further urothelial dysfunctions, abnormalities in 
detrusor activity and afferent nerve pathway. However, this was not the case in 
urothelial cell studies where the overall mediator levels were mostly unchanged one 
week following initial and repeat treatments. Therefore, it would be interesting to 
determine if the urothelium becomes hyperplasic in vivo, and if this increases the 
levels of urothelial mediators during a period recovery and also after a series of 
repeat intravesical treatments.  
Anti-cholinergic medications such as oxybutynin are commonly used for the 
treatment of OAB. A recent study by Johnson et al. (2013) reported use of 
oxybutynin for symptom prophylaxis in bladder cancer patient receiving intravesical 
BCG in fact increased urinary frequency and burning on urination compared to 
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placebo. This highlights the need for an alternative approach to manage the adverse 
effects associated with intravesical treatment. Treating the inflammation and 
restoring the urothelial abnormalities may be a potential management of adverse 
effects reported by patients while maintaining efficacy of the intravesical 
chemotherapeutic agents that are currently available. Restoring or improving the 
protective bladder barrier has been utilised as a treatment approach for inflammatory 
bladder conditions (Bassi et al., 2011), including oral pentosan polysulfate and 
bladder instillations with hyaluronic acid, chondroitin sulfate and heparin. These 
treatments claim to repair the bladder GAG layer and some were recently shown to 
be efficacious in clinical studies (Damiano et al., 2011; Nickel et al., 2010; Nordling 
and van Ophoven, 2008; Parsons et al., 1993). However, restoring the barrier 
components or treating inflammation at early stages should be cautious and must be 
evaluated thoroughly before a trial as it may prevent uptake of these agents by 
tumour cells or halt the anti-tumour actions of these agents that appear to be effective 
at least in part by provoking an immune response.  
 
Inflammation and abnormal detrusor activity 
Inflammation of the urothelium may also suggest potential presentation of 
inflammation in the deeper detrusor muscle layer in which enhanced release of 
cytokines from the urothelium can also elicit inflammatory responses in detrusor 
muscle or it may be a concurrent effect. Previously, detrusor myocytes have not 
received significant attention in inflammatory diseases such as IC/PBS. However, 
many clinical studies using bladder biopsies from IC/PBS patients and animal 
models of bladder inflammation including CYP-induced cystitis found inflammatory 
changes in the bladder muscular layer, especially mast cell infiltration (Chuang et al., 
2009; Girard et al., 2011; Sant et al., 2007). A recent study by Zhao et al. (2015) has 
demonstrated numerous mast cell infiltration in the detrusor muscle layer in a rat 
model of CYP-induced cystitis, indicating inflammation in this layer. In normal 
conditions, mast cells are rarely found in bladder muscle tissue and do not circulate 
in their mature form (Galli et al., 2005). However, when the detrusor myocytes are 
stimulated with IL-1β or TNF-α, the detrusor myocytes can release inflammatory 
mediators, including IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), and 
chemokine (C-C motif) ligand 5 (CCL5), which promote mast cell recruitment, 
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proliferation and maturation in the detrusor muscle layer (Bouchelouche et al., 2006a; 
Bouchelouche et al., 2006b; Galli et al., 2005). 
Gap junctions are clusters of intercellular channels that provide direct cell-cell 
exchange of ions and small molecules, thus they have fundamental roles in excitable 
tissues (nerve and muscle) by allowing electrical transmission between cells 
(Connors and Long, 2004; Severs et al., 2004). Gap junction channels are composed 
of integral membrane proteins called connexins. In humans, there are 20 members of 
connexin gene family, of which the best-studied member is connexin 43 (Cx43) 
(Sohl and Willecke, 2003). The role of gap junctions for the function of bladder 
detrusor muscle is still a matter for debate but previously study has suggested a 
potential role in modulation of bladder voiding. Mori et al. (2005) reported a 
decrease in the number of gap junctions as well as a decrease in cellular membrane 
expression of Cx43 in the rat detrusor muscle with partial bladder outlet obstruction 
(P-BOO) as compared to control. Most importantly, in rats that demonstrated 
significantly low number of the gap junctions, no contraction was observed, 
suggesting that the normal signals that contribute to voiding function could be 
transported directly through the gap junction. Previous studies have demonstrated 
that the gap junctions in the urothelium or detrusor muscle can function as key 
modulators for non-neurogenic mechanisms of various hyperactive bladder 
conditions (Imamura et al., 2009; Imamura et al., 2013; Negoro et al., 2012; Negoro 
et al., 2013). Mice with CYP-induced cystitis have shown significantly upregulated 
expression of Cx43, more pronounced spontaneous contraction and frequent voiding 
compared to control. These overactive conditions were attenuated by gap junction 
inhibitors (Okinami et al., 2014). The effect of the three cytotoxic agents on the 
detrusor gap junction communication is unknown, but downregulation of gap 
junction proteins by doxorubicin has been reported in hearts (Zhang et al., 2011) and 
liver epithelial cells (Abdelmohsen et al., 2005).  Modulation of connexin expression 
and gap junction intercellular communication (GJIC) by inflammatory cytokines has 
been demonstrated in various tissues. TNF-α decreased both Cx43 expression and 
GJIC in human epidermal keratinocytes and in rat glioma cells. Reduced expression 
of Cx43 and GJIC by transforming growth factor-β1 (TGFβ1) has been reported in 
rat hepatic stellate cells. A study by Rama et al. (2006) has demonstrated a 
significant upregulation of Cx43 expression and GJIC after TGFβ1 stimulation. In 
contrast, Neuhaus and his colleagues (2009) reported significantly reduced Cx43 
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expression and GJIC by TGFβ1 in cultured human detrusor smooth muscle cells 
(hBSMC). A recent study using hBSMC by Heinrich et al. (2011) has demonstrated 
upregulation of GJIC after IL-6 simulation. IL-4 and TGFβ1 decreased both Cx43 
expression and GJIC, and TNF-α increased Cx43 expression. Therefore, it can be 
postulated that the affected muscle responsiveness by the three agents in this thesis 
may be due to inflammation-associated changes in the detrusor gap junctions. 
Accordingly, it would be advantageous to determine if there are changes in these gap 
junctions after treatment with the three agents of interest. This would confirm the 
potential role of the gap junctions as non-neurogenic mechanisms of OAB conditions 
following cytotoxic drug treatments. 
 
Inflammation and sensitisation of afferent nerves / neuroplasticity 
As demonstrated in tissues and cultured cells, urothelial cells are capable of secreting 
mediators including ATP, ACh and PGE2 that can influence the underlying smooth 
muscle and nerves. These urothelial mediators are closely associated with 
overactivity and pain of the bladder, symptoms that patients report after intravesical 
treatment. Mediator release was shown to be affected by the three agents in this 
thesis but changes mostly returned to normal levels during recovery studies. In the 
setting of urothelial hyperplasia that may be induced by inflammation, as discussed 
above these mediators could potentially be further enhanced in clinical situations. 
However, in long-term prospective when inflammation and hyperplasia subside in 
patients there may be another mechanism that can contribute to the adverse effects.  
Nerve growth factor (NGF) is a signaling protein expressed widely in various cells 
including urothelial cells, smooth muscle cells and mast cells (Steers et al., 1991). 
NGF affects bladder afferent nerves and is responsible for the growth and 
maintenance of sensory neurons (Steers, 2002). Previous studies have demonstrated a 
potential role of NGF as a chemical mediator of pathology-induced changes in C-
fiber afferent nerve excitability and reflex bladder activity (Vizzard, 2000; 
Yos himura, 1999). After spinal cord injury, increased level of NGF in the bladder 
(Vizzard, 2000, 2006) as well as increased levels in the lumbosacral spinal cord and 
dorsal root ganglia of rats have been reported (Satoshi et al., 2003). Also, various 
studies have demonstrated that administration of NGF into the spinal cord or 
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intravesical administration of NGF induce nociceptive response and bladder 
hyperactivity, and increases the firing frequency of dissociated bladder afferent 
neuron (Chuang et al., 2001; Dmitrieva et al., 1997; Lamb et al., 2004; Satoshi et al., 
2003; Vizzard, 2006; Yoshimura et al., 2006; Zvara and Vizzard, 2007). Thus, NGF 
may lead to sensitisation of afferent nerves, enhancement of synaptic transmission, 
and pain sensation as well as increased urinary frequency (Figure 7.1). 
 
 
Figure 7.1: Nerve growth factor (NGF) is released from target cells under irritation due to 
inflammation, obstruction, or denervation. NGF sensitizes afferent nerves, enhances synaptic 
transmission, and produces pain sensation as well as increased urinary frequency (Kuo et al., 
2010).  
 
There is abundant evidence supporting that NGF may play a significant role in the 
link between inflammation and altered pain signaling. An increased expression of 
NGF has been reported in bladder biopsies from women with IC/PBS (Liu and Kuo, 
2007; Lowe et al., 1997).  A study by Lowe et al. (1997) has shown higher levels of 
NGF in samples obtained from patients with IC/PBS compared to control. Liu & 
Kuo (2007) has demonstrated significantly increased level of the NGF mRNA 
compared to control. In addition, Okragly et al. (1999) reported increased levels of 
NGF in the bladder tissue and urine of patients with IC/PBS. Furthermore, studies 
using inflammatory models of cystitis induced by CYP or LPS in rats or mice have 
Copyright © MedReviews®, LLC. Reprinted 
with permission of MedReviews®,  
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demonstrated increased levels of NGF production (Coelho et al., 2015; Gonzalez et 
al., 2005; Ho et al., 2011). A study by Dupont et al. (2001), which e valuate d 
chemical (formalin), immune (LPS) and mechanical (chromic catgut) inflammation 
at various times compared to control bladders, has found that bladder inflammation 
in general resulted in a 50% increase in the levels of NGF production and 52% to 58% 
enlargement of peripheral neurons. Steers et al. (1991) also reported a potential 
correlation between NGF and neuroplasticity by an increase in both the dimensions 
of afferent and efferent neurons as well as increase in the levels of NGF in rats with 
bladder outlet obstruction compared to normal bladders. The findings of this thesis 
have identified signs of efferent nerve damage by decreased neurogenic responses in 
detrusor muscle tissues. This leaves the possibility of damaged nerves to proliferate 
and lead to hypertrophy, causing sensitisation of the efferent neurotransmission in 
the long-term. Therefore, further investigation into the effects of DOX, MMC and 
EPR on NGF production and morphology of sensory and motor neurons 
(neuroplasticity) may explain long-term symptoms including pain, frequency, and 
urgency that the patients experience even after the initial inflammatory stimulus has 
subsided or the resolution of bladder inflammation. 
 
Concluding remarks  
The work of this thesis has provided support for the previous findings that urinary 
bladder function changes in an age-associated manner. To the best of my knowledge, 
the results presented here is the first to report the effect of ageing in porcine bladder 
function. Consequently, this lead to the finding that aged porcine bladders, as 
compared to young bladders, is a better research model for mimicking bladder 
conditions of seniors that are more affected by bladder cancer. In this thesis, 
treatment with the intravesical chemotherapeutic agents, doxorubicin, MMC, and 
epirubicin, demonstrated various changes in local bladder mechanisms including 
alterations in the release of non-neuronal mediators from the urothelium, detrusor 
muscle contractility and relaxation, efferent neurotransmission, urothelial integrity, 
and inflammatory responses. One of the most important findings in this study was 
the persistent induction of inflammatory cytokines and it is my hypothesis that this 
may be the key to pathogenesis of the urological adverse effects reported in bladder 
cancer patients following intravesical treatment. Future research into the role of 
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inflammation could further our understanding of bladder toxicity mechanisms for 
these agents as well as other overactive and inflammatory bladder conditions. 
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